

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES**

---

**SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

---

**COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS**

This section provides the terms and conditions under which prescription services will be paid by the Medicaid Program and a description of the authorized benefits for eligible beneficiaries.

**Terms and Conditions****Licensed Prescribers**

Payment will be made for prescription services only when issued by a licensed prescribing practitioner who has an active Medicaid prescriber number. (Refer to Section 37.5.6 - Prescribers for detailed information about prescribers).

**Eligible Beneficiaries**

The Medicaid Program will only reimburse pharmacy claims when the beneficiary is eligible on the date of service. Pharmacy claims submitted with a date of service after a beneficiary's date of death are not allowed. (Refer to Chapter 1 – General Information and Administration of the *Medicaid Services Manual* for additional information on Medicaid eligibility).

**Rebate Agreements**

In accordance with Section 4401 of the Omnibus Budget Reconciliation Act of 1990 (OBRA '90), the Medicaid Program will pay only for those drug products for which the pharmaceutical company has entered into a federal rebate agreement with the U.S. Department of Health and Human Services (DHHS).

**NOTE:** The listing of Medicaid drug federal rebate participating pharmaceutical companies can be accessed at: [www.lamedicaid.com/Provweb1/Forms/Drug\\_appendices/APNDC.pdf](http://www.lamedicaid.com/Provweb1/Forms/Drug_appendices/APNDC.pdf). This listing is updated periodically and is posted on the Louisiana Medicaid website. **Providers should take note of the effective dates of the labeler codes.**

Coverage will be provided for those drug products labeled by the pharmaceutical companies that have entered into a rebate agreement. As new pharmaceutical companies enter into rebate agreements, labeler codes will be added.

The therapeutic categories, e.g., cough and cold preparations, anorexics and cosmetic drugs, will remain non-payable. The *Medicaid Drug Federal Rebate Participation Pharmaceutical*

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

*Companies* listing and additional information can be accessed at: [www.lamedicaid.com/Provweb1/Forms/Drug\\_appendices/APNDC.pdf](http://www.lamedicaid.com/Provweb1/Forms/Drug_appendices/APNDC.pdf) or by visiting Section 37.5.1 of this manual chapter.

**Medically Accepted Indications**

A drug must be medically necessary and prescribed for medically accepted indications to be eligible for reimbursement.

As defined by Section 1927(k)(6) of the Social Security , the term “medically accepted indication” means any use for a covered outpatient drug which is approved by the Food and Drug Administration (FDA) under the Federal Food, Drug and Cosmetic Act or the use of which is supported by one or more citations included or approved for inclusion in any of the following compendia: *American Hospital Formulary Service Drug Information*, *United States Pharmacopeia – Drug Information* (or its successor publications), and *DRUGDEX Information System*.

**Drug Utilization Review**

OBRA ‘90 also requires that states have a Drug Utilization Review (DUR) program in place and that this program assures that prescriptions are appropriate, are medically necessary and not likely to result in adverse medical results. The DUR program must include prospective drug review, retrospective drug review, and an educational program. (Refer to Section 37.5.12 - Patient Counseling, Drug Utilization Review (DUR) for detailed information regarding DUR).

**Patient Counseling Requirement**

The Louisiana Board of Pharmacy’s regulations require patient counseling, patient profiles, and prospective drug review, in accordance with OBRA ‘90.

**Patient Counseling Documentation**

Section 1927(g)(2)(ii)(I) of OBRA ‘90 requires that the pharmacist offer to discuss with each Medicaid beneficiary or a caregiver, in person whenever practicable, or by toll-free telephone for long distance calls, matters which, in his/her professional judgment, the pharmacist deems significant. Such counseling is subject to standards for counseling in accordance with the Louisiana Board of Pharmacy Regulations at LAC, 46:LIII, §517. Such counseling is to be provided unless refused by the beneficiary or caregiver. The Pharmacy Program will require counseling documentation for all prescriptions reimbursed by Louisiana Medicaid. According to

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES**

---

**SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

---

the patient counseling standards in the OBRA'90, patient counseling begins with, and focuses on providing information related to the immediately prescribed drug. The only documentation required is a "yes" or "no" checked on the form next to the patient's signature to indicate whether he or she accepted the offer to provide this information. Counseling records must be retained in the pharmacy for five years from the date of payment and must be readily retrievable upon audit.

**NOTE:** Refer to Section 37.5.12 of this manual chapter for detailed information.

**Pharmacy Signature and Delivery Logs**

Pharmacy providers must obtain a signature from the patient or caregiver confirming the receipt of the prescription(s). This applies to all prescription pick-ups, home and facility deliveries. Claim submission is not proof that the prescription(s) or prescription order was actually furnished.

**Pharmacy Pick-up**

1. The signature log documentation should include the prescription number(s) and the date the prescription was picked up. If multiple prescriptions are being picked up at one time, a single signature will be sufficient for all of the patient's prescriptions;
2. Electronic signatures for receipt are permitted only if retrievable upon audit and kept on file by the pharmacy;
3. Obtaining a signature to confirm receipt of prescription(s) can be part of a counseling log; and
4. The signature confirmation must be maintained by the dispensing pharmacy for five years from the date of payment and must be retrievable upon audit.

**Facility Delivery/Mail Order/Specialty**

1. A signature is required at the time of delivery;
2. The signature documentation must also include the list of prescription number(s) and date the medication(s) was/were delivered. A single signature will be sufficient for all the medication in the delivery;

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES**

---

**SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND  
EXCLUSIONS****PAGE(S) 142**

---

3. Electronic signatures for receipt or electronic tracking slips for delivery are permitted only if retrievable on audit;
4. A waiver signature form is not an acceptable practice and such forms will not serve as confirmation of delivery; and
5. Confirmation of the delivery must be maintained by the pharmacy for five years from the date of payment and must be retrievable on audit. Delivery industry tracking receipts that contain a signature (e.g., FedEx, UPS, and USPS) qualify as a signature for receipt of delivery.

**Home Delivery**

1. If a pharmacy provider chooses to have a pharmacy representative deliver prescription(s) to a beneficiary's home, the pharmacy should inform the beneficiary or designee of the pharmacy's delivery schedule, verify the date and location for the delivery, and notify the beneficiary or designee that a signature will be required at the time of delivery; and
2. The pharmacy representative will obtain a signature from the beneficiary or their designee confirming the delivery. A waiver signature form is not an acceptable practice, and such forms will not serve as confirmation of delivery. Delivery confirmation must be maintained by the pharmacy for five years from the date of payment and must be retrievable upon audit. Electronic signatures for receipt are permitted only if retrievable and kept on file by the pharmacy.

**Prescription Duration**

Scheduled narcotic prescriptions must be filled within six months of the date issued excluding Schedule II narcotic prescriptions. Schedule II narcotic prescriptions will expire 90 days after the date of issue in accordance with the Louisiana Board of Pharmacy regulations. Prescriptions for non-controlled substances expire after 11 authorized refills or one year after the date prescribed, whichever comes first.

**Prescription Transfers**

The transfer of prescriptions, including those for Schedule III-V narcotics, must be in accordance with the Louisiana Board of Pharmacy regulations.

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES**

---

**SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND  
EXCLUSIONS****PAGE(S) 142**

---

**Date of Service**

The date of service is based on the adjudication process. The pharmacy staff should evaluate any prospective warnings or alerts based on internal software, or the Louisiana Program response generated during the claim submission. Based on this clinical review, the date the prescription was adjudicated is the service date except when long-term care eligibility determination is delayed.

**Prescription Refills**

Prescription refills can be provided if they are authorized specifically by the prescribing practitioner. Prescriptions for non-controlled substances have a one-year expiration and an 11-refill maximum from the date prescribed, whichever comes first.

Refills for Scheduled III-V narcotics have a six month expiration and a five refill maximum from the date prescribed, whichever comes first.

**No refills are allowed on Schedule II prescriptions.**

**National Drug Code**

In order to be reimbursed for a pharmacy claim, prescribed items must have an assigned National Drug Code (NDC).

**Prescriptions Received via Telecommunication**

Most prescriptions are acceptable when received by telephone or other telecommunication device in accordance with state and federal regulations. Providers must file and log prescriptions received via telecommunication as they would any other written or electronic prescriptions.

**Tamper Resistant Prescription Policy**

Written, non-electronic prescriptions for Medicaid beneficiaries are required to be written on tamper-resistant pads.

The “Transitional Medical Assistance (TMA), Abstinence Education and QI Program Extension Act of 2007” (H.R. 3668) and the “U.S. Troop Readiness, Veterans’ Health Care, Katrina Recovery and Iraq Accountability Appropriations Act of 2007” (H.R. 2206) states that all

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

handwritten prescriptions or those printed from an electronic medical record (EMR), or an ePrescribing application must contain all three characteristics listed below. Exceeding these guidelines is permissible if:

1. One or more industry-recognized features designed to prevent unauthorized copying of a completed or blank prescription form;
2. One or more industry-recognized features designed to prevent the erasure or modification of information written on the prescription by the prescriber; and
3. One or more industry-recognized features designed to prevent the use of counterfeit prescription forms.

This provision applies to all written (non-electronic) prescriptions for outpatient drugs including over-the-counter drugs reimbursed by Pharmacy Program, regardless of whether Medicaid is the primary or secondary payer.

It is the responsibility of the prescriber to obtain and purchase tamper-resistant prescription pads.

**NOTE:** The *Table of Tamper Resistant Prescription Criteria and Examples* can be accessed in Section 37.5.12 at:

[www.lamedicaid.com/Provweb1/manuals/App\\_L\\_Tamper\\_Res\\_Prescription.pdf](http://www.lamedicaid.com/Provweb1/manuals/App_L_Tamper_Res_Prescription.pdf)

**Excluded Prescriptions**

The tamper-resistant requirement does not apply to prescriptions which are communicated by the prescriber to the pharmacy electronically, verbally or by facsimile.

**Confirming Non-Compliant Prescriptions**

If a prescription does not meet the requirements for tamper-resistance, pharmacies may obtain verbal confirmation and document appropriately. The pharmacy does not need to speak with the prescriber directly. They may receive confirmation from a nurse or administrative staff person who has authority to act on behalf of the prescriber.

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142****Emergency Fills**

Emergency fills with non-compliant written prescriptions are permissible as long as the prescriber provides a verbal, faxed, electronic or compliant written prescription within 72 hours after the date on which the prescription was filled. If an emergency fill is confirmed with a verbal order, the pharmacist must document the call on the face of the written prescription.

**Authorized Benefits**

Provided below are the authorized medications and/or supplies which are payable under Louisiana Medicaid.

**NOTE:** Refer to “Quantity Limitations” in this section and Section 37.3 - Reimbursement Services for detailed information regarding authorized benefits.

**Legend Drugs**

Legend drugs are drugs that require a prescription or that have the following statement on the label, “Caution: Federal law prohibits dispensing without a prescription.” Medicaid reimbursement is available for most legend drugs that are dispensed in outpatient settings.

**NOTE:** Refer to “Non-Covered Services” in this section for detailed information regarding legend drugs.

**Legend Vitamin and Mineral Products**

Only the following legend vitamin and mineral products will be reimbursed by the Pharmacy Program:

Vitamin B 12 preparations	Vitamin E preparations	Pediatric vitamin preparations
Vitamin A preparations	Vitamin K preparations	Legend prenatal vitamins for pregnant and lactating beneficiaries
Vitamin B preparations	Calcium replacement	Magnesium salt replacement
Vitamin B1 preparations	Folic Acid preparation	Prescription strength fluoride as a single entity
Vitamin B6 preparations	Geriatric vitamin preparations	Urinary pH modifiers (Phosphorus)
Vitamin C preparations	Multivitamin preparations	

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

Vitamin D preparations

Niacin preparations

**Injectable Drugs**

Reimbursement is provided for most injectable drugs for outpatient beneficiaries when supplied by community pharmacies, long-term care (LTC) pharmacies, and home infusion pharmacies that are enrolled as Medicaid providers.

Some antibiotic and oncologic injections administered in practitioners offices and clinics are reimbursed through the Professional Services Program.

**Non-Legend Drugs**

Only a limited number of non-legend or over-the-counter (OTC) drugs can be reimbursed by the Louisiana Medicaid program. For Medicaid reimbursement, these drugs must be prescribed by licensed practitioners. **Providers must bill the NDC from the actual package dispensed. Also, the drug manufacturer must participate in the federal rebate program.**

The following non-legend drugs are covered when an authorized prescriber has written a prescription:

1. Insulin;
2. Sodium chloride solution for inhalation therapy;
3. Contraceptives, topical;
4. Urinary pH modifiers; and
5. Other non-legend drugs that have Pharmacy Program approval.

**Non-Legend Items and Supplies**

Only a limited number of non-legend items and supplies can be reimbursed by the Medicaid Program. In order to receive Medicaid reimbursement, these items and supplies must be prescribed by licensed practitioners. **(Providers must bill the NDC from the actual package dispensed):**

1. OTC Vitamin D preparations;



**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES**

---

**SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND  
EXCLUSIONS****PAGE(S) 142**

---

2. OTC Vitamin E preparations;
3. OTC Niacin preparations;
4. OTC Calcium replacement agents;
5. OTC Magnesium replacement agents;
6. OTC Phosphate replacement agents;
7. OTC Iron replacement agents;
8. Normal saline and heparin flushes;
9. Disposable needles and syringes used to administer insulin;
10. Test strips for determining blood glucose levels;
11. Lancets;
12. Urine test strips (e.g., Clinitest® and Clinistix®);
13. Family planning items; and
14. Other non-legend items and supplies that have Pharmacy Program approval.

**Total Parenteral Nutrition**

Total Parenteral Nutrition (TPN) and associated supplies and equipment are covered services in the Pharmacy Program. (Refer to Section 37.5.10 - Total Parenteral Nutrition for additional information).

**Medication Administration**

Enrolled pharmacies may be reimbursed for the administration of the influenza vaccine. Pharmacists who have the “Authority to Administer” authorized by the Louisiana Board of Pharmacy may administer the vaccine. (Refer to Section 37.5.11 - Medication Administration for detailed information).

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES**

---

**SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND  
EXCLUSIONS****PAGE(S) 142**

---

**Non-Covered Services****Drugs Excluded From Coverage**

The following drugs and/or therapeutic categories are excluded from coverage:

1. Anorexics – Medicaid does not reimburse for anorexics with the exception of orlistat;
2. Compounded prescriptions (mixtures of two or more ingredients; the individual drugs will continue to be reimbursed);
3. Cosmetic drugs;
4. Cough and cold preparations;
5. Drug Efficacy Study Implementation (DESI) Drugs (refer to those drugs that the FDA has proposed to withdraw from the market because they lack substantial evidence of effectiveness);
6. Erectile dysfunction drugs;
7. Experimental drugs;
8. Fertility drugs when used for fertility treatment;
9. Medications which are included in the reimbursement to a facility, i.e. hospitals, skilled nursing facility for beneficiaries receiving benefits under Part A of Title XVIII, mental hospitals, or some other nursing facilities;
10. Narcotics prescribed only for narcotic addiction;
11. Non-legend or OTC drugs or items with some exceptions; and
12. Vaccines covered in other programs.

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES**

---

**SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

---

**Durable Medical Equipment/Supplies Excluded**

Durable medical equipment (DME) and supplies, other than those included in this section, are not covered in the Pharmacy Program. These items are covered in the Home Health Program and must be billed to that program. (Refer to Chapter 18 - Durable Medical Equipment of the *Medicaid Services Manual* for specific information covered through the DME program).

**Prior Authorization and Single Preferred Drug List**

The Medicaid Program administers a prior authorization process for pharmacy services. This process utilizes a single preferred drug list (PDL) for selected therapeutic classes. Drugs included on the PDL are preferred. Drugs in these classes that are not included on the PDL require prescribers to obtain prior authorization.

**PDL Provider Notification**

Lists of covered drug products, including those that require prior authorization, will be posted on the Louisiana Medicaid website.

**Prior Authorization Process General Information**

The prior authorization process provides for a turn-around response by either telephone or other telecommunications device within 24 hours of a prior authorization (PA) request. In emergency situations, providers may dispense at least a 72 hour or a three day supply of medication.

**Prior Authorization and Single PDL Information Site**

The *Louisiana Medicaid Single Preferred Drug List (PDL)/Non-Preferred Drug List (NPDL)* and the *Louisiana Uniform Prescription Drug Prior Authorization Form* and its instructions can be accessed at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf> or by visiting Section 37.5.5 of this manual chapter.

**Who Can Obtain Prior Authorization**

The prescribing practitioner is responsible for obtaining prior authorization. Pharmacist or beneficiary calls/requests will not be accepted. The prescribing practitioner must have and provide his/her valid individual Louisiana Medicaid prescribing provider number to obtain prior authorization. Only individual provider numbers will be accepted. The prescribing practitioner

---

CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES

---

SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND  
EXCLUSIONSPAGE(S) 142

---

may obtain the prior authorization by telephone, facsimile or mail. Refer to the Section 37.5.4 – Contact Information for access to additional information on prior authorization. In addition, refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

The Prior Authorization Unit's hours of operation are 8:00 am to 6:00 pm Central Time, Monday through Saturday.

**NOTE:** If a prescribing practitioner does not have an individual prescriber number, refer to Section 37.5.6 - Prescribers for detailed information.

**Prior Authorization Request Form**

The Louisiana Uniform Prescription Drug Prior Authorization Form must be used by the prescriber to request a prior authorization. The form and its instructions can be accessed at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf> or by visiting Section 37.5.5 of this manual chapter.

**Emergency Procedures**

Prescriptions indicating emergency situations shall be dispensed in a minimum quantity of a three day supply. **Refills for the dispensing of the non-preferred products in these emergency situations are not permitted.** The beneficiary's practitioner must contact the Prior Authorization Unit (RxPA) to request authorization to continue the medication past the emergency supply, and a new prescription must be issued.

This process may be used when the RxPA Unit is closed (Sundays; Monday – Saturday before 8:00 am and after 6:00 pm) or when the PA system is unavailable. The pharmacist may also use professional judgment in situations that would necessitate an emergency supply.

**The prescribing practitioner must indicate that the prescription is an emergency Rx on the face of the prescription if hard copy or if the prescription is called in to the pharmacy, the emergency status of the prescription must be communicated to the pharmacist who must indicate "Emergency Rx" on the hard copy prescription. When the pharmacist determines the prescription is an emergency, the pharmacist must indicate "Emergency by Pharmacist" on the hard copy prescription.**

---

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES**

---

**SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND  
EXCLUSIONS****PAGE(S) 142**

---

**NOTE:** The Point of Sale (POS) *User Guide* can be accessed at:  
[www.lamedicaid.com/Provweb1/Pharmacy/LAPOS\\_User\\_Manual\\_static.pdf](http://www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf) or by visiting  
Section 37.5.1 for detailed claim submission and processing information.

Beneficiaries are exempt from paying co-payments for emergency situations.

Monitoring of emergency prescriptions/beneficiaries is conducted on an ongoing basis through management reports, pharmacy provider audits, and other monitoring programs to review the number of and the reasons for these prescriptions.

**Hospital Discharge Prescriptions for Atypical Antipsychotic Agents**

When a beneficiary is discharged from a hospital with a prescription for an atypical antipsychotic prescription, the prescribing practitioner must indicate on the face of the prescription, if hard copy, that the prescription is a “Hospital Discharge”. If the prescription is called in to the pharmacy, the “Hospital Discharge” status of the prescription must be communicated to the pharmacist who must indicate “Hospital Discharge” on the hard copy prescription.

In situations where the prescribing practitioner is unavailable and the pharmacist determines the prescription is a “Hospital Discharge” prescription, the pharmacist must indicate “Hospital Discharge on the hard copy prescription.

Claims for “Hospital Discharge” prescriptions needing prior authorization will be submitted using the same process used for an emergency override.

**Prescriptions for “Hospital Discharge” products shall be dispensed in a minimum quantity of a three-day supply, and refills for the dispensing of the non-preferred products are not permitted.** The beneficiary’s practitioner must contact the RxPA Unit to request authorization to continue the medication past the “Hospital Discharge” supply, and a new prescription must be issued.

**Prescriptions Issued Prior to the Effective Dates of Prior Authorization**

The prior authorization process does not impact original prescriptions (or refills) issued by a prescribing practitioner prior to a drug’s effective date of prior authorization.

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES**

---

**SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

---

**Beneficiaries with Retroactive Eligibility**

Drugs that are not on the PDL are sometimes dispensed to patients who are awaiting Medicaid eligibility determinations. Pharmacy providers will be reimbursed for these claims when the date of service falls within the beneficiaries' retroactive time period. The retroactive time period is defined as the time period between the first date of eligibility and the date that the beneficiary's eligibility is placed on the beneficiary file. Pharmacy providers shall submit these claims electronically.

**Important Facts**

When a beneficiary elects to self-pay for an original prescription which requires prior authorization, attempts to have Medicaid pay for the refill of this prescription will result in the pharmacy claim being denied.

If an approved prior authorization exists in the system, the pharmacy claim will bypass the prior authorization edit and continue with existing POS edits. If an approved prior authorization does not exist, the pharmacy claim will be denied through the POS system.

An approved prior authorization does not guarantee payment of the claim by Medicaid. It only indicates that the drug has been approved as a course of treatment within the Medicaid Program. All existing POS claim edits will continue to be applied.

The prior authorization process does not verify a beneficiary's Medicaid eligibility. It only verifies that the beneficiary is "on file" (i.e., has a valid Medicaid ID number on file – not that the beneficiary is eligible on the date of service). Beneficiary eligibility will continue to be verified by the Pharmacy POS subsystem or through the Medicaid Eligibility Verification System (MEVS) or Recipient Eligibility Verification System (REVS) automated beneficiary eligibility systems.

Only practitioners' individual prescriber numbers are accepted to request prior authorization of a non-preferred drug. Any provider number other than an individual prescribing provider number **WILL NOT** be accepted to prior authorize non-preferred drugs.

**Clinical Authorization**

There are certain medications that require clinical authorization. Clinical authorization is a prescriber initiated request for authorization on a selected number of drugs.

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES**

---

**SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

---

Prescribers must complete the *Louisiana Uniform Prescription Drug Prior Authorization Form* in full. The clinical authorization criteria can be used as a reference when completing the form. Clinical authorization requests should be faxed or mailed to the RxPA Unit. (Refer to Section 37.5.4 – Contact Information in this manual chapter for contact information).

**NOTE:** Refer to the Single Preferred Drug List (PDL) to access the clinical authorization drug list, forms, criteria, and instructions at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Monthly Service Limit****Limit**

Medicaid reimburses up to four prescriptions per calendar month per beneficiary. Claims including those for emergency prescriptions and prior-authorization prescriptions that are in excess of four per calendar month per beneficiary will deny.

**Exceptions to Limit**

The following federally mandated beneficiary groups are exempt from the four prescriptions per calendar month limitations:

1. Persons under 21 years of age;
2. Persons who are residents of long-term care institutions, such as nursing homes and Individuals with Intellectual Disabilities (ICF/IID) facilities; and
3. Beneficiaries who are pregnant.

**Limit Override Procedures**

The four prescriptions per month limit can be exceeded when the prescriber determines an additional prescription is medically necessary and communicates the following information to the pharmacist on the hard prescription, by telephone or other telecommunications device:

1. “Medically necessary override; and
2. A valid diagnosis code that directly relates to each drug prescribed that is over the four prescription limit (an International Classification of Diseases, Tenth Revision,

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES**

---

**SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

---

Clinical Modification (ICD-10-CM, or its successor) literal description is not acceptable).

The prescriber should use the Electronic Clinical Drug Inquiry (e-CDI) in his/her clinical assessment of the beneficiary's disease state or medical condition and the current drug regimen before making a determination that more than four prescriptions per calendar month is required by the beneficiary. (Refer to Section 37.5.4 for details on how to access the e-CDI).

Printed statements without the prescribing practitioner's signature, check-off boxes or stamped signatures are not acceptable documentation.

An acceptable statement and diagnosis code are required for each prescription in excess of four for each calendar month.

Pharmacists and prescribers are required to maintain documentation to support the override of a prescription limitation.

**NOTE:** Refer to Section 37.5.1 to access the *POS User Guide* to obtain detailed billing instructions and override procedures at:

[www.lamedicaid.com/Provweb1/Pharmacy/LAPOS\\_User\\_Manual\\_static.pdf](http://www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf)

**Drugs with Special Payment Criteria/Limitations**

Coverage of some drugs is limited to special criteria being met. These are explained below.

**NOTE:** Refer to Section 37.5.8 - Claim Submission for detailed override information as well as Section 37.5.1 to access the *POS User Guide* for detailed billing instructions, where applicable, at: [www.lamedicaid.com/Provweb1/Pharmacy/LAPOS\\_User\\_Manual\\_static.pdf](http://www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf)

**Age and Gender Restricted Drugs**

Certain drugs have age and gender restrictions placed on them. For further assistance, providers should contact the Molina Provider Helpdesk (Refer to Section 37.5.4 for contact information).

**Acne Agents**

Pharmacy claims for select acne agents have a quantity limit and clinical authorization requirement.



**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES**

---

**SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

---

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access the Single Preferred Drug List (PDL), which is inclusive of the preferred/non-preferred drug list, clinical authorization list, drug specific forms, criteria, and POS edits (i.e. maximum daily dose and quantity limits) at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Allergen Extracts**

Pharmacy claims for allergen extracts are subject to clinical authorization, physician prescriber requirements and an auto-injectable epinephrine prescription requirement for reimbursement.

**Physician Prescriber Requirements for Allergen Extracts**

Prescribers of allergen extracts must have a specialty of 1) Allergy, 2) Otolaryngology, Laryngology, Rhinology, or 3) Ophthalmology, Otolaryngology, Laryngology, Rhinology for reimbursement.

**Auto-Injectable Epinephrine Requirement for Allergen Extracts**

Pharmacy claims for allergen extracts require a pharmacy claim for an auto-injectable epinephrine product within the last year for reimbursement.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access the Single Preferred Drug List (PDL), which is inclusive of the preferred/non-preferred drug list, clinical authorization list, drug specific forms, criteria, and POS edits (i.e. maximum daily dose and quantity limits) at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Anti-Anxiety Drugs**

Pharmacy claims for solid oral dosage forms of alprazolam IR (Xanax®), clordiazepoxide (Librium®), lorazepam (Ativan®), oxazepam (Serax®), clonazepam (Klonopin®), clorazepate (Tranxene®), and diazepam (Valium®) have quantity limits of 90 units per rolling 30 days.

Quantity limits will be bypassed for clonazepam (Klonopin®), clorazepate (Tranxene®), and diazepam (Valium®) when an acceptable diagnosis code is submitted.

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

Acceptable diagnosis codes that will bypass the edit are:

ICD-10-CM Diagnosis Code	Description
P90	Convulsions in Newborn
G40.*	Epilepsy, Seizures
R56.*	Other Convulsions

**Alprazolam ER (Xanax XR®) and Alprazolam ODT (Niravam®)**

Pharmacy claims for alprazolam ER (Xanax XR®) and alprazolam ODT (Niravam®) are subject to the following for reimbursement:

1. Age Restriction; and
2. Diagnosis Code Requirements.

Pharmacy claims for alprazolam ER (Xanax XR®) also have quantity limits.

**Age Restriction**

Pharmacy claims for alprazolam ER (Xanax XR®) and alprazolam ODT (Niravam®) will deny at POS for beneficiaries 17 years old or younger on the date of service.

**Diagnosis Code Requirements**

Pharmacy claims for alprazolam ER (Xanax XR®) and alprazolam ODT (Niravam®) require a diagnosis code. The diagnosis code must be documented by the prescriber or pharmacist. The diagnosis code may be communicated to the pharmacist electronically, via telephone, or facsimile. After consultation with the prescriber, the pharmacist must document the diagnosis code on the hard copy prescription or in the pharmacy's electronic recordkeeping system. The diagnosis code is required for the claim submission.

Acceptable diagnosis codes for alprazolam ER (Xanax XR®) are:

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

ICD-10-CM Diagnosis Code	Description
F40.01	Panic Disorder with Agoraphobia
F41.0	Panic Disorder without Agoraphobia

Acceptable diagnosis codes for alprazolam ODT (Niravam®) are:

ICD-10-CM Diagnosis Code	Description
F41.1	Generalized Anxiety Disorder
F40.01	Panic Disorder with Agoraphobia
F41.0	Panic Disorder without Agoraphobia

**Quantity Limits**

There is a quantity limit of 30 units per rolling 30 days for alprazolam ER (Xanax XR®).

**Analeptics: Armodafinil (Nuvigil®), Modafinil (Provigil®), Pitolisant (Wakix®), and Solriamfetol (Sunosi®)****Age Restriction**

Pharmacy claims for armodafinil (Nuvigil®) and modafinil (Provigil®) will deny at POS when the beneficiary is 16 years of age or younger.

Pharmacy claims for solriamfetol (Sunosi®) and pitolisant (Wakix®) will deny at POS when the beneficiary is less than 18 years old.

**Diagnosis Code Requirements**

Pharmacy claims for armodafinil (Nuvigil®) and modafinil (Provigil®) require an appropriate diagnosis code documented on the hardcopy prescription or in the pharmacy's electronic recordkeeping system by the prescriber or pharmacist. The diagnosis code may be communicated to the pharmacist electronically, via telephone, or facsimile. After consultation with the prescriber, the pharmacist must document the diagnosis code on the hard copy prescription or in the pharmacy's electronic recordkeeping system. The diagnosis is required for claim submission.

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

The appropriate diagnosis codes are listed in the chart:

Medication	Description of Diagnosis	ICD-10-CM Diagnosis Code
Armodafinil (Nuvigil®); Modafinil (Provigil®)	Obstructive Sleep Apnea	G47.33
	Circadian rhythm sleep disorder, shift work type	G47.26
	Narcolepsy	G47.4*
Solriamfetol (Sunosi™)	Obstructive Sleep Apnea	G47.33
	Narcolepsy	G47.4*
Pitolisant (Wakix®)	Narcolepsy	G47.4*

\* Any number or letter or combination of **UP TO FOUR** numbers and letters of an assigned ICD-10-CM diagnosis code

**Therapeutic Duplication**

Pharmacy claims for armodafinil (Nuvigil®) and modafinil (Provigil®) will deny at POS when there is an active claim on the beneficiary's file for either armodafinil (Nuvigil®) or modafinil (Provigil®).

**Therapeutic Duplication with Stimulants**

Pharmacy claims for armodafinil (Nuvigil®) and modafinil (Provigil®) will deny at POS when there is an active claim on the beneficiary's file for other stimulants or atomoxetine (Strattera®).

Pharmacy claims for solriamfetol (Sunosi®) or pitolisant (Wakix®) will deny at POS when there is an active claim on the beneficiary's file for either solriamfetol (Sunosi®), pitolisant (Wakix®), modafinil (Provigil®) or armodafinil (Nuvigil®). Also, modafinil (Provigil®) and armodafinil (Nuvigil®) should deny at POS when there is an active claim on the beneficiary's file for either solriamfetol (Sunosi®) or pitolisant (Wakix®).

Pharmacy claims for solriamfetol (Sunosi®) or pitolisant (Wakix®) will deny if there is an active claim on the beneficiary's file for another stimulant or atomoxetine (Strattera®).

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142****Concurrent Use with Sedative Hypnotics**

Pharmacy claims for armodafinil (Nuvigil®) and modafinil (Provigil®) will deny at POS when there is an active claim on the beneficiary's file for a sedative hypnotic.

If in the professional judgment of the prescriber a determination is made which necessitates therapy with modafinil (Provigil®) or armodafinil (Nuvigil®) and a sedative hypnotic, the pharmacist may override this edit. After consultation with the prescriber to verify the necessity of both agents, the pharmacist must document on the hardcopy prescription the prescriber's reason for concurrent therapy. The reason for service code, professional service code and result of service code used in submitting the claim must also be documented on the hardcopy prescription or in the pharmacy's electronic recordkeeping system.

Pharmacy claims for solriamfetol (Sunosi®) or pitolisant (Wakix®) will deny if there is an active claim on the beneficiary's file for a sedative hypnotic. Pharmacy claims for a sedative hypnotic will deny if there is an active claim on the beneficiary's file for solriamfetol (Sunosi®) or pitolisant (Wakix®).

**Agalsidase Beta (Fabrazyme®)**

Pharmacy claims for agalsidase beta (Fabrazyme®) require a diagnosis code for reimbursement.

ICD-10-CM Diagnosis Code	Diagnosis Description
E75.21	Fabry (-Anderson) Disease

A pharmacy claim for agalsidase beta (Fabrazyme®) will deny with a therapeutic duplication if there is an active claim on the beneficiary's file for migalastat (Galafold®). Conversely, pharmacy claims for migalastat (Galafold®) will deny with a therapeutic duplication if there is an active claim on the beneficiary's file for agalsidase beta (Fabrazyme®).

**Alglucosidase (Lumizyme®)**

Pharmacy claims for alglucosidase (Lumizyme®) require a diagnosis code for reimbursement.

ICD-10-CM Diagnosis Code	Diagnosis Description
E74.02	Pompe Disease

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142****Amikacin Inhalation Suspension (Arikayce®)**

Pharmacy claims for amikacin inhalation suspension (Arikayce®) require a diagnosis code for reimbursement.

ICD-10-CM Diagnosis Code	Diagnosis Description
A31.0, A31.2	Mycobacterium avium complex

**Anticoagulants**

Prescriptions for select anticoagulants are subject to the following clinical edits for reimbursement:

1. Quantity limits; and
2. Duration of therapy.

**Quantity Limits**

The quantity limits for anticoagulant agents are listed in the chart below:

Generic	Representative Brand	Dosage Form	Quantity Limit
Apixaban	Eliquis®	Tablet	60 units/30 days
Apixaban Starter Pack	Eliquis® Starter Pack	Tablet Dose Pack	1 unit/365 days
Dabigatran Etexilate Mesylate	Pradaxa®	Capsule	60 units/30 days
Dalteparin Sodium	Fragmin®	Vial/Syringe	60 units/30 days
Edoxaban Tosylate	Savaysa®	Tablet	30 units/30 days
Enoxaparin Sodium	Lovenox®	Vial/Syringe	60 units/30 days
Fondaparinux Sodium	Arixtra®	Syringe	30 units/30 days
Rivaroxaban 2.5mg	Xarelto®	Tablet	60 units/30 days
Rivaroxaban 10mg, 15mg & 20mg	Xarelto®	Tablet	30 units/30 days
Rivaroxaban Starter Pack	Xarelto® Starter Pack	Tablet Dose Pack	1 unit/365 days

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142****Duration of Therapy**

The duration of therapy for select anticoagulant agents are listed in the chart below:

Generic	Representative Brand	Maximum Duration of Therapy*
Dalteparin	Fragmin®	35 days
Enoxaparin	Lovenox®	35 days
Fondaparinux Sodium	Arixtra®	35 days

\*Maximum 35-day course of therapy within a 90-day period

**Antidepressant Medications**

Prescriptions for antidepressant medications will require an approved clinical authorization for beneficiaries under 6 years of age. Pharmacy claims for antidepressant medications will be checked for therapeutic duplication.

**Therapeutic Duplication**

Pharmacy claims for a tricyclic antidepressant will deny if there is an active claim on the beneficiary's file for a tricyclic antidepressant.

Pharmacy claims for selective serotonin reuptake inhibitors (SSRIs) will deny if there is an active claim on the beneficiary's file for a SSRI.

**Antihistamine/ Decongestant Products**

Prescribed single-entity antihistamines are covered for all beneficiaries. Antihistamine-decongestant combinations are covered for all beneficiaries when prescribed for the medically approved indication of allergic rhinitis (seasonal or perennial).

The program, in accordance with the Social Security Act Section 1927 (d) (2), excludes drugs or classes of drugs containing cough and cold agents when those products are prescribed for the treatment of cough and cold.

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142****Therapeutic Duplication**

Pharmacy claims for first and/or second generation antihistamines and antihistamine-decongestant products will deny if there is an active claim on the beneficiary's file for another first and/or second generation antihistamine or antihistamine-decongestant product. A change in therapy from an antihistamine to an antihistamine-decongestant or the reverse will have override provisions.

**Exclusions**

Claims for diphenhydramine, hydroxyzine HCL, and hydroxyzine pamoate are excluded from the therapeutic duplication.

After consultation with the prescribing provider, the pharmacist may override the therapeutic duplication. The pharmacist must document on the hardcopy prescription or in the pharmacy's electronic recordkeeping system the following:

1. The reason the prescribing provider chose to override the therapeutic duplication; and
2. The National Council for Prescription Drug Program (NCPDP) DUR override codes used in submitting the claim.

**NOTE:** Refer to "Prospective Drug Utilization Policies/Limits/Edits" in this section for policy regarding first and second generation antihistamines and combination agents included in the therapeutic duplication edit.

**Anti-Infective, Anti-Fungal, and Corticosteroids**

Pharmacy claims for select anti-infective, anti-fungal, and corticosteroids have quantity limits.

Medication	Dosage Form	Quantity Limit
Ciclopirox Olamine 0.77%	Suspension	60ml/30 days
Ciprofloxacin HCl 0.2%	Otic Solution	2 packs of 14 singles/30 days
Clobetasol Propionate 0.05%	Cream	100gm/30 days
Clobetasol Propionate 0.05%	Ointment	120gm/30 days
Clobetasol Propionate 0.05%	Solution	100ml/30 days
Doxycycline Hyclate / Monohydrate	Capsule	60 caps of any strength/30 days



**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

Econazole Nitrate 1%	Cream	85gm/30 days
Gentamicin Sulfate 0.3%	Ophthalmic Ointment	3.5gm/30 days
Gentamicin Sulfate 0.3%	Ophthalmic Solution	5ml/30 days
Gentamicin Sulfate 0.1%	Cream	30gm/30 days
Gentamicin Sulfate 0.1%	Ointment	30gm/30 days
Itraconazole 100mg	Capsule	120 caps/30 days
Itraconazole 100mg	Capsule Pulsepak	1 pack (28 caps) / 28 days
Itraconazole 65mg	Capsule	120 caps/30 days
Ketoconazole 2%	Shampoo	120ml/30 days
Ketoconazole 2%	Cream	60gm/30 days
Mupirocin 2%	Cream	30gm/30 days
Mupirocin 2%	Ointment	22gm/30 days
Nystatin 100,000 units/gm	Cream	60gm/30 days
Nystatin 100,000 units/gm	External Powder	60gm bottle; 2 bottles/30 days
Nystatin 100,000 units/gm	Ointment	60gm/30 days

**Antiretroviral Agents**

Pharmacy claims for select antiretroviral agents require a diagnosis code for reimbursement.

The following chart lists acceptable diagnosis codes:

<b>ICD-10-CM Diagnosis Code</b>	<b>Diagnosis Description</b>
B16.1	Acute hepatitis B with delta-agent without hepatic coma
B16.2	Acute hepatitis B without delta-agent with hepatic coma
B16.9	Acute hepatitis B w/o delta-agent and without hepatic coma
B18.0	Chronic viral hepatitis B with delta-agent
B18.1	Chronic viral hepatitis B without delta-agent
B19.1	Unspecified viral hepatitis B
B19.10	Unspecified viral hepatitis B without hepatic coma
B19.11	Unspecified viral hepatitis B with hepatic coma

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

<b>ICD-10-CM Diagnosis Code</b>	<b>Diagnosis Description</b>
B20	Human immunodeficiency virus [HIV] disease
B97.35	Human immunodeficiency virus, type 2 [HIV 2] as the cause of diseases classified elsewhere
W46.0XXA	Contact with hypodermic needle (initial enc.)
W46.0XXD	Contact with hypodermic needle (subsequent enc.)
W46.1XXA	Contact with contaminated hypodermic needle (initial enc.)
W46.1XXD	Contact with contaminated hypodermic needle (subsequent enc.)
Z20.2	Contact with and (suspected) exposure to infections with a predominantly sexual mode of transmission
Z20.6	Contact with and (suspected) exposure to HIV
Z20.828	Contact with and (suspected) exposure to other viral communicable diseases
Z20.89	Contact with and (suspected) exposure to other communicable diseases
Z20.9	Contact with and (suspected) exposure to unspecified communicable disease
Z22.51	Carrier of viral hepatitis B
Z72.5	High risk sexual behavior
Z72.51	High risk heterosexual behavior
Z72.52	High risk homosexual behavior
Z72.53	High risk bisexual behavior
Z77.21	Contact with and (suspected) exposure to potentially hazardous body fluids
Z77.9	Other contact with and (suspected) exposure hazardous to health

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142****Antisense Oligonucleotides: Nusinersen sodium (Spinraza®) and Eteplirsen (Exondys 51®)**

Pharmacy claims for nusinersen sodium (Spinraza®) and eteplirsen (Exondys 51®) will be subject to the following for reimbursement:

1. Clinical authorization; and
2. Diagnosis code requirements.

**Clinical Authorization Requirement**

Pharmacy claims for nusinersen sodium (Spinraza®) and eteplirsen (Exondys 51®) require an approved clinical authorization.

**Diagnosis Code Requirement**

The acceptable diagnosis codes for nusinersen sodium (Spinraza®) and eteplirsen (Exondys 51®) are listed in the chart.

Medication	Diagnosis	ICD-10-CM Diagnosis Code
Nusinersen Sodium (Spinraza®)	Spinal Muscular Atrophy	G12.0; G12.1
Eteplirsen (Exondys 51®)	Duchenne Muscular Dystrophy	G71.0

\* -- any number or letter or combination of UP TO FOUR numbers and letters of an assigned ICD-10-CM diagnosis code

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Antipsychotic Agents**

Pharmacy claims for antipsychotic medications are subject to the following clinical edits:

1. Diagnosis Code Requirement;

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

2. Age and Dosage Limits; and
3. Therapeutic Duplication.

**Diagnosis Code Requirement on All Antipsychotic Medications**

Prescriptions for antipsychotic agents require appropriate diagnosis codes documented on all prescriptions.

The numeric diagnosis code must be documented on the hardcopy prescription by either the prescriber or the pharmacist. The diagnosis code may be communicated to the pharmacist electronically, via telephone, or facsimile. After consultation with the prescriber, the pharmacist must document the diagnosis code on the hard copy prescription or in the pharmacy's electronic recordkeeping system. The diagnosis code is required for the claim submission.

Pharmacy claims for antipsychotic medications that have a missing or invalid diagnosis code will deny at POS.

**NOTE:** The ICD-10-CM Diagnosis Codes can be accessed by the following link to the Louisiana Medicaid Single PDL for Fee-for-Service and Managed Care Organizations at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf> or by visiting Section 37.5.1 of this manual chapter.

If the prescriber does not indicate a diagnosis code, and the pharmacist determines the beneficiary cannot wait to receive the medication, the pharmacy provider may override the denial. The pharmacist must document "Emergency" on the hard copy prescription or in the pharmacy's electronic recordkeeping system and the reason for the emergency.

Antipsychotic agents are also subject to prospective drug utilization reviews when a third antipsychotic agent is submitted for payment.

**Age and Dosage Limits**

Pharmacy claims for selected antipsychotic medications will be subject to age and dosage limits.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES**

---

**SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

---

**Quantity Limits**

Pharmacy claims for selected antipsychotic medications have quantity limits.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Therapeutic Duplication**

Pharmacy claims for a beneficiary with an active oral antipsychotic prescription on file will deny when an additional pharmacy claim for a second oral antipsychotic prescription is submitted.

Pharmacy claims for a beneficiary with an active injectable antipsychotic prescription on file will deny when an additional pharmacy claim for a second injectable antipsychotic prescription is submitted.

**Asenapine (Secuado®)**

Pharmacy claims for asenapine (Secuado®) will be subject to the following:

1. Maximum daily dose;
2. Quantity limit; and
3. Therapeutic duplication.

**Maximum Daily Dose**

Pharmacy claims for asenapine (Secuado®) for beneficiaries 0-17 years of age will deny at POS when the maximum daily dose exceeds 0 mg.

**Quantity Limit**

Pharmacy claims for asenapine (Secuado®) will have a quantity limit of 30 patches per 30 days.

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES**

---

**SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

---

**Therapeutic Duplication**

A pharmacy claim for asenapine (Secuado<sup>®</sup>) will deny with a therapeutic duplication if the beneficiary has an active prescription on file for any traditional and/or atypical oral antipsychotic. Conversely, a pharmacy claim submitted for a traditional or atypical oral antipsychotic will deny if the beneficiary has an active prescription on file for asenapine (Secuado<sup>®</sup>).

**Attention Deficit Disorder (ADD) and Attention Deficit Hyperactivity Disorder (ADHD) Agents**

Prescriptions for Attention Deficit Disorder (ADD) and Attention Deficit Hyperactivity Disorder (ADHD) agents will require an appropriate diagnosis code for reimbursement. ADD/ADHD will be checked for therapeutic duplication.

The numeric diagnosis code must be documented on the hardcopy prescription by either the prescriber or the pharmacist. The diagnosis code may be communicated to the pharmacist electronically, via telephone, or facsimile. After consultation with the prescriber, the pharmacist must document the diagnosis code on the hard copy prescription or in the pharmacy's electronic recordkeeping system. The diagnosis code is required for the claim submission.

Pharmacy claims for ADD and ADHD medications that have a missing or invalid diagnosis code will deny at POS.

When beneficiaries are established on ADD/ADHD medications, but the diagnosis codes submitted are not included in the table of covered diagnoses, prescribing providers may call the RxPA Unit (Refer to Section 37.5.4 for contact information.)

**NOTE:** Refer to the link to access the *POS User Guide* for detailed billing instructions at: [www.lamedicaid.com/Provweb1/Pharmacy/LAPOS\\_User\\_Manual\\_static.pdf](http://www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf)

**Therapeutic Duplication**

Pharmacy claims for ADD/ADHD medications will be subject to a therapeutic duplication.

An incoming pharmacy claim for a short-acting ADD/ADHD medication will deny when there is an active claim on file for another short-acting ADD/ADHD medication. An incoming claim for

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES**

---

**SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

---

a long-acting ADD/ADHD medication will deny when there is an active claim on file for another long-acting ADD/ADHD medication.

An incoming pharmacy claim for an ADD/ADHD medication will deny when there is an active claim on file for another ADD/ADHD medication written by a different prescriber.

**Behavioral Health Medications for Beneficiaries 6 Years of Age and Younger**

Pharmacy claims for behavioral health medications for beneficiaries 6 years of age and younger require an approved clinical authorization for reimbursement.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access the Single Preferred Drug List (PDL), which is inclusive of the preferred/non-preferred drug list, clinical authorization list, drug specific forms, criteria, and POS edits (i.e. maximum daily dose and quantity limits) at:

<http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Clinical Authorization for ADD/ADHD Medications for Beneficiaries Less Than 6 years of Age**

Pharmacy claims for ADD/ADHD medications for beneficiaries less than 6 years of age require an approved clinical authorization for reimbursement.

**Buprenorphine and Buprenorphine/Naloxone Agents (Bunavail, Suboxone®, and Zubsolv®)**

Prescriptions for buprenorphine and buprenorphine/naloxone agents (i.e. Bunavail®, Suboxone®, and Zubsolv®) are only reimbursed when the following criteria are met:

1. The prescriber is a physician;
2. The physician has an X Drug Enforcement Administration (DEA) number;
3. The prescriber is licensed to prescribe buprenorphine and buprenorphine/naloxone agents (i.e. Bunavail®, Suboxone®, and Zubsolv®) and has provided a copy of his/her current Controlled Substance Registration Certificate indicating the X DEA number and a copy of a Provider Enrollment File Update Form to Provider Enrollment;

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

4. Concurrent prescriptions for opioid analgesics and/or benzodiazepines are only reimbursed when written by the same physician who prescribed the buprenorphine or buprenorphine/naloxone;
5. Beneficiaries must be sixteen years of age or older;
6. Prescriptions for Suboxone® (buprenorphine/naloxone) are allowed a maximum daily dose of 24mg/day (based on buprenorphine);
7. Prescriptions for buprenorphine agents are allowed a maximum daily dose of 24mg/day; and
8. Prescriptions for Zubsolv® are allowed a maximum of up to 17.1 mg/day (based on buprenorphine) per beneficiary for an initial 90 consecutive day period. After the initial 90 day period, a maximum daily dose of up to 11.4 mg/day (based on buprenorphine) is allowed per beneficiary.

**Diagnosis Code Requirement**

Prescriptions for buprenorphine agents require an appropriate diagnosis code documented on the hard copy prescription after written or verbal consultation with the physician. The diagnosis code is required for the claim submission.

Acceptable diagnosis codes are as follows:

ICD-10-CM Diagnosis Code(s)	Description
F11.2*	Opioid Type Dependence

\* - any number or letter or combination of UP TO FOUR numbers and letters of an assigned ICD-10-CM diagnosis code

Buprenorphine Agents are also subject to prospective drug utilization reviews when concurrent opioid analgesics (i.e. Suboxone, and Zubsolv®) are written by the same physician.

**NOTE:** Refer to “Prospective Drug Utilization Policies/Limits/Edits; Therapeutic Duplication” in this section for further policy as well as the *POS User Guide* accessed by visiting Section 37.5.1 for detailed billing information at:

[www.lamedicaid.com/Provweb1/Pharmacy/LAPOS\\_User\\_Manual\\_static.pdf](http://www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf)



**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142****Quantity Limits on Buprenorphine-Naloxone Products**

The quantity limits for buprenorphine/naloxone products are listed in the following chart:

Product	Dose Form Route	Buprenorphine/Naloxone Strength		Quantity Limit (units/day)
Bunavail®	Film Buccal	2.1mg	0.3mg	1
		4.2mg	0.7mg	2
		6.3mg	1mg	2
Buprenorphine/Naloxone	Tablet Sublingual	2mg	0.5mg	1
		8mg	2mg	2
Suboxone®	Film Sublingual	2mg	0.5mg	1
		4mg	1mg	1
		8mg	2mg	2
		12mg	3mg	2
Zubsolv®	Tablet Sublingual	1.4mg	0.36mg	1
		2.9mg	0.71mg	1
		5.7mg	1.4mg	1
		8.6mg	2.1mg	2
		11.4mg	2.9mg	1

**Concurrent Opioid Analgesic and/or Benzodiazepine Therapies**

1. Concurrent opioid analgesic, benzodiazepine, and/or any buprenorphine containing agent prescriptions written by a different prescriber for beneficiaries on a buprenorphine agent will deny. There are no override provisions through the POS system using NCPDP service codes;
2. Incoming prescriptions for buprenorphine agents will deny when there is an active prescription for any buprenorphine containing agent on the beneficiary's file. There are no override provisions through the POS system using NCPDP service codes; and
3. When a beneficiary has an active prescription for any opioid analgesic and/or any buprenorphine containing agent by the same prescriber, the incoming prescription will deny as a therapeutic duplication. The pharmacist must contact the physician

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

for his/her authorization to assure the physician wants concurrent therapy before overriding the denial edit and filling the incoming prescription.

**Buprenorphine Buccal Film (Belbuca®)**

Prescriptions for buprenorphine buccal film (Belbuca®) will be reimbursed when:

1. A valid diagnosis code is entered at claims submission; and
2. The maximum daily dose limit of 1800 mcg/day is not exceeded.

All diagnosis codes are acceptable **EXCEPT** for the following:

ICD-10-CM Diagnosis Code(s)	Description
F11.2*	Opioid Type Dependence

\* - any number or letter or combination of UP TO FOUR numbers and letters of an assigned ICD-10-CM diagnosis code

**Buprenorphine Extended-Release Injection (Sublocade®)**

Buprenorphine extended-release injection (Sublocade®) will be reimbursed when the following criteria is met:

1. Prescriber requirements;
2. Age requirements;
3. Diagnosis code requirements;
4. Quantity limits; and
5. Therapeutic duplication.

**Prescriber Requirements**

The prescriber is:

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

1. A physician;
2. Has an XDEA number; and
3. Is licensed to prescribe buprenorphine extended-release injection (Sublocade®) and has provided a copy of his/her current Controlled Substance Registration Certificate indicating XDEA number and a copy of a Provider Enrollment File Update form to Provider Enrollment.

**Age Requirements**

1. The patient must be 18 years of age or older.

**Diagnosis Code Requirements**

Prescriptions for buprenorphine agents require an appropriate diagnosis code entered at claim submission. The diagnosis code may be documented on the hard copy prescription or by the pharmacist after written or verbal consultation with the physician.

ICD-10-CM Diagnosis Code (s)	Description
F11.2*	Opioid Type Dependence

**Quantity Limits**

Buprenorphine extended-release injection (Sublocade®) have a quantity limit of one pre-filled syringe per rolling 30 days.

**Therapeutic Duplication**

When a patient has an active prescription for any opioid analgesic (including buprenorphine) written by the same prescriber, the incoming buprenorphine prescription will deny as a therapeutic duplication. **Override provisions are available.** The pharmacist will have to contact the physician for his/her authorization to verify the physician wants concurrent therapy.

---

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES**

---

**SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

---

Concurrent opioid analgesic and/or benzodiazepines prescriptions written by a different prescriber for patients on buprenorphine will deny. **There are no provisions for overrides.**

Incoming prescriptions for buprenorphine agents will deny when there is an active prescription for buprenorphine agents on the beneficiary's file. **There are no provisions for overrides.**

**NOTE:** The *POS User Guide* can be accessed by visiting Section 37.5.1 for detailed billing instructions and override procedures at:

[www.lamedicaid.com/Provweb1/Pharmacy/LAPOS\\_User\\_Manual\\_static.pdf](http://www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf)

**Buprenorphine Implant Kit (Probuphine®)**

Buprenorphine implant kit (Probuphine®) will be reimbursed when the following criteria is met:

1. Prescriber requirements;
2. Age requirements;
3. Diagnosis code requirements;
4. Quantity limits; and
5. Therapeutic duplication.

**Prescriber Requirements**

The prescriber is:

1. A physician;
2. Has an XDEA number; and
3. Is licensed to prescribe buprenorphine implant (Probuphine®) and has provided a copy of his/her current Controlled Substance Registration Certificate indicating XDEA number and a copy of a Provider Enrollment File Update form to Provider Enrollment.

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142****Age Requirements**

1. The patient must be 16 years of age or older.

**Diagnosis Code Requirements**

Prescriptions for buprenorphine agents require an appropriate diagnosis code entered at claim submission. The diagnosis code may be documented on the hard copy prescription or by the pharmacist after written or verbal consultation with the physician.

ICD-10-CM Diagnosis Code (s)	Description
F11.2*	Opioid Type Dependence

**Quantity Limits**

Buprenorphine implant kits (Probuphine®) have a quantity limit of two implant kits per 720 rolling days.

**Therapeutic Duplication**

When a patient has an active prescription for any opioid analgesic (including buprenorphine) written by the same prescriber, the incoming buprenorphine prescription will deny as a therapeutic duplication. **Override provisions are available.** The pharmacist will have to contact the physician for his/her authorization to verify the physician wants concurrent therapy.

Concurrent opioid analgesic and/or benzodiazepines prescriptions written by a different prescriber for patients on buprenorphine will deny. **There are no provisions for overrides.**

Incoming prescriptions for buprenorphine agents will deny when there is an active prescription for buprenorphine agents on the beneficiary's file. **There are no provisions for overrides.**

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

**NOTE:** The *POS User Guide* can be accessed by visiting Section 37.5.1 for detailed billing instructions and override procedures at:

[www.lamedicaid.com/Provweb1/Pharmacy/LAPOS\\_User\\_Manual\\_static.pdf](http://www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf)

**Buprenorphine Transdermal Patches (Butrans®)**

Pharmacy claims for Buprenorphine Transdermal Patches (Butrans®) require an appropriate diagnosis code for reimbursement. The diagnosis code must be written on the hardcopy prescription by the prescribing practitioner or by the pharmacist after consultation with the prescriber. Claims submitted without a diagnosis code or with a diagnosis code related to the management of addictive disorders or substance abuse will deny.

There is no provision to override the denial when the diagnosis code is related to the management of addictive disorders or substance abuse. When the prescribing provider does not indicate a diagnosis code on the prescription and when the prescriber cannot be reached, a denial for a missing diagnosis code may be overridden if the pharmacist determines that the beneficiary cannot wait to receive the medication.

When the cumulative daily dosage for Buprenorphine Transdermal Patches (Butrans®) exceeds the maximum daily dosage, the claim will deny. The maximum daily dosage for this agent is 480 mcg/24hr (20mcg/hr). Do not exceed a dose of one 20mcg/hr buprenorphine patch. Refer to prescribing information. Each patch is intended to be worn for seven days.

There is no provision for override through the POS system for Buprenorphine Transdermal Patches (Butrans®) when the maximum daily dosage is exceeded.

**Cannabidiol (Epidiolex®)**

Pharmacy claims for cannabidiol (Epidiolex®) have a prior use requirement (in a previous 365-day period) of the following:

1. **ONE** paid claim for cannabidiol (Epidiolex®); **OR**
2. A paid claim in the previous 365 days for at least **TWO** of the following agents (brand/generic or preferred/non-preferred formulations) below:
  - a. Clobazam;

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES**

---

**SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

---

- b. Felbamate;
- c. Lamotrigine;
- d. Levetiracetam;
- e. Rufinamide;
- f. Topiramate; and
- g. Valproate derivatives.

**Cariprazine (Vraylar®) and Cariprazine (Vraylar®) Therapy Pack****Dose Limit for cariprazine (Vraylar®)****Beneficiaries 15 Years of Age or Younger**

All pharmacy claims for any strength of cariprazine (Vraylar®) for beneficiaries 15 years of age or younger will deny.

**Beneficiaries 16 – 17 Years of Age**

Pharmacy claims for cariprazine (Vraylar®) for beneficiaries 16 – 17 years of age, with a dose greater than 4.5mg/day, will deny. Overrides will be addressed by faxing a Rx PA16 to the RXPA Unit.

**Beneficiaries 18 Years of Age or Older**

Pharmacy claims for cariprazine (Vraylar®) for beneficiaries 18 years of age or older, with a dose greater than 6 mg/day, will deny.

After consultation with the prescriber to verify the necessity of exceeding 6mg/day for beneficiaries 18 years of age and older, the pharmacist may override the denial. The reason for service code, professional service code and result of service code used in submitting the claim must be documented on the hardcopy prescription or in the pharmacy's electronic recordkeeping system.

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES**

---

**SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

---

**NOTE:** The *POS User Guide* can be accessed at: [www.lamedicaid.com/Provweb1/Pharmacy/LAPOS\\_User\\_Manual\\_static.pdf](http://www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf) or by visiting Section 37.5.1 for detailed billing instructions and override procedures.

**Age Limit for Cariprazine (Vraylar®) Therapy Pack****Beneficiaries 15 Years of Age or Younger**

All pharmacy claims for any strength of cariprazine (Vraylar®) therapy pack will deny for beneficiaries 15 years of age or younger. There are no override provisions through the POS system using NCPDP service codes.

**Quantity Limit for Cariprazine (Vraylar®) Therapy Pack**

Pharmacy claims for cariprazine (Vraylar®) therapy pack will have a quantity limit of one package per beneficiary (not to exceed one package per 18 months). There are no override provisions through the POS system using NCPDP service codes.

**Diagnosis Requirement for Cariprazine (Vraylar®) and Cariprazine (Vraylar®) Therapy Pack**

Pharmacy claims for cariprazine (Vraylar®) and cariprazine (Vraylar®) therapy pack require a valid diagnosis code submitted at POS. The diagnosis code must be documented on the hardcopy prescription or in the pharmacy's electronic recordkeeping system.

Prescribing providers may call Louisiana Medicaid RxPA Unit for guidance when beneficiaries are established on antipsychotic medications but the diagnosis codes submitted are not included in the table of covered diagnoses.

When the diagnosis code written on the prescription is not included in the list of covered diagnoses, and when the pharmacist cannot reach the prescriber or when the RxPA Unit is closed, the pharmacist, using his/her professional judgment, may deem the filling of the antipsychotic prescription to be an "emergency". In these emergency cases, the pharmacist must indicate "Emergency Prescription" on the hardcopy prescription or in the pharmacy's electronic recordkeeping system and may override the diagnosis code requirement.



**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142****Prior Use for Cariprazine (Vraylar®) and Lurasidone (Latuda®)**

Pharmacy claims for cariprazine (Vraylar®) and lurasidone (Latuda®) will be approved at POS if there is evidence of prior use of the requested medication or a preferred generic antipsychotic agent.

If there is no evidence of prior use of the requested medication or a preferred generic antipsychotic agent within the previous 90 days, claims submitted for cariprazine (Vraylar®) and lurasidone (Latuda®) will reject due to a prior use of a preferred generic requirement.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access the Single Preferred Drug List (PDL), which is inclusive of the preferred/non-preferred drug list, clinical authorization list, drug specific forms, criteria, and POS edits (i.e. maximum daily dose and quantity limits) at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Carisoprodol**

Pharmacy claims for carisoprodol will deny when the quantity exceeds 90 tablets per rolling 90 days. The quantity limit is cumulative and applies to all strengths and combinations of carisoprodol. The pharmacy claim will deny as exceeding the program's maximum allowed. **There are no provisions for overrides.**

**Cefiderocol (Fetroja)**

Pharmacy claims for cefiderocol (Fetroja®) have a clinical authorization requirement.

**Codeine**

Pharmacy claims for products containing codeine have an age limit for reimbursement. The acceptable age limits are listed in the chart.

Description	Age (Y=Year)
Codeine (Single Ingredient)	≥18 Y

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

Codeine Combination Product	≥12 Y
-----------------------------	-------

**Collagenase Topical (Santyl®)**

Prescriptions for collagenase topical (Santyl®) will have a quantity limit of seven (7) 90 gram tubes per prescription, for a total of 630 grams.

**Contraceptive Agents****Drospirenone/Ethinylestradiol/Levomefolate Calcium (Beyaz®)**

Pharmacy claims for Drospirenone/Ethinyl Estradiol/Levomefolate Calcium (Beyaz®) require an appropriate diagnosis code for reimbursement. Claims submitted with diagnosis codes for cosmetic indications will deny.

**Etonogestrel (Nexplanon®)**

Pharmacy claims for Etonogestrel (Nexplanon®) will be limited to one implant every two years.

If the prescriber chooses to exceed the quantity limit for Etonogestrel (Nexplanon®), the pharmacist may override the limit after consultation with the prescribing practitioner. The pharmacist must document the NCPDP override codes and reason for the override on the hardcopy prescription or in the pharmacy's electronic recordkeeping system.

**Etonogestrel/Ethinyl Estradiol Vaginal Ring (Nuvaring®)**

Prescription claims for Etonogestrel/Ethinyl Estradiol vaginal ring (Nuvaring®) for quantities of four and greater will deny. There is no provision for override as these claims exceed the program maximum of a 100 day supply.

In addition, there will be a valid days' supply range dependent on the quantity billed:

1. If quantity = 1, then Days' Supply must be 21 to 28;
2. If quantity = 2, then Days' Supply must be 42 to 56; and
3. If quantity = 3, then Days' Supply must be 63 to 84.

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

Pharmacists are allowed to override the denial on days' supply after consultation with the prescriber.

**NOTE:** The *POS User Guide* can be accessed by visiting Section 37.5.1 for detailed billing instructions and override procedures at:

[www.lamedicaid.com/Provweb1/Pharmacy/LAPOS\\_User\\_Manual\\_static.pdf](http://www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf)

**Oral Contraceptive Agents**

Oral contraceptive agents will have an age limit of 12-55 years of age per program policy for legacy Medicaid.

Pharmacy claims for oral contraceptive agents are subject to an **educational alert** encouraging the submission of a diagnosis code at POS. The acceptable diagnosis codes for oral contraceptives as a family planning benefit or for menstrual disorders are listed in the chart.

ICD-10-CM Diagnosis Code	Diagnosis Description
Z30*	Encounter for oral contraceptive management
F32.81	Premenstrual dysphoric disorder
N92*	Excessive, frequent and irregular menstruation

\*any number or letter or combination of UP TO FOUR numbers and letters of an assigned ICD-10-CM diagnosis code.

**Medroxyprogesterone Acetate Injectable**

Prescription claims for Medroxyprogesterone Acetate injectable for female beneficiaries billed with a quantity of one and a days' supply less than 84 will deny. Quantities of two and greater will not be payable with no provision for override as they exceed the program maximum of a 100 days' supply.

Claims for Medroxyprogesterone Acetate sub-q 104 injectable for female beneficiaries, billed with a quantity of 0.65 and a days' supply less than 84, will deny. Quantities of 1.3 and greater will not be payable, with no provision for override, as they exceed the program maximum of a 100 days' supply.

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

Pharmacists are allowed to override the denial on days' supply after consultation with the prescriber.

**NOTE:** The *POS User Guide* can be accessed by visiting Section 37.5.1 for detailed billing instructions and override procedures at:

[www.lamedicaid.com/Provweb1/Pharmacy/LAPOS\\_User\\_Manual\\_static.pdf](http://www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf)

**Norelgestromin /Ethinyl Estradiol Transdermal Patches (Ortho-Evra) ®)**

Reimbursement of these contraceptive transdermal patches when dispensed using the package size of three must be billed in multiples of three. If the quantity billed is not a multiple of three, the claim will deny. There are no provisions for override.

**Crisaborole (Eucrisa®)**

Pharmacy claims for crisaborole (Eucrisa®) are subject to a quantity limit of 300 gm per rolling 365 days.

Pharmacy claims for crisaborole (Eucrisa®) are also subject to a prior use edit. If there is no evidence of prior use of crisaborole (Eucrisa®), a topical corticosteroid or a topical calcineurin inhibitor within the previous 180 days, pharmacy claims submitted for crisaborole (Eucrisa®), will deny.

**Cytokine and Cell-Adhesion Molecule (CAM) Antagonists**

Prescriptions for cytokine and cell-adhesion molecule (CAM) antagonists will be reimbursed when the prescriber has obtained an approved clinical authorization.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Cystic Fibrosis Agents**

Pharmacy claims for select oral agents for the treatment of cystic fibrosis require prior authorization.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142****Deferasirox (Exjade®, Jadenu®)**

Pharmacy claims for deferasirox (Exjade®, Jadenu®) are subject to diagnosis code requirements and age limitations.

**Beneficiaries 2 years of age and less**

Pharmacy claims for deferasirox (Exjade®, Jadenu®) will deny for beneficiaries 2 years of age or less.

**Beneficiaries 2-9 years of age**

Pharmacy claims for deferasirox (Exjade®, Jadenu®) require a valid diagnosis code for reimbursement. The diagnosis code must be documented on the hard copy prescription or in the pharmacy's electronic recordkeeping system. The pharmacist can document the diagnosis code after electronic or verbal consultation with the prescribing practitioner.

**Beneficiaries 10 years of age and older**

Pharmacy claims for deferasirox (Exjade®, Jadenu®) require a valid diagnosis code for reimbursement. The diagnosis code must be documented on the hard copy prescription or in the pharmacy's electronic recordkeeping system. The pharmacist can document the diagnosis code after electronic or verbal consultation with the prescribing practitioner.

The appropriate diagnosis codes for deferasirox (Exjade®) are listed in the chart:

Covered Indications at POS	ICD-10-CM Diagnosis Code
<b>2-9 years of age</b>	
Chronic iron overload due to blood transfusion	E83.111
<b>10 years of age and older</b>	
Chronic iron overload due to blood transfusion	E83.111
Chronic iron overload in non-transfusion-dependent thalassemia (NTDT) syndromes	D56.0, D56.1, D56.5, D56.8, D57.4*

\* - any number or letter or combination of UP TO FOUR numbers and letters of an assigned ICD-10-CM diagnosis code

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142****Desmopressin (Nocdurna®)**

Pharmacy claims for desmopressin (Nocdurna®) have a quantity limit.

Generic Name	Brand Name	Quantity Limit
Desmopressin	Nocdurna®	30 tablets/day

**Diabetic Testing Supplies**

The Pharmacy Program reimburses claims for prescribed diabetic testing supplies. Diabetic testing supplies will have a diagnosis code requirement and quantity limit.

Diagnosis Description	ICD-10-CM Diagnosis Code	Quantity Limit
Diabetes Due to Other Conditions or Causes	E08*, E09*, E013*	100/102 Test Strips/90 days and 100/102 Lancets/90 days
Type 2 Diabetes Mellitus	E11*	
Type 1 Diabetes Mellitus	E10*	
Gestational Diabetes; Diabetes Mellitus in Pregnancy	O24.4*; O24*	200/204 Test Strips/30 days and 200/204 Lancets/30 days
Long-Term (Current) Use of Insulin (Insulin Treated Non- Type 1 Diabetes Mellitus)	Z79.4*	

\*any number or letter or combination of UP TO FOUR numbers or letters of an assigned ICD-10-

CM diagnosis code. All diabetic supply claims submitted to Medicaid will deny when beneficiaries are Medicare Part B eligible. Medicare Part B covers diabetic supplies for all diabetic beneficiaries regardless of insulin requirements. Pharmacy providers shall submit these claims to the Medicare durable medical equipment regional carrier (DMERC). These claims will then automatically cross

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

over to the Medicaid fiscal intermediary for payment of the coinsurance and deductible amounts, where applicable.

Diabetic supplies and glucometers for long-term care beneficiaries are not covered in the Medicaid Pharmacy Program or through prior authorization because they are covered in the nursing facility per diem rate.

It is allowable for Medicare Part B to be billed if the long-term care beneficiary is eligible for the benefit. Medicaid is not obligated to pay the coinsurance and deductible if the items are included in the Medicaid per diem. The Medicaid fiscal intermediary will automatically deny any crossover claims for diabetic supplies for long-term care beneficiaries.

**NOTE:** Refer to Section 37.5.7 - Medicare Prescription Drug Coverage for detailed information.

**Dextromethorphan/Quinidine (Nuedexta®)**

Pharmacy claims for dextromethorphan/quinidine (Nuedexta®) are subject to the quantity limit listed in the chart.

Generic Name	Brand Name	Quantity Limit
Dextromethorphan/Quinidine	Nuedexta®	60 tablets/30 days

**Diroximel Fumarate (Vumerity®)**

Pharmacy claims for diroximel fumarate (Vumerity®) are subject to the quantity limit listed in the chart.

Generic Name	Brand Name	Quantity Limit
Diroximel Fumarate	Vumerity®	1 starter bottle (106 capsules)/365 days
		1 maintenance bottle (120 capsules)/30 days

**Dichlorphenamide (Keveyis®)**

Pharmacy claims for dichlorphenamide are subject to a quantity limit of 120 tablets/30 days.

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142****Dofetilide (Tikosyn®)**

Pharmacy claims for dofetilide (Tikosyn®) have a clinical authorization requirement.

**Doxepin Cream (Prudoxin®, Zonalon®)**

Pharmacy claims for doxepin cream will be subject to the following edits:

1. Diagnosis code requirement;
2. Age limit;
3. Quantity limit; and
4. Therapeutic duplication.

**Diagnosis Code Requirement**

Pharmacy claims for doxepin cream (Prudoxin®, Zonalon®) require a diagnosis code. The acceptable diagnosis codes are listed in the chart.

Generic Name	Brand Name	Description of Diagnosis	ICD-10-CM Diagnosis Code
Doxepin Cream	Prudoxin®, Zonalon®	Atopic Dermatitis	L20*
		Lichen Simplex Chronicus	L28.0

\*any number or letter or combination of UP TO FOUR numbers and letters of an assigned ICD-10-CM diagnosis code

**Age Limit**

Pharmacy claims for doxepin cream (Prudoxin®, Zonalon®) will deny when the beneficiary is less than 18 years old.

**Quantity Limit**

Pharmacy claims for doxepin cream (Prudoxin®, Zonalon®) will have a quantity limit of 45 grams per rolling 30 days.



**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142****Therapeutic Duplication**

Pharmacy claims for doxepin cream (Prudoxin®, Zonalon®) will deny with a therapeutic duplication if there is an active claim on the beneficiary's file for doxepin cream (Prudoxin®, Zonalon®).

**Eculizumab (Soliris®)**

Pharmacy claims for eculizumab (Soliris®) require a diagnosis code for reimbursement.

ICD-10-CM Diagnosis Code*	Diagnosis Description
D59.3	Hemolytic-uremic syndrome
D59.5	Paroxysmal nocturnal hemoglobinuria [Marchiafava-Micheli]
G36.0	Neuromyelitis Optica Spectrum Disorder (NMOSD)
G70.0	Myasthenia Gravis

\* - any number or letter or combination of UP TO FOUR numbers and letters of an assigned ICD-10-CM diagnosis code

**Edaravone (Radicava®)**

Pharmacy claims for edaravone (Radicava®) require a diagnosis code. The diagnosis code must be documented on the prescription or in the pharmacy's electronic recordkeeping system. The pharmacist can document the diagnosis code after electronic or verbal consultation with the prescribing practitioner.

Generic Name	Brand Name	Diagnosis	ICD-10-CM Diagnosis Code
Edaravone	Radicava ®	Amyotrophic lateral sclerosis	G12.21

**Epinephrine Injection (Generic, EpiPen®, and EpiPen Jr®)**

Prescriptions for epinephrine injection have the following quantity limits for reimbursement.

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

Medication	Quantity Limit
Epipen® (Brand and Generic) Epipen Jr® (Brand and Generic)	4 boxes of 2 syringes (8 syringes total) per rolling 365 days

**Esketamine Intranasal (Spravato®)**

Pharmacy claims for esketamine intranasal (Spravato®) require an approved clinical authorization for reimbursement.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access the Single Preferred Drug List (PDL), which is inclusive of the preferred/non-preferred drug list, clinical authorization list, drug specific forms, criteria, and POS edits (i.e. maximum daily dose and quantity limits) at:

<http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Elagolix (Orilissa®)**

Pharmacy claims for elagolix (Orilissa®) require an approved clinical authorization for reimbursement.

**Empagliflozin/Linagliptin/Metformin HCl (Trijardy®)**

Pharmacy claims for empagliflozin/linagliptin/metformin HCl (Trijardy®) are subject to the following:

1. Prior use requirement;
2. Quantity limits; and
3. Therapeutic Duplication.

**Prior Use Requirement**

An incoming claim for empagliflozin/linagliptin/metformin (Trijardy® XR), will deny if there is no evidence of one of the following in paid claims:

1. At least a 90-day supply of ONE of the following in the previous 180-day period:

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

- a. Metformin AND either a DPP-4 or an SGLT2;
- b. A combination product of DPP-4/metformin or SGLT2/metformin; or
- c. At least a 60-day supply of empagliflozin/linagliptin/metformin (Trijardy® XR) in the previous 90-day period.

**Quantity Limit**

Pharmacy claims for empagliflozin/linagliptin/metformin HCl (Trijardy XR®) have the following quantity limits listed in the chart:

Generic Name	Brand Name	Quantity Limit
Empagliflozin/linagliptin/ metformin HCl	Trijardy® XR 10/5/1000	30 tablets / 30 days
	Trijardy® XR 25/5/1000	30 tablets / 30 days
	Trijardy® XR 5/2.5/1000	60 tablets / 30 days
	Trijardy® XR 12.5/2.5/1000	60 tablets / 30 days

**Therapeutic Duplication**

A pharmacy claim for empagliflozin/linagliptin/metformin HCl (Trijardy XR®) will deny at POS when there is an active claim on the beneficiary's file for another DPP-4 inhibitor or a SGLT2 Inhibitor. Conversely, a claim for a DPP-4 inhibitor or a SGLT2 Inhibitor will deny at POS when there is an active claim on the beneficiary's file for empagliflozin/linagliptin/metformin HCl (Trijardy XR®).

**Eptinezumab-jjmr (Vyepti™)**

Pharmacy claims for eptinezumab-jjmr (Vyepti™) have a quantity limit of 3 single dose vials (100 mg/mL)/90 days.

**Fertility Agents**

Fertility preparations, when they are used solely for the treatment of infertility, are not reimbursable. The drugs include Clomiphene citrate tablets 50mg, Urofollitropin ampules 75IU,

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

and Menotropins ampules 150IU and 75IU. If prescriptions for these products are prescribed for any indications other than infertility, the physician shall certify the indication, in his own handwriting, on the prescription. In order for the pharmacist to be reimbursed for the product, a hard copy claim along with a copy of the original prescription will have to be submitted to the fiscal intermediary for processing indicating a diagnosis other than infertility.

**Galcanezumab Injection (Emgality®)**

Prescriptions for galcanezumab-gnlm (Emgality®) 100 mg single-dose pen/syringe will have a quantity limit of one (1) carton of three (3) single-dose syringes per 30 days.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions.

**Givosiran (Givlaari®)**

Pharmacy claims for Givosiran (Givlaari®) have a clinical authorization requirement.

**Granulocyte Colony Stimulating Factor Agents (GCSF)**

The GCSF agents are listed in the following chart:

<b>Granulocyte Colony Stimulating Factor (GCSF) Agents</b>
Filgrastim (Neupogen®)
Filgrastim-aafi (Nivestym®)
Filgrastim-sndz (Zarxio®)
Pegfilgrastim (Neulasta®)
Pegfilgrastim-jmdb (Fulphila®)
Sargramostim (Leukine®)
Tbo-filgrastim (Granix®)

Prescriptions for Granulocyte Colony Stimulating Factor agents will be reimbursed when the prescriber has obtained an approved clinical authorization.

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES**

---

**SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND  
EXCLUSIONS****PAGE(S) 142**

---

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Growth Hormone**

Prescriptions for Growth Hormone will be reimbursed when:

1. The prescriber has obtained an approved clinical authorization; and
2. An acceptable diagnosis code has been submitted with the pharmacy claim.

**Diagnosis Code Requirement**

Pharmacy claims for Growth Hormone will require an acceptable diagnosis code for reimbursement.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Hepatitis C Virus Direct-Acting (DAA) Antiviral Agents**

Hepatitis C Direct Acting Antiviral Agent(s) may be subject to clinical edits.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Hemophilia Agents**

Pharmacy claims for select hemophilia agents have a diagnosis code requirement.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access the Single Preferred Drug List (PDL), which is inclusive of the preferred/non-preferred drug list, clinical authorization list, drug specific forms, criteria, and POS edits (i.e. maximum daily dose and quantity limits) at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142****Hereditary Angioedema (HAE) Agents**

Pharmacy claims for Hereditary Angioedema agents require an approved clinical pre-authorization for reimbursement. The select HAE agents are as follows:

1. C1 Inhibitor, Human Injection (Berinert®);
2. C1 Inhibitor, Human Injection (Cinryze®);
3. C1 Inhibitor, Human Injection (Haegarda®);
4. C1 Inhibitor (Recombinant) Injection (Ruconest®);
5. Ecallantide Injection (Kalbitor®);
6. Icatibant Acetate Injection (Firazyr®); and
7. Lanadelumab Injection (Takhzyro®).

Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Hormones**

Pharmacy claims for select hormones have a diagnosis code requirement. (See chart below).

Generic-Brand Example	Diagnosis	ICD-10-CM Diagnosis Code
Goserelin Acetate (1 month) – Zoladex® 3.6mg	Breast Cancer (Female)	C50.1*
	Dysfunctional Uterine Bleeding	N89.7, N92.5, N93.8
	Endometriosis	N80.*
	Prostate Cancer	C61
Goserelin Acetate (3 month) – Zoladex® 10.8mg Histrelin Acetate – Vantas® Leuprolide Acetate – Eligard®, Lupron Depot®	Prostate Cancer	C61

## CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES

## SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS

PAGE(S) 142

7.5mg, 22.5mg (3 month), 30mg (4 month), 45mg (6 month) Triptorelin Pamoate – Trelstar®		
Histrelin Acetate –Supprelin LA® Leuprolide Acetate – Lupron Depot– Ped®, Fensolvi® Triptorelin Pamoate – Triptodur®	Central Precocious Puberty	E30.1, E30.8
Leuprolide Acetate – Lupron®	Central Precocious Puberty	E30.1, E30.8
	Prostate Cancer	C61
Leuprolide Acetate – Lupron Depot® 3.75mg, 11.25mg (3 month)	Endometriosis	N80.*
	Uterine Leiomyoma	D25.*
Hydroxyprogesterone – Makena®, Generic, Authorized Generic	Pregnancy with History of Preterm–Labor	O09.21*
Nafarelin Acetate – Synarel®	Central Precocious Puberty	E30.1, E30.8
	Endometriosis	N80.*
Oral Contraceptives  <b>Educational alert:</b> At Point–of–Sale Suggests a diagnosis code if one is not submitted on the pharmacy claim  <b>Applies to FFS and All MCOs as of 10/1/18</b>	Premenstrual Dysphoric Disorder	F32.81
	Excessive and Frequent Menstruation	N92*
	Encounter for Contraceptive Management	Z30*
Progesterone – Crinone®  <b>Applies to FFS and All MCOs as of 8/1/19</b>	Secondary Amenorrhea	N91.1*

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142****Hydroxyprogesterone Caproate (Makena®)**

Hydroxyprogesterone Caproate (Makena®) is a covered pharmacy and medical benefit.

Prescriptions for hydroxyprogesterone caproate (Makena®) require the following for reimbursement:

1. The prescriber has submitted an acceptable diagnosis code of O09.21\* Pregnancy with a history of pre-term labor;
2. The acceptable diagnosis code must be documented on the hardcopy prescription or in the pharmacy's electronic recordkeeping system. The diagnosis code may be communicated to the pharmacist from the prescriber (or prescriber's agent) electronically, via telephone, or facsimile; and
3. The acceptable diagnosis code must be submitted at POS.

When the prescriber does not indicate a diagnosis code on the prescription and the prescriber cannot be reached, a denial for a missing diagnosis code may be overridden by the pharmacist. The pharmacist must also document "Emergency Prescription" on the hardcopy prescription or in the pharmacy's electronic recordkeeping system.

**NOTE:** The *POS User Guide* can be accessed by visiting Section 37.5.1 for detailed billing instructions and override procedures at:

[www.lamedicaid.com/Provweb1/Pharmacy/LAPOS\\_User\\_Manual\\_static.pdf](http://www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf)

**Immune Globulin (Human)****Imiquimod**

Pharmacy claims for imiquimod require a diagnosis code. (See chart below).

Generic-Brand Example	Diagnosis	ICD-10-CM Diagnosis Code
Imiquimod – Zyclara® 2.5%	Actinic Keratosis	L57.0



**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

Imiquimod – Zyclara® 3.75%	Actinic Keratosis	L57.0
	External Genital Warts (Condylomata Acuminata)	A63.0
Imiquimod – Aldara® 5%	Actinic Keratosis	L57.0
	External Genital Warts (Condylomata Acuminata)	A63.0
	Superficial Basal Cell Carcinoma	C44.1*

\*any number or letter or combination of UP TO FOUR numbers and letters of an assigned ICD-10-CM diagnosis code

Pharmacy claims for select Immune Globulin (Human) agents have a clinical authorization requirement.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access the Single Preferred Drug List (PDL), which is inclusive of the preferred/non-preferred drug list, clinical authorization list, drug specific forms, criteria, and POS edits (i.e. maximum daily dose and quantity limits) at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Incretin Mimetic/Enhancers**

Prescriptions for incretin mimetic/enhancers are subject to the following:

1. Prior use of metformin or another incretin mimetic/enhancer;
2. Quantity limits; and
3. Maximum daily dose limits.

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142****Prior Use of Metformin Required**

An incoming pharmacy claim for an incretin mimetic/enhancer will require evidence of previous use of metformin or a paid claim for the requested medication or another medication within the same therapeutic class.

An incoming claim for an incretin mimetic/enhancer will deny if there is no evidence of a paid claim(s) for at least 90 days of metformin therapy OR there is no evidence of at least 60 days of paid claims for the requested medication (or another incretin mimetic/enhancer).

**Maximum Daily Dose Limit**

<b>Medication (Brand Name Example)</b>	<b>Maximum Dose</b>
Alogliptin (Nesina®)	25mg/day
Alogliptin/Metformin (Kazano®)	25mg/2000mg per day
Alogliptin/Pioglitazone (Oseni®)	25mg/45mg per day
Exenatide (Bydureon®, Bydureon® BCise™)	2mg/week
Exenatide (Byetta®)	20mcg/day
Linagliptin (Tradjenta®)	5mg/day
Linagliptin/Metformin (Jentadueto®, Jentadueto XR®)	5mg/2000mg per day
Liraglutide (Victoza®)	1.8mg/day
Lixisenatide (Adlyxin®, Adlyxin® Starter Kit)	20mcg/day
Pramlintide (Symlin®)	Type 1 diabetes: 60mcg SQ immediately prior to each major meal
	Type 2 diabetes: 120mcg SQ immediately prior to each major meal
Saxagliptin (Onglyza®)	5mg/day
Saxagliptin/Metformin ER (Kombiglyze XR®)	5mg/2000mg per day
Semaglutide (Ozempic®)	1mg/week
Sitagliptin (Januvia®)	100mg/day
Sitagliptin/Metformin (Janumet®, Janumet XR®)	100mg/2000mg per day

\*Authorization at POS is required to exceed maximum doses.

The maximum dose for select incretin mimetic/enhancers are listed in the chart.

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142****Quantity Limit**

Medication (Brand Name Example)		Maximum Dose	
Dulaglutide (Trulicity®)		0.5 ml or 1 syringe per week	
Generic Name	Brand Name	Diagnosis	ICD-10-CM Diagnosis Code
Inotersen	Tegsedi®)	Polyneuropathy of hereditary transthyretin-mediated amyloidosis	E85.1

**Inotersen (Tegsedi®)**

Pharmacy claims for inotersen (Tegsedi®) require a diagnosis code. The diagnosis code must be documented on the prescription or in the pharmacy's electronic recordkeeping system. The pharmacist can document the diagnosis code after electronic or verbal consultation with the prescribing practitioner.

**Interferons**

Select interferons have a diagnosis code requirement. (See chart below).

Generic-Brand Example	Diagnosis	ICD-10-CM Diagnosis Code
Interferon Alfa-2B Recombinant – Intron A®	AIDS–Related Kaposi's Sarcoma	C46.*
	Chronic Hepatitis B	B18.0, B18.1
	Chronic Hepatitis C	B18.2
	External Genital Warts (Condylomata Acuminata)	A63.0
	Follicular Lymphoma	C82.*
	Hairy Cell Leukemia	C91.4*
	Melanoma	C43.*

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

Interferon Gamma-1B – Actimmune®	Chronic Granulomatous Disease	D71
	Malignant Osteopetrosis	Q78.2
Peginterferon Alfa-2A – Pegasys®	Chronic Hepatitis B	B18.0, B18.1
	Chronic Hepatitis C	B18.2
Peginterferon Alfa-2B – Sylatron®	Melanoma	C43.*

\*any number or letter or combination of UP TO FOUR numbers and letters of an assigned ICD-10-CM diagnosis code

**Isotretinoin**

Isotretinoin capsules will be covered only if a handwritten prescription signed by the prescribing practitioner, with no provisions for refills, is submitted.

**Ivermectin (Stromectol®)**

Pharmacy claims for ivermectin (Stromectol®) require an approved diagnosis code for reimbursement at POS.

**Ketorolac**

Pharmacy claims for oral forms of ketorolac will deny for a quantity greater than 20 or the day supply is greater than five days as exceeding the program's maximum allowed. The pharmacist may override the denial after consultation with the prescriber. The prescriber must supply the diagnosis code and the rationale for using greater than a five day supply of ketorolac. The diagnosis code is required for the claim submission.

**NOTE:** The *POS User Guide* can be accessed by visiting Section 37.5.1 for detailed billing instructions and override procedures at:

[www.lamedicaid.com/Provweb1/Pharmacy/LAPOS\\_User\\_Manual\\_static.pdf](http://www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf)

**Lasmiditan (Reyvow®)**

Pharmacy claims for lasmiditan (Reyvow®) have a quantity limit of 8 tablets per 30 days.

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES**

---

**SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

---

**Lefamulin (Xenleta™)**

Pharmacy claims for lefamulin (Xenleta™) have a clinical authorization requirement.

**Lemborexant (Dayvigo™)**

Pharmacy claims for lemborexant (Dayvigo™) have a quantity limit of 7 tablets / 30 days and maximum daily dose of 10 mg/day.

**L-glutamine oral powder (Endari®)**

Pharmacy claims for l-glutamine oral powder (Endari®) require an approved clinical authorization for reimbursement.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Linezolid (Zyvox®)**

Prescriptions for linezolid (Zyvox®) injections, tablets, and oral suspension will only be reimbursed when the prescriber has obtained an approved clinical authorization.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Lipotropics: Lomitapide (Juxtapid®), Mipomersen (Kynamro®), Alirocumab (Praluent®), and Evolocumab (Repatha®)**

Prescriptions for lomitapide (Juxtapid®), mipomersen (Kynamro®), alirocumab (Praluent®), and evolocumab (Repatha®) will be reimbursed when:

1. The prescriber has obtained an approved clinical authorization.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND  
EXCLUSIONS****PAGE(S) 142****Lumacaftor/Ivacaftor (Orkambi®)****Clinical Authorization**

Pharmacy claims for lumacaftor/ivacaftor (Orkambi®) will be reimbursed at POS when the prescriber has obtained an approved clinical authorization.

Override provisions should be addressed through the Clinical Authorization process.

**Diagnosis Code Requirements**

Pharmacy claims for lumacaftor/ivacaftor (Orkambi®) require a valid ICD-10-CM diagnosis code. The diagnosis code must be documented on the hardcopy prescription or in the pharmacy's electronic recordkeeping system. The following table lists the acceptable diagnosis code for lumacaftor/ivacaftor (Orkambi®).

Diagnosis	ICD-10-CM Diagnosis Code(s)
Cystic fibrosis	E84.*

\* - any number or letter or combination of UP TO FOUR numbers and letters of an assigned ICD-10-CM diagnosis code

Lumacaftor/ivacaftor (Orkambi®) claims submitted at POS without a valid diagnosis code will deny.

Prescribing providers may call the RxPA Unit for guidance when beneficiaries are established on medications but the ICD-10-CM diagnosis code(s) submitted are not included in the covered diagnoses.

When the diagnosis code written on the prescription is not included in the list of covered diagnoses AND when the pharmacist cannot reach the prescriber OR when the RxPA Unit is closed, the pharmacist, using his/her professional judgment, may deem the filling of the prescription to be an "emergency". In these emergency cases, the pharmacist must indicate "Emergency Prescription" on the hardcopy prescription or in the pharmacy's electronic recordkeeping system AND may override the diagnosis code requirement.

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142****Lumateperone (Caplyta™)**

Prescriptions for lumateperone (Caplyta™) are subject to the following edits:

1. Clinical authorization;
2. Diagnosis Code Requirement;
3. Maximum Daily Dose; and
4. Therapeutic Duplication.

**Clinical Authorization Requirement**

Pharmacy claims submitted for lumateperone (Caplyta™) will require a clinical authorization for beneficiaries 0-5 years old.

**Diagnosis Code Requirement**

Pharmacy claims for lumateperone (Caplyta™) require a valid diagnosis code at POS.

Diagnosis	ICD-10-CM Diagnosis Code
Schizophrenia	F20.*

\* any number or letter or combination of UP TO FOUR numbers and letters of an assigned ICD-10-CM diagnosis code

**Maximum Daily Dose Limit**

Pharmacy claims submitted for lumateperone (Caplyta™) for beneficiaries 6-17 years old will deny.

Pharmacy claims submitted for lumateperone (Caplyta™) for beneficiaries 18 years old or older will deny when the dose exceeds 42mg/day.

**Therapeutic Duplication**

Pharmacy claims for lumateperone (Caplyta™) will deny if the beneficiary has an active prescription on file for a traditional or atypical oral antipsychotics. Pharmacy claims submitted

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

for a traditional or atypical oral antipsychotic will deny if the beneficiary has an active prescription on file for lumateperone (Caplyta™).

**Monoclonal Antibodies (Respiratory): Benralizumab Injection (Fasenra®), Mepolizumab Injection (Nucala®), Omalizumab (Xolair), and Reslizumab Injection (Cinqair®)****Benralizumab Injection (Fasenra®), Mepolizumab Injection (Nucala®), Reslizumab Injection (Cinqair®)**

Prescriptions for benralizumab injection (Fasenra®), mepolizumab injection (Nucala®), and reslizumab injection (Cinqair®) will only be reimbursed when the prescriber has obtained an approved clinical authorization.

**Omalizumab (Xolair®)**

Prescriptions for omalizumab (Xolair®) will be reimbursed when the following criteria are met:

1. The prescriber has obtained prior authorization for the beneficiary to receive the omalizumab or the beneficiary has an existing prior authorization for omalizumab; and
2. The beneficiary is 12 years of age or older on the date of service.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access the Single Preferred Drug List (PDL), which is inclusive of the preferred/non-preferred drug list, clinical authorization list, drug specific forms, criteria, and POS edits (i.e. maximum daily dose and quantity limits) at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Pimavanserin (Nuplazid®)**

Prescriptions for pimavanserin (Nuplazid®) are subject to:

1. An approved clinical authorization;
2. Diagnosis code requirement; and
3. Quantity limit.



**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142****Diagnosis Code Requirement**

Pharmacy claims for pimavanserin (Nuplazid®) will require a diagnosis code of G20 (Parkinson's disease).

**Quantity Limit**

Pharmacy claims for pimavanserin (Nuplazid®) have a quantity limit of 60 (17mg) tablets or 30 (34mg) capsules per rolling 30 days.

**Mosquito Repellents**

Prescriptions for mosquito repellents are covered to decrease the risk of exposure to the Zika virus. Mosquito repellent coverage will be limited to Medicaid beneficiaries:

1. Who are pregnant; or
2. Of childbearing years (women and men 14-44 years of age) who are trying to conceive.

A prescription will be required to cover one of the following products:

Product Name	Ounces	Bill As
Cutter Backwoods 25 percent Spray	6 oz.	170 g
Cutter Skinsations 7 percent Spray	6 oz.	177 mL
OFF! Family Care 15 percent Spray	2.5 ounces	71 g
OFF! Deep Woods Dry 25 percent Spray	4 ounces	113 g
OFF! Deep Woods 25percent Spray	6 ounces	170 g
OFF! Active 15 percent Spray	6 ounces	170 g
Repel Sportsmen 25 percent Spray	6.5 ounces	184 g
Repel Sportsmen Max 40 percent Spray	6.5 ounces	184 g
Natrapel 20 percent Picaridin	5 ounces	177 mL

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

Product Name	Ounces	Bill As
Sawyer Insect Repellent 20 percent Picaridin	4 ounces	118 mL

**Quantity Limit**

One bottle of mosquito repellent will be covered every rolling 30 days.

**Age Restriction**

Pharmacy claims for mosquito repellents have an age limit of 14 to 44 (of childbearing) years of age.

**Multiple Sclerosis (MS) Treatment Agents**

Prescriptions for Multiple Sclerosis treatment agents will be reimbursed when the prescriber has obtained an approved clinical authorization.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Naloxone**

Pharmacy claims for naloxone have a quantity limit requirement for reimbursement. Refer to the chart below.

Description	Dosage Form	Strength	Units per 90 Rolling Days	Representative Brand
Naloxone	Injectable Solution	0.4mg/ml	2	Naloxone
Naloxone	Injectable Solution Cartridge	0.4mg/ml	2	Naloxone
Naloxone	Injectable Solution Prefilled Syringe	1mg/ml	2	Naloxone

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

Description	Dosage Form	Strength	Units per 90 Rolling Days	Representative Brand
Naloxone	Injectable Solution (5ml, 10ml, 20ml)	1mg/ml	1	Naloxone
Naloxone	Injectable Solution (10ml)	0.4mg/ml	1	Naloxone
Naloxone	Injectable Solution Auto-Injector	0.4mg/0.4ml	2	Evzio®
Naloxone	Nasal Liquid	4mg/0.1ml	2	Narcan®

**Nicotine Transdermal Patches, Gum and Spray**

Nicotine transdermal patches, nicotine polacrlix gum, and nicotine spray are covered only with a handwritten prescription signed by the prescribing practitioner. There are no provisions for refills. The physician will need to rewrite a prescription each time.

Also, physicians must certify, in their own handwriting, either directly on the prescription or on an attachment to the prescription that the beneficiary is enrolled in a physician-supervised behavioral program in order for Medicaid to provide coverage for nicotine adhesive patches, gum and spray. Pharmacy providers should verify that the above noted documentation is written on, or attached to, the prescription when the prescription is dispensed.

This information must be retained by the pharmacy as evidence of compliance with program policy, and it must be readily retrievable when requested by audit staff.

**Nintedaib (Ofev®)**

Pharmacy claims for nintedaib (Ofev®) have a clinical authorization requirement and quantity limit of 60 capsules/30 days.

**Orlistat**

Medicaid will provide reimbursement to outpatient pharmacies for orlistat prescriptions based on the following criteria:

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

1. An authorized prescriber has hand written the prescription - no facsimiles allowed;
2. Patient is 12 years of age or older;
3. The prescription is an original—no refills are allowed;
4. The prescription is for a maximum of 90 capsules **and** 30 days' supply;
5. The beneficiary has a documented current body mass index (BMI) of 27 or greater and the prescriber had identified the BMI, in his/her handwriting, on the dated prescription or a dated and signed attachment to the prescription;
6. The beneficiary has other risk factors warranting the use of Orlistat and the prescriber has identified an approved diagnosis code in his/her handwriting, on the dated prescription or a dated and signed attachment to the prescription; and
7. There are no provisions for override of the prospective drug utilization edits, i.e., early refill (ER) and duplicate drug (ID) editing.

The following risk factors, as identified by ICD-10-CM **numeric codes only**, are acceptable:

ICD-10-CM Code	Description
E11.*	Type II Diabetes
R73.02	Impaired Glucose Tolerance
E15, E16.1	Hyperinsulinemia
E78.0-E78.5	Dyslipidemia
I10, I11.*, I12.*, I13.*, I15.*	Hypertension
I21.*, I22.*, I24.*, I25.*	Ischemic Heart Disease
I70	Atherosclerosis
I73	Other peripheral vascular diseases
K21.0, K21.9	Gastric Reflux Disease

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

ICD-10-CM Code	Description
M16.*, M17.*	Osteoarthritis of Hips/Knees
G47.30	Sleep Apnea
I60.*, I61.*, I62.*, I63.*, I65.*, I66.*, I67.*, I68.*, I69.*	Cerebrovascular Disease
G93.2	Pseudotumor cerebri
I83.2	Varicose Veins of the lower extremities with ulcer and inflammation
I80.0	Phlebitis & Thrombophlebitis of the superficial vessels of the lower extremities
I80.1	Phlebitis & Thrombophlebitis of the femoral vein
I80.2	Phlebitis & Thrombophlebitis of other deep vessels
I80.3	Phlebitis & Thrombophlebitis of lower extremities, unspecified
I83.0	Varicose veins of lower extremities, with ulcer
I83.1	Varicose veins of lower extremities, with inflammation
I83.9	Varicose veins of lower extremities, without mention of ulcer & inflammation

Drug-Brand Name Example	Diagnosis	ICD-10-CM Diagnosis Code
Orlistat – Xenical®	Atherosclerosis	I70.*
	Cerebrovascular Disease	I60.*, I61.*, I62.*, I63.*, I65.*, I66.*, I67.*, I68.*, I69.*
	Dyslipidemia	E78.0–E78.5
	Gastric Reflux Disease	K21.0, K21.9
	Hyperinsulinemia	E15, E16.1
	Hypertension	I10, I11.*, I12.*, I13.*, I15.*
	Impaired Glucose Tolerance	R73.02

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

	Ischemic Heart Disease	I21.*, I22.*, I24.*, I25.*
	Osteoarthritis of Hips/Knees	M16.*, M17.*
	Other Peripheral Vascular Diseases	I73.*
	Phlebitis & Thrombophlebitis of Lower Extremities, unspecified	I80.3
	Phlebitis & Thrombophlebitis of Other Deep Vessels	I80.2*
	Phlebitis & Thrombophlebitis of the Femoral Vein	I80.1*
	Phlebitis & Thrombophlebitis of the Superficial Vessels of the Lower Extremities	I80.0*
	Pseudotumor Cerebri	G93.2
	Sleep Apnea	G47.30
	Type 2 Diabetes	E11.*
	Varicose Veins of Lower Extremities, with Inflammation	I83.1*
	Varicose Veins of Lower Extremities, without Mention of Ulcer and Inflammation	I83.9
	Varicose Veins of Lower Extremities, with Ulcer	I83.0*
	Varicose Veins of the Lower Extremities with Ulcer and Inflammation	I83.2*

The prescriber identified diagnosis code must be included in the claim submission. The required supporting documentation for coverage must be retained by the pharmacy as evidence of compliance with program policy, and it must be readily retrievable when requested by audit staff.

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES**

---

**SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

---

**Onasemnogene Abeparvovec Injection (Zolgensma®)**

Pharmacy claims for onasemnogene abeparvovec injection (Zolgensma®) require a clinical authorization.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Oxybate Salts (Calcium, Magnesium, Potassium, and Sodium) Oral, (Xywav®)**

Pharmacy claims for oxybate salts (calcium, magnesium, potassium and sodium) oral, (Xywav™) require clinical authorization and may be subject to a therapeutic duplication.

Incoming prescriptions for oxybate salts (calcium, magnesium, potassium and sodium) oral, (Xywav™) will deny with a therapeutic duplication when there is an active prescription on the beneficiary's file for a CNS depressant medication, whether as a single entity or as a component of a combination product. An active prescription is a prescription in which the days' supply has not expired. Alternately, incoming prescriptions for a CNS depressant medication will deny with a therapeutic duplication when there is an active prescription on the beneficiary's file for oxybate salts (calcium, magnesium, potassium and sodium) oral, (Xywav™).

**Ozanimod (Zeposia®)**

Pharmacy claims for ozanimod (Zeposia®) require an approved clinical authorization for reimbursement.

**Palivizumab (Synagis®)**

Prescriptions for palivizumab (Synagis®) will only be reimbursed when prescriptions meet the following criteria:

1. The prescriber has obtained an approved clinical authorization.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES**

---

**SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND  
EXCLUSIONS****PAGE(S) 142**

---

**Respiratory Syncytial Virus Season**

Louisiana's respiratory syncytial virus (RSV) activity may be followed during the RSV season by frequently accessing the Center for Disease Control's website. (Refer to Section 37.5.4 for web address). The RSV season in Louisiana begins November 1<sup>st</sup> and ends March 31<sup>st</sup>.

**Age Restriction**

Palivizumab claims for beneficiaries who are 24 months of age or younger on November 1<sup>st</sup> of the current RSV season meet the POS age requirement.

**Early Refill**

Palivizumab claims will only process for payment every 28 days. When a pharmacy submits a claim for Synagis® and there is an active paid Synagis® claim on file, the incoming claim will deny. An active prescription is a prescription in which the days' supply has not expired.

**Maximum Number of Doses Allowed**

Claims billed for Synagis® outside the allowable number of doses will deny. Based upon the diagnosis code submitted, a maximum of five doses of Synagis® will be reimbursed each RSV season. If the initial dose is given in October, the fifth and final dose should be given in February. If initial dose is given in November, the fifth and final dose should be given in March.

**Medical Reconsideration for Palivizumab (Synagis®)**

Medical reconsideration of a denied clinical authorization decision may be requested by the prescribing practitioner. Medical reconsideration requires completion of the Palivizumab Request for Reconsideration Form.

**Palivizumab Criteria ICD-10-CM Code and Medication List**

**NOTE:** Any accepted diagnosis code listed on the Palivizumab Clinical Authorization Form must have supporting documentation attached. Supporting documentation is supplemental information submitted to support the patient meeting the criteria and may include copies of progress notes, hospital discharge notes, pediatric cardiologist consult notes, chart notes, pharmacy profiles, etc.



**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142****Neuromuscular Disorders**

Acceptable ICD-10 codes include:

ICD-10-CM Code	Description
A80.0-A80.39	Infantile paralysis
G31.9	Cerebral degenerations
G25.3	Myoclonus
G11.1, G11.4	Spinocerebellar disease
G12.0	Werdnig-Hoffman disease (Infantile spinal muscular atrophy)
G12.1, G12.8, G12.9	Spinal muscular atrophy
G12.2*	Motor neuron disease

Exclude (but not limited to) the following (i.e. the following are NOT accepted):

ICD-10-CM Code	Description
G80*	Cerebral palsy
G40.3*	Generalized convulsive epilepsy
G40.4*	Grand mal seizures
G40*	Epilepsy
Q05*	Spina bifida
P90	Newborn seizures
R56*	Infantile seizures

**Congenital Abnormalities of the Airways**

Acceptable ICD-10 codes include:

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

ICD-10-CM Code	Description
G47.35	Congenital central alveolar hypoventilation syndrome
Q32.0, Q32.1	Other diseases of the trachea and bronchus, not elsewhere classified (Must specify Tracheomalacia or tracheal stenosis)
Q31.1, Q31.5, Q32.1, Q32.4	Other anomalies of larynx, trachea, and bronchus (Must specify congenital tracheal stenosis, subglottic stenosis, atresia of trachea, laryngomalacia, or absence or agenesis of bronchus, trachea)
Q33.0	Congenital cystic lung
Q33.3, Q33.6	Agenesis, hypoplasia, and dysplasia of the lung
Q33.4	Congenital bronchiectasis
Q38.2	Macroglossia
Q38.5	Uvula anomaly
J98.6	Diaphragmatic paralysis
Q87.3	Beckwith-Wiedemann syndrome

Exclude (but not limited to) the following (i.e. the following are NOT accepted):

ICD-10-CM Code	Description
Q33.9	Anomaly of lung, unspecified
Q33.1, Q33.8	Other anomaly of the lung

**Chronic Lung Disease**

Acceptable ICD-10 code:

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

ICD-10-CM Code	Description
P27*	Chronic respiratory disease arising in the perinatal period (CLD/BPD/Interstitial pulmonary fibrosis of prematurity/Wilson-Mikity syndrome)

Exclude (but not limited to) the following (i.e. the following are NOT accepted):

ICD-10-CM Code	Description
J05.0	Croup
J06*	URI
J20*	Bronchitis
J21*	Bronchiolitis
J45*	Asthma
R06.2	Wheezing

**Congenital Heart Diseases**

Per AAP guidelines, prophylaxis with palivizumab in children with chronic heart disease (CHD) should be made on the degree of cardiovascular compromise. CHD that is deemed hemodynamically insignificant will not meet criteria. Documentation must specifically support CHD being hemodynamically significant (e.g. medications, etc.).

Acceptable ICD-10 codes include:

**Acyanotic CHD**

ICD-10-CM Code	Description
Q23.0	Aortic stenosis
I37.0, I37.1, I37.2, Q22.1, Q22.2	Pulmonary valve disorders (incompetence, insufficiency, regurgitation, and stenosis)

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

ICD-10-CM Code	Description
I42*, I43	Cardiomyopathy (must be moderate to severe)
Q21.0	Ventricular septal defect
Q21.1	Atrial septal defect
Q21.2	Atrioventricular canal (endocardial cushion defect)
Q22.3	Anomalies of pulmonary valve congenital
Q22.1	Pulmonic stenosis
Q23.0	Congenital stenosis of aortic valve (congenital aortic stenosis) [Excludes: congenital subaortic stenosis; supravalvular aortic stenosis]
Q23.3	Congenital mitral insufficiency
Q25.0	Patent ductus arteriosus
Q25.1	Coarctation of the aorta
Q25.2, Q25.3	Atresia and stenosis of aorta (absence, aplasia, hypoplasia, stricture of the aorta) Supra (valvular)-aortic stenosis [Excludes: congenital aortic (valvular) stenosis or stricture; hypoplasia of aorta in hypoplastic left heart syndrome]

**NOTE:** Must currently be receiving medication to control congestive heart failure.

**Cyanotic CHD**

ICD-10-CM Code	Description
Q20.0	Truncus arteriosus
Q20.3	Transposition of the great vessels
Q21.3	Tetralogy of Fallot

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

ICD-10-CM Code	Description
Q22.0	Atresia, congenital
Q22.4	Tricuspid atresia and stenosis, congenital
Q22.5	Ebstein's anomaly
Q23.4	Hypoplastic left heart
Q22.6	Hypoplastic right heart
Q25.5	Pulmonary atresia
Q26.2	Total anomalous pulmonary venous return

**NOTE:** Does not require use of medication/must not have had or completed surgical correction.

**Pulmonary Hypertension**

ICD-10-CM Code	Description
I26.0*	Acute cor pulmonale
I27.0	Primary pulmonary hypertension
I27.2	Other chronic pulmonary heart disease (pulmonary hypertension, secondary)
P29.3	Persistent fetal circulation (persistent pulmonary hypertension/primary pulmonary hypertension of newborn)

\*any number or letter or combination of UP TO FOUR numbers and letters of an assigned ICD-10-CM diagnosis code

**Acceptable Medications Used in CHD**

Digoxin	ACE Inhibitors	Supplemental oxygen
Beta Blockers	Nitroglycerin	Diuretics
Calcium Channel Blockers	Anti-Coagulants	

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

**NOTE:** Refer to “Prospective Drug Utilization Policies/Limits/Edits”, and as well as the *POS User Guide* accessed at: [www.lamedicaid.com/Provweb1/Pharmacy/LAPOS\\_User\\_Manual\\_static.pdf](http://www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf) or by visiting Section 37.5.1 for detailed claims filing information.

**Penicillamine (Cuprimine®, Depen®)**

Pharmacy claims for penicillamine (Cuprimine®, Depen®) have quantity limits. The quantity limits are listed in the chart.

Generic Name	Brand Name	Quantity Limit
Penicillamine	Cuprimine®	240 capsules/30 days
	Depen®	240 tablets/30 days

**Pyrimethamine (Daraprim®)**

Prescriptions for pyrimethamine (Daraprim®) will be reimbursed when:

1. The prescriber has obtained an approved clinical authorization.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access the Single Preferred Drug List (PDL), which is inclusive of the preferred/non-preferred drug list, clinical authorization list, drug specific forms, criteria, and POS edits (i.e. maximum daily dose and quantity limits) at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Schedule II Narcotic Agents**

All prescriptions for Schedule II narcotic agents require a diagnosis code indicating the reason for use documented on the hardcopy prescription. The diagnosis code must be written on the hardcopy prescription by the prescribing practitioner or by the pharmacist after consultation with the prescriber.

Except for methadone, when the prescribing practitioner does not indicate a diagnosis code on the prescription and when the prescriber cannot be reached, a denial for a missing diagnosis code may be overridden if the pharmacist determines that the beneficiary cannot wait to receive the medication.

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

Schedule II narcotic agents are also subject to prospective drug utilization reviews which address quantity limits.

**NOTE:** Refer to “Prospective Drug Utilization Policies/Limits/Edits” in this section for further information.

**Fentanyl Buccal and Sublingual Agents**

Claims for fentanyl buccal and sublingual agents (Abstral®, Actiq®, Fentora® and Onsolis®) **must** contain a cancer-related diagnosis code in order for the claim to process for payment through the POS System.

Acceptable diagnosis codes are as follows:

ICD-10-CM Code Range	Description
C00.*-C96*	Cancer

Buccal and sublingual agents are subject to prospective drug utilization reviews which address quantity limits.

**Diagnosis Code Requirement**

Pharmacy claims for fentanyl nasal solution (Lazanda®) and fentanyl sublingual liquid (Subsys®) require an appropriate diagnosis code documented on the hardcopy prescription by either the prescriber or pharmacist. The pharmacist may document the diagnosis code after electronic or verbal consultation with the prescribing practitioner on the hardcopy prescription or in the pharmacy’s electronic recordkeeping system.

**Age Restriction**

Claims for fentanyl nasal solution (Lazanda®) and fentanyl sublingual liquid (Subsys®) will deny when the beneficiary is 17 years of age or younger.

**Methadone**

All prescriptions for methadone must have a diagnosis code for payment. There are no provisions for an override of methadone when a diagnosis code is omitted. Methadone products when used

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

for the treatment of opioid addiction in detoxification or maintenance programs shall only be dispensed by opioid treatment programs certified by the Substance Abuse and Mental Health Services Administration.

Prescriptions for methadone will be reimbursed when the prescriber has obtained an approved clinical authorization.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Morphine ER (Avinza®)**

When the cumulative daily dosage for Morphine ER (Avinza®) exceeds the maximum daily dosage, the claim will deny. The maximum daily dosage for this agent is 1600mg per day. There is no provision for override through the POS system for Morphine ER (Avinza®) when the maximum daily dosage is exceeded.

**Oxycodone/Acetaminophen 7.5/325mg (Xartemis XR®)**

Prescriptions for oxycodone/acetaminophen (Xartemis XR®) require an appropriate diagnosis code documented on the hard copy prescription by the prescriber or pharmacist. The pharmacist may document the diagnosis code after electronic or verbal consultation with the prescribing practitioner on the hardcopy prescription or in the pharmacy's electronic recordkeeping system.

Pharmacy claims for oxycodone/acetaminophen (Xartemis XR®) have a quantity limit of 30 units every 15 days within a 30-day period.

**Paroxetine Mesylate (Brisdelle®)**

Pharmacy claims for paroxetine mesylate (Brisdelle®) require submission of a valid diagnosis code at POS for reimbursement. The diagnosis code must be documented on the hardcopy prescription or in the pharmacy's electronic recordkeeping system. The following table lists the acceptable diagnosis codes for paroxetine mesylate (Brisdelle®).

Medication	ICD-10-CM Diagnosis Code*	Diagnosis Description
	E28.310	Moderate to severe vasomotor symptoms associated with menopause
	E89.41	



**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

Paroxetine Mesylate (Brisdelle®)	N95.1	
-------------------------------------	-------	--

**Patisiran (Onpattro®)**

Pharmacy claims for patisiran (Onpattro®) require a diagnosis code. The diagnosis code must be documented on the prescription or in the pharmacy's electronic recordkeeping system. The pharmacist can document the diagnosis code after electronic or verbal consultation with the prescribing practitioner.

Generic Name	Brand Name	Diagnosis	ICD-10-CM Diagnosis Code
Patisiran	Onpattro®	Polyneuropathy of hereditary transthyretin-mediated amyloidosis	E85.1

**Perampanel (Fycompa®)****Age Limit**

Pharmacy claims for perampanel (Fycompa®) will deny for beneficiaries under four years of age.

After consultation with the prescriber to verify the necessity of prescribing perampanel (Fycompa®) for a beneficiary under four years of age, the pharmacist may override the age restriction. The reason for service code, professional service code and result of service code used in submitting the claim must be documented on the hardcopy prescription or in the pharmacy's electronic recordkeeping system.

**NOTE:** The *POS User Guide* can be accessed at:

[www.lamedicaid.com/Provweb1/Pharmacy/LAPOS\\_User\\_Manual\\_static.pdf](http://www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf) or by visiting Section 37.5.1 for detailed billing instructions and override procedures.

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142****Pirfenidone (Esbriet®)**

Pharmacy claims for pirfenidone (Esbriet®) have a clinical authorization requirement and quantity limit of 90 capsules or tablets/30 days.

**Progesterone (Crinone® 4%)**

Pharmacy claims for progesterone (Crinone® 4%) will require a diagnosis code for payment.

Generic Name	Brand Name	Diagnosis	ICD-10-CM Diagnosis Code
Progesterone micronized	Crinone® 4%	Secondary Amenorrhea	N91.1

\*Any number or letter or combination of UP TO FOUR numbers and letters of an assigned ICD-10-CM diagnosis code.

**Quinine Sulfate**

Pharmacy claims for quinine sulfate (Qualaquin®) 324mg have a quantity limit of 42 capsules/7 day supply per 365 days.

**Riluzole (Rilutek®, Tiglutik®)**

Pharmacy claims for riluzole (Rilutek®), Tiglutik®) require a diagnosis code. The diagnosis code must be documented on the prescription or in the pharmacy's electronic recordkeeping system. The pharmacist can document the diagnosis code after electronic or verbal consultation with the prescribing practitioner.

Generic Name	Brand Name	Diagnosis	ICD-10-CM Diagnosis Code
Riluzole	Rilutek®; Tiglutik®	Amyotrophic lateral sclerosis	G12.21

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142****Rimegepant (Nurtec™ ODT)**

Pharmacy claims for rimegepant (Nurtec™ODT) have a quantity limit of 16 tablets per 30 days.

**Risdiplam (Evrysdi™)**

Pharmacy claims for risdiplam (Evrysdi™) have a quantity limit and clinical authorization requirement.

Generic Name	Brand Name	Quantity Limit
Risdiplam	Evrysdi™	160 ml (2-80 ml bottles)

**Risankizumab Injection (Skyrizi®)**

Pharmacy claims for risankizumab injection (Skyrizi®) require a clinical authorization.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Roflumilast (Daliresp®)**

Pharmacy claims for roflumilast (Daliresp®) require an approved clinical authorization for reimbursement.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Selumetinib (Koselugo™)**

Pharmacy claims for selumetinib (Koselugo®) have a clinical authorization requirement and quantity limit of 120 capsules/30 days.

**Semaglutide (Rybelsus®)**

Pharmacy claims for semaglutide (Rybelsus®) are subject to a prior use and quantity limit edit.

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

Pharmacy claims for semaglutide (Rybelsus®) will have a quantity limit of 30 tablets/30 days. Pharmacy claims for semaglutide (Rybelsus®) will require previous use of metformin or a paid claim for semaglutide (Rybelsus®) or another Incretin Mimetic Enhancers. An incoming claim for semaglutide (Rybelsus®) will deny if there is no evidence of a paid claim(s) for at least 90 days of metformin therapy in the previous 180-day period or if there is no evidence of paid claims of at least 60 days of semaglutide (Rybelsus®) or other Incretin Mimetic/Enhancers within the previous 90 days.

**Short-Acting Beta<sub>2</sub> Agonist Inhalers**

Prescriptions for short- acting beta<sub>2</sub> agonist inhalers (SABAs) (i.e albuterol, levalbuterol, and pirbuterol):

1. Require an appropriate diagnosis code; and
2. Are subject to a maximum quantity of six short-acting beta<sub>2</sub> agonist inhalers per calendar year.

**Diagnosis Code Requirement**

The diagnosis code must be documented on the hardcopy prescription by either the prescriber or pharmacist. The diagnosis code may be communicated to the pharmacist electronically, via telephone or facsimile.

Diagnosis codes which bypass the six inhaler limit are noted below:

<b>Generic – Brand Example</b>	<b>Diagnosis Description</b>	<b>ICD-10-CM Diagnosis Code(s)</b>
Albuterol – ProAir HFA®, ProAir RespiClick®, ProAir Digihaler®, Proventil HFA®, Ventolin HFA® <b>YQ</b> Levalbuterol – Xopenex HFA® <b>YQ</b> <i>Yearly Quantity Limit (YQ)</i>	Bronchitis, not specified	J40
	Chronic Airway Obstruction	J44.9
	Cystic Fibrosis	E84.*
	Emphysema	J43.*
	Obstructive Chronic Bronchitis, Chronic Obstructive Asthma	J44.*

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES**

---

**SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND  
EXCLUSIONS****PAGE(S) 142**

---

\* – any number or letter or combination of **UP TO FOUR** numbers and letters of an assigned ICD-10-CM diagnosis code.

Pharmacy claims that do not indicate a diagnosis code on the prescription and the prescriber cannot be reached; a denial for a missing diagnosis code may be overridden by the pharmacist entering the emergency override.

**Quantity Limit**

If the prescriber chooses to exceed the quantity limit, the prescriber must provide the reason why the limit needs to be exceeded. The pharmacist may override the limit after consultation with the prescriber. The pharmacist must document on the hardcopy prescription or in the pharmacy's electronic record-keeping system the following:

1. The prescriber's reason why the limit needs to be exceeded; and
2. The NCPDP DUR override codes used in submitting the claim.

If the prescriber cannot be reached, the pharmacist may override the quantity limit by entering the emergency override. The pharmacist must document "Emergency" on the hardcopy prescription and the reason for entering the emergency override.

**Therapeutic Duplication**

Pharmacy claims billed for concurrent use of different SABAs will deny with a therapeutic duplication. After consultation with the prescribing provider, the pharmacist may override the therapeutic duplication. This consultation is necessary to confirm that:

1. The prescriber is aware of the current active SABA claim; and
2. The addition of a different SABA is necessary (i.e., a change in therapy).

To bill concurrent therapy with different SABAs, the pharmacist must document on the hardcopy prescription or the pharmacy's electronic recordkeeping system the following:

1. The reason why an additional SABA was requested by the prescriber; and
2. The NCPDP DUR override codes used in submitting the claim.

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

**NOTE:** Refer to ‘Drugs with Special Payment Criteria/Limitations’ in this section for further policy regarding short-acting beta2 agonist inhalers.

**Sickle Cell Anemia Treatment Agents**

Select sickle cell anemia treatment agents may require prior authorization or clinical authorization.

Pharmacy claims for voxelotor (Oxbryta®) are limited to a quantity of 90 tablets per 30 days.

**Sildenafil (Revatio®) and Tadalafil (Adcirca®)**

Prescriptions for Sildenafil (Revatio®) and Tadalafil (Adcirca®) are payable when prescribed for primary pulmonary hypertension. An appropriate diagnosis code must be documented on all prescriptions by either the prescriber or the pharmacist. The diagnosis code may be communicated to the pharmacist electronically, via telephone, or facsimile. The diagnosis code is required for the claim submission.

The following diagnosis codes are acceptable:

ICD-10-CM Code	Description
I27.0, I27.2, I27.89, P29.3	Pulmonary Arterial Hypertension

**Skeletal Muscle Relaxants**

Pharmacy claims for skeletal muscle relaxants that contain codeine (carisoprodol-aspirin-codeine) will deny at the POS if the beneficiary is less than 12 years of age.

Pharmacy claims for skeletal muscle relaxants are subject to a quantity limit. (See chart below.)

Medication	Quantity Limit per 30 days
Baclofen 10mg	120 Units
Baclofen 20mg	120 Units
Cyclobenzaprine 5mg	90 Units

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

Cyclobenzaprine 7.5mg	90 Units
Cyclobenzaprine 10mg	90 Units
Cyclobenzaprine 15mg	30 Units
Cyclobenzaprine 30mg	30 Units
Tizanidine 2mg	90 Units
Tizanidine 4mg	90 Units
Tizanidine 6mg	180 Units

**Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors and Combination Products**

Prescriptions for Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors and combination products will be reimbursed when:

1. The prescriber has obtained an approved clinical authorization.

**Prior Use of Metformin Required (SGLT2 Inhibitors Only)**

An incoming pharmacy claim for a SGLT2 inhibitor will require evidence of previous use of metformin or a paid claim for the requested medication or another medication within the same therapeutic class.

An incoming claim for a SGLT2 inhibitor will deny if there is not a paid claim(s) for at least 90 days of metformin therapy OR there is no evidence of at least 60 days of paid claims for the requested medication (or another SGLT2 inhibitor).

**Exception:** Pharmacy claims submitted for dapagliflozin (Farxiga®) will bypass the POS prior drug use requirement for metformin and SGLT2 when submitted with an appropriate bypass diagnosis code of heart failure (I50\*) or chronic kidney disease (N18\*).

**NOTE:** \* can be any number or letter or combination of **UP TO FOUR** numbers and letters of an assigned ICD-10-CM diagnosis code.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142****Sodium Oxybate (Xyrem®)****Clinical Pre-Authorization**

Pharmacy claims for sodium oxybate (Xyrem®) will be reimbursed when the prescriber has obtained an approved clinical authorization. A diagnosis of narcolepsy or cataplexy must be submitted in the clinical authorization process.

**Therapeutic Duplication**

Pharmacy claims for sodium oxybate (Xyrem®) will deny when the beneficiary has an active claim on file for a CNS depressant. Claims for CNS depressants will deny when the beneficiary has an active claim on file for sodium oxybate (Xyrem®).

CNS depressant medications include the following agents, whether given as a single entity or as a component of a combination product:

Alprazolam	Dantrolene	Metaxalone	Quazepam
Baclofen	Diazepam	Methadone	Ramelteon
Buprenorphine	Dihydrocodeine	Methocarbamol	Remifentanyl
Buspirone	Doxepin	Midazolam	Secobarbital
Butabarbital	Estazolam	Morphine	Sufentanil
Butalbital	Eszopiclone	Nalbuphine	Suvorexant
Butorphanol	Fentanyl	Opium	Tapentadol
Carisoprodol	Flurazepam	Orphenadrine	Tasimelteon
Chlordiazepoxide	Hydrocodone	Oxazepam	Temazepam
Chlorzoxazone	Hydromorphone	Oxycodone	Tizanidine
Clonazepam	Levorphanol	Oxymorphone	Tramadol
Clorazepate	Lorazepam	Paregoric	Triazolam
Codeine	Meperidine	Pentazocine	Zaleplon
Cyclobenzaprine	Meprobamate	Phenobarbital	Zolpidem

The therapeutic duplication edit for sodium oxybate (Xyrem®) and CNS depressants can be overridden in emergency circumstances. These claims will require consultation and approval from the prescribing provider to override the therapeutic duplication. After consultation with the prescribing provider, the pharmacist may override the therapeutic duplication with the emergency override. The pharmacist must document “**Emergency**” on the hardcopy prescription and the reason why the prescribing provider choose to override the therapeutic duplication.



**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Somatropin**

Pharmacy claims for Somatropin (Genotropin®, Humatrope®, Norditropin®, Nutropin®, Nutropin AQ®, Omnitrope®, Saizen®, Serostim®, Tev-Tropin®, and Zorbtive®) require an appropriate diagnosis code for reimbursement. The numeric code must be documented on the hardcopy prescription by either the prescriber or the pharmacist. The diagnosis code may be communicated to the pharmacist electronically, via telephone, or facsimile.

There are no overrides for this edit. However, the pharmacist may contact the prescriber for a valid diagnosis code and resubmit the claim.

The following chart addresses acceptable diagnosis code(s) which are in accordance with the reimbursement criteria for somatropin.

ICD-10-CM Diagnosis Code(s)	Diagnoses
N25.0	Growth failure in children associated with: <ul style="list-style-type: none"> <li>Renal insufficiency or chronic kidney disease</li> </ul>
Q87.1	<ul style="list-style-type: none"> <li>Noonan Syndrome</li> </ul>
Q87.1	<ul style="list-style-type: none"> <li>Prader-Willi Syndrome</li> </ul>
Q96	<ul style="list-style-type: none"> <li>Turner Syndrome</li> </ul>
P05.1	<ul style="list-style-type: none"> <li>Small for gestational age at birth (fetal growth retardation) who fail to manifest catch-up growth or with no catch-up growth</li> </ul>
R62.52	Short Stature in children (idiopathic or SHOX deficiency) <ul style="list-style-type: none"> <li>Short stature</li> <li>Lack of expected normal physiological development in childhood</li> </ul>
E23.0	Pituitary dwarfism
E23.0	Panhypopituitarism
E23.1, E89.3	Iatrogenic pituitary disorders

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

K90.2, K91.2	(Zorbitive® only) Short Bowel Syndrome in patients receiving specialized nutritional support: <ul style="list-style-type: none"> <li>• Blind Loop Syndrome</li> <li>• Other unspecified post-surgical nonabsorption</li> </ul>
R64	(Serostim® only) HIV-associated cachexia or wasting

**Suvorexant (Belsomra®)**

Pharmacy claims for suvorexant (Belsomra®) are subject to a maximum daily dosage limit of 20 mg/day.

**Tafamidis (Vyndaqel®, Vyndamax®)**

Pharmacy claims for tafamidis (Vyndaqel®, Vyndamax®) have a quantity limit.

Generic Name	Brand Name	Quantity Limit
Tafamidis	Vyndaqel®	120 capsules/30 days
Tafamidis	Vyndamax®	30 capsules/30days

**Tasimelteon (Hetlioz®)**

Prescription claims for tasimelteon (Hetlioz®) will have the following clinical edits:

1. Clinical Authorization;
2. Maximum Daily Dose; and
3. Therapeutic Duplication.

**Clinical Authorization for tasimelteon (Hetlioz®)**

Pharmacy claims for tasimelteon (Hetlioz®) will be reimbursed at POS when the prescriber has obtained an approved clinical authorization.

Override provisions should be addressed through the Clinical Authorization process.

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Maximum Dose for tasimelteon (Hetlioz®)**

Pharmacy claims for tasimelteon (Hetlioz®) have a maximum daily dose of 20mg/day. There are no override provisions through the POS system using NCPDP service codes.

**Therapeutic Duplication for tasimelteon (Hetlioz®)**

Pharmacy claims for tasimelteon (Hetlioz®) will deny at POS if there is an active claim for another sedative-hypnotic agent.

After consultation with the prescriber to verify the necessity of the therapeutic duplication, the pharmacist may override the therapeutic duplication.

The pharmacist must document the override codes on the hardcopy prescription or in the pharmacy's electronic recordkeeping system.

**Tazarotene (Tazorac®)**

Pharmacy claims for Tazarotene (Tazorac®) require an appropriate diagnosis code for reimbursement. The prescribing provider must document the diagnosis code on the hard copy prescription or may communicate the diagnosis code to the pharmacist electronically, via telephone, or facsimile.

The acceptable diagnosis codes are:

ICD-10-CM Code	Description
L40*	Psoriatic Arthritis

\* - any number or letter or combination of UP TO FOUR numbers and letters of an assigned ICD-10-CM diagnosis code

Pharmacy providers may direct questions to the Provider Help Desk concerning overrides for this edit. (Refer to Section 37.5.4 for contact information).

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

**NOTE:** The *POS User Guide* can be accessed at: [www.lamedicaid.com/Provweb1/Pharmacy/LAPOS\\_User\\_Manual\\_static.pdf](http://www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf) or by visiting Section 37.5.1 for detailed billing instructions and override procedures.

**Tedizolid Phosphate (Sivextro®)**

Prescriptions for tedizolid phosphate (Sivextro®) will be reimbursed when:

1. The prescriber has obtained an approved clinical pre-authorization.

**Tesamorelin (Egrifta®)**

Pharmacy claims for tesamorelin (Egrifta®) require a diagnosis code. The diagnosis code must be documented on the prescription or in the pharmacy's electronic recordkeeping system. The pharmacist can document the diagnosis code after electronic or verbal consultation with the prescribing practitioner.

**Tiotropium Bromide (Spiriva Respimat®)**

Pharmacy claims for tiotropium bromide (Spiriva Respimat®) will require a diagnosis code.

Medication	Description of Diagnosis	ICD-10 Code
Spiriva Respimat® 1.25 mcg (tiotropium bromide)	Asthma	J45*
Spiriva Respimat® 2.5 mcg (tiotropium bromide)	COPD	J44*

\*any number or letter or combination of UP TO FOUR numbers and letters of an assigned ICD-10\_CM diagnosis code.

**Tobramycin/Nebulizer (Kitabis Pak®)**

Pharmacy claims for tobramycin (Kitabis Pak®) will require a diagnosis code for payment.

Generic Name	Brand Name	Diagnosis	ICD-10-CM Diagnosis Code
Tobramycin Nebulizer	Kitabis Pak® 4%	Cystic Fibrosis with Pseudomonas	E84*

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

\*Any number or letter or combination of UP TO FOUR numbers and letters of an assigned ICD-10\_CM diagnosis code.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Tolvaptan (Samsca®)**

Pharmacy claims for tolvaptan (Samsca®) have quantity limits. The quantity limits for tolvaptan (Samsca®) are listed in the chart.

Generic Name	Brand Name	Quantity Limit
Tolvaptan	Samsca® 15mg	30 tablets/30 days
	Samsca® 30 mg	60 tablets/30 days

**Tramadol**

Pharmacy claims for tramadol containing products have an age limit for reimbursement. The acceptable age limits are listed in the chart.

Description	Age (Y=Year)
Tramadol	≥17 Y
Tramadol Combination Product	≥17 Y

**Trifarotene (Aklief®)**

Pharmacy claims for trifarotene (Aklief®) will deny at POS when the beneficiary is younger than 9 years of age or older than 20 years of age.

**Triptans**

Pharmacy claims for triptans for beneficiaries under 18 years of age will require a valid diagnosis code for reimbursement. Triptans are identified in the following chart:

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

Generic Name	Representative Brand(s)
Almotriptan	Axert®
Eletriptan	Relpax®
Frovatriptan	Frova®
Naratriptan	Amerge®
Rizatriptan	Maxalt®, Maxalt MLT®
Sumatriptan	Alsuma®, Imitrex®, Sumavel®, Zecuity®
Zolmitriptan	Zomig®, Zomig ZMT®

The acceptable ICD-10-CM diagnosis codes for triptans in beneficiaries less than 18 years of age are as follows:

Drug-Brand Example	Diagnosis	ICD-10-CM Diagnosis Code
Almotriptan – Axert® Eletriptan – Relpax® Frovatriptan – Frova® Naratriptan – Amerge® Rizatriptan – Maxalt®, Maxalt MLT® Sumatriptan [Oral, Nasal] – Imitrex®, Onzetra Xsail®, Tosymra® Sumatriptan [Injection] – Zembrace SymTouch® Zolmitriptan – Zomig®, Zomig ZMT®	Migraine	G43.0*, G43.1*, G43.7*
Sumatriptan [Injection] – Imitrex®, Sumavel®	Migraine	G43.0*, G43.1*, G43.7*
	Cluster Headache, Acute	G44.009

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES**

---

**SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

---

**Ubrogepant (Ubrelyv®)**

Pharmacy claims for ubrogepant (Ubrelyv®) have a quantity limit of 16 tablets per 30 days.

**Vaccines (Adult)**

Louisiana Medicaid will reimburse enrolled **pharmacies** for select adult immunizations administered by a pharmacist with the “Authority to Administer” authorized by the Louisiana Board of Pharmacy. For COVID-19 vaccines only, the administration of the vaccine may be given by a pharmacist, and/or qualified pharmacy technician and/or state-authorized pharmacy intern acting under the supervision of a qualified pharmacist during a Public Health Emergency (PHE). Vaccine reimbursement includes reimbursement for the ingredient cost and administration fee. Reimbursement for the COVID-19 vaccine is for the administration fee only.

**Pharmacist Requirements**

For adult vaccine reimbursement, the pharmacist shall:

1. Be registered with the Louisiana Board of Pharmacy with the “Authority to Administer” vaccines;
2. Be registered as a Louisiana Medicaid provider;
3. Inform the individual that the administration of an immunization or vaccine is not to be construed as being in lieu of an annual preventive visit with the individual's primary care or family physician;
4. Access the Louisiana Immunization Network for Kids (LINKS) prior to immunization administration, if possible, to verify appropriate utilization according to the Advisory Committee on Immunization Practices (ACIP) to prevent duplication, unnecessary doses, inappropriate age, etc.;
5. Report each immunization to the Louisiana Department of Health, Office of Public Health's LINKS at the time of the immunization or as soon as reasonably possible, thereafter;

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

6. Report all adverse events observed or which are reported to the pharmacist to the Vaccine Adverse Events Reporting System, or its successor program; and further, the pharmacist shall refer the patient with an adverse event to appropriate medical care;
7. Report certain data elements to the CDC for each COVID-19 dose administered within 24 hours of administration, as a vaccination Provider;
8. Ensure that pharmacy technicians and/or state-authorized pharmacy interns administering COVID-19 vaccines meet PREP Act qualifications. The qualified pharmacy technicians and/or state-authorized pharmacy interns act under the supervision of a qualified pharmacist. The supervising qualified pharmacist of qualified pharmacy technicians and/or state-authorized interns must comply with CDC, state, and federal requirements for COVID-19 vaccine administration; and
9. Request the name of a patient's primary care provider prior to the administering of any immunization. The pharmacist shall notify the primary care provider, by written or electronic communication, as soon as reasonably possible that the immunization was administered.

All 340B pharmacies carved-in to Medicaid may bill vaccines and the administration fee for adults (19 years and older) at POS as a pharmacy benefit.

There will be no copay assessed on adult vaccine claims. Third party billing policy will apply and Medicaid will be the payer of last resort.

Pharmacy claims for vaccines will bypass POS edits for the four prescription monthly limit and pharmacy Lock-In.

The following chart lists select adult vaccines with age limits covered when administered by a pharmacist as a pharmacy claim:

Adult Vaccines	Brand Name Examples	Age Limit
Hepatitis A Adult	Vaqta®, Havrix®	≥ 19 years
Hepatitis A-Hepatitis B Adult	Twinrix®	≥ 19 years
Hepatitis B Adult	Heplisav-B®, Engerix-B®	≥ 19 years



**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

HPV-Human Papillomavirus 9 Valent	Gardasil ® 9	19-45 years
Influenza Vaccine	Various Brands	≥ 19 years*
Measles, Mumps, & Rubella	M-M-R®II	≥ 19 years
Meningococcal Conjugate (Groups A, C, Y and W-135)	Menveo®, Menactra®	≥ 19 years
MENB – Meningococcal Group B	Trumenba®, Bexsero®	≥ 19 years
Pneumococcal- 13-valent	Prevnar 13™	≥ 19 years
Pneumococcal Polysaccharide (23 Valent)	Pneumovax®23	≥ 19 years
Tetanus and Diphtheria Toxoids	TDVAX®	≥ 19 years
Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis	Adacel®, Boostrix®	≥ 19 years
Varicella	Varivax®	≥ 19 years
Zoster Vaccine Recombinant, Adjuvanted	Shingrix®	≥ 50 years
Zoster Vaccine Live	Zostavax®	≥ 60 years

\*There are select age ranges for specific influenza vaccines based on the package insert.

**NOTE:** The *POS User Guide* can be accessed at:

[www.lamedicaid.com/Provweb1/Pharmacy/LAPOS\\_User\\_Manual\\_static.pdf](http://www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf) or by visiting Section 37.5.1 for detailed billing instructions and override procedures.

**COVID-19 Vaccine**

Currently, the Pfizer and Moderna COVID-19 vaccines administration are covered by the Louisiana Medicaid pharmacy program. This coverage also includes home administration of the COVID-19 vaccine. The FDA has authorized Pfizer COVID-19 vaccine for emergency use in children ages 5-11. The COVID-19 vaccine will be covered for beneficiaries five (5) years of age and older for the Pfizer product and 18 years of age and older for the Moderna and Johnson & Johnson (Janssen) products. The age requirement may be updated in the future in accordance with current Emergency Use Authorizations (EAUs). The COVID-19 vaccines are covered for the administration of the initial series, 3<sup>rd</sup> dose, and booster shot. Additional COVID-19 vaccines will be covered as they receive EUA.

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142****COVID-19 Vaccine Requirements for 3<sup>rd</sup> Dose**

Pharmacy claims will be reimbursed for the administration of the 3<sup>rd</sup> dose COVID-19 vaccine (Pfizer and Moderna only) in immunocompromised beneficiaries. The 3<sup>rd</sup> dose must be the same manufacturer as the previously administered COVID-19 vaccine series. The 3<sup>rd</sup> dose (for Pfizer and Moderna only) in immunocompromised beneficiaries can be given 28 days after the 2<sup>nd</sup> dose.

**COVID-19 Vaccine Requirements for Booster Shot**

The administration of the booster shot is reimbursed for all three COVID-19 vaccines (Pfizer, Moderna, and Janssen) in beneficiaries 18 years of age and older. The booster shot can be of any approved COVID-19 vaccine manufacturer (Pfizer, Moderna, and Janssen) allowing a “mix and match” of previously administered COVID-19 vaccines. The booster shot can be administered 6 months after the initial series is completed.

**Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors**

Prescriptions for Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors: deutetrabenazine (Austedo®), tetrabenazine (Xenazine®), and valbenazine (Ingrezza®) will be reimbursed when:

1. The prescriber has obtained an approved clinical authorization.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Voxekitir (Oxbryta®)**

Pharmacy claims for voxekitir (Oxbryta®) have a clinical authorization requirement and quantity limit of 90 tablets/30 days.

**Zoledronic Acid (Reclast®)**

Pharmacy claims for zoledronic acid (Reclast®) are subject to the quantity limit listed in the chart.

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

Generic Name	Brand Name	Quantity Limit
Zoledronic Acid	Reclast®	1 vial/365 days

**Diagnosis Code Requirement for Selected Medications**

Prescriptions for selected medications require a diagnosis code for reimbursement for both FFS Medicaid and the MCOs. The diagnosis code should be documented on the hardcopy prescription by the prescriber or pharmacist. The pharmacist may document the diagnosis code on the hardcopy prescription or in the pharmacy's electronic recordkeeping system after electronic or verbal consultation with the prescribing practitioner.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access drug specific forms, criteria, and instructions at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>

**Prospective Drug Utilization Policies/Limits/Edits**

Prospective drug utilization review (UniDUR) consists of criteria set forth by the state-established DUR board which monitors for inappropriate use of medications and identifies potential drug conflicts. UniDUR is designed to work alongside the POS claims processing and eligibility systems. Prospective Drug Utilization Review displays alert messages, based on severity level, to alert of any possible harmful effects that a medication may have on a patient. The alerts generated are caused by various combinations of interactions between a beneficiary's condition, beneficiary's historical drug prescription records on file and the current medications prescribed for them.

Professional judgment regarding appropriate drug use is the responsibility of the pharmacist. Improper use of DUR override codes by pharmacy staff may result in the disallowance of these override codes and administrative sanctions by Medicaid and the Board of Pharmacy.

UniDUR has predetermined standards to monitor:

1. Duration of therapy;
2. Early refill;
3. Duplicate drug therapy;

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES**

---

**SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

---

4. Pregnancy and FDA Category X drugs;
5. Therapeutic duplication;
6. Drug to drug interaction;
7. Unnecessary drug therapy;
8. Age and gender restrictions;
9. Maximum dosage;
10. Quantity Limits; and
11. Drugs to diagnosis.

**NOTE:** Refer to Section 37.5.12 for an overview of Patient Counseling, Drug Utilization Review (DUR).

**Duration of Therapy Limits****H<sub>2</sub> Antagonists & Sucralfate**

The program utilizes a duration of therapy module for H<sub>2</sub> antagonists, and sucralfate for beneficiaries who are 16 and older. Acute dosage guidelines for these drugs are monitored. H<sub>2</sub> antagonists have a duration of therapy limit of 180 days in a rolling 365 days. Sucralfate has a duration of therapy limit of 90 days per calendar year. Acute dosing of H<sub>2</sub> antagonists and sucralfate requires documentation of an appropriate diagnosis code. When authorized by the prescriber, claims beyond the duration of therapy limit can be processed through the POS system at the pharmacy. The chronic use of these agents at full therapeutic dosage is generally not indicated.

The acute dosage schedules of these drugs are as follows:

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

<b>H<sub>2</sub> Antagonists &amp; Sucralfate</b>		
<b>Generic Description</b>	<b>Acute mg/day dose</b>	<b>Duration of Therapy</b>
Ranitidine HCl	300	180 days
Cimetidine	1200	180 days
Nizatidine	300	180 days
Famotidine	40	180 days
Sucralfate	4000	90 days

Maintenance dose drug therapy will continue to be payable after the duration of therapy has been exceeded with prescriber authorization.

If, in the professional judgment of the prescriber, a determination is made to continue acute therapy beyond the appropriate duration of therapy, the prescriber must indicate in writing on the prescription or a signed and dated attachment, a diagnosis code necessitating the continuation of acute therapy. Beneficiary specific diagnosis information from the prescriber via facsimile is acceptable.

Only the prescriber who issues a prescription is authorized to sign off on a diagnosis override.

For acute therapy to continue as a reimbursable service beyond the above listed therapy limits, duration of therapy, the pharmacy provider must supply the reason for service code, professional service code and result of service code.

**NOTE:** The *POS User Guide* can be accessed at: [www.lamedicaid.com/Provweb1/Pharmacy/LAPOS\\_User\\_Manual\\_static.pdf](http://www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf) or by visiting Section 37.5.1 for detailed billing instructions and override procedures.

Select diagnosis codes which may justify the long-term usage of sucralfate are listed below.

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

ICD-10-CM Diagnosis Code(s)	Diagnosis
B96.81	<i>H. pylori</i>
C96.2	Malignant Mast Cell Tumors
D44.0, D44.2, D44.9	Multiple Endocrine Adenomas
E16.4	Zollinger-Ellison Syndrome
K20.9	Esophagitis, Unspecified
K21.0	Reflux Esophagitis
K20.8	Abscess of Esophagus
K22.1*	Ulcer of Esophagus with or without bleeding
K22.7*	Barrett's Esophagus
K25.*	Gastric Ulcer
K26.*	Duodenal Ulcer
K27.*	Peptic Ulcer
K29.*	Gastritis/Duodenitis
K30	Gastric Hyperacidity
K21.9	Gastroesophageal Reflux Disease (GERD)
K50.*	Crohn's Disease
K86.0, K86.1	Chronic Pancreatitis
K92.2	Gastrointestinal Hemorrhage

\* - any number or letter or combination of UP TO FOUR numbers and letters of an assigned ICD-10-CM diagnosis code

Select diagnosis codes which may justify the long-term usage of H<sub>2</sub> antagonists are listed below:

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

ICD-10-CM Diagnosis Code(s)	Diagnosis
C96.2*	Malignant Mast Cell Tumors
D44.0, D44.2, D44.9	Multiple Endocrine Adenomas
E16.4	Zollinger-Ellison Syndrome
K20.9	Esophagitis, Unspecified
K21.0	Reflux Esophagitis
K20.8	Abscess of Esophagus
K22.1*	Ulcer of Esophagus with or without bleeding
K22.7*	Barrett's Esophagus
K25.*	Gastric Ulcer
K26.*	Duodenal Ulcer
K27.*	Peptic Ulcer
K29.*	Gastritis/Duodenitis
K30	Gastric Hyperacidity
K21.9	Gastroesophageal Reflux Disease (GERD)
K50.*	Crohn's Disease
K86.0, K86.1	Chronic Pancreatitis
K92.2	Gastrointestinal Hemorrhage

\* Any number or letter or combination of **UP TO FOUR** numbers and letters of an assigned ICD-10-CM diagnosis code

**Proton Pump Inhibitors (PPIs)**

Prescriptions for Proton Pump Inhibitors have a duration of therapy of 180 days in a rolling 365 days.

**Diagnosis Codes Exempt from the Duration of Therapy Limit for PPIs**

Select diagnosis codes are exempt and bypass the duration of therapy edit for PPIs. (See the following chart for the listing).

Diagnosis	ICD-10-CM Diagnosis Code(s)
Abscess of Esophagus	K20.8
Angiodysplasia of Stomach and Duodenum (with OR without Mention of Hemorrhage)	K31.81*

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

Atrophic Gastritis with Hemorrhage	K29.41
Barrett's Esophagus	K22.7*
Cerebral Palsy ( <i>new Aug 2019</i> )	G80*
Chronic Pancreatitis	K86.0, K86.1
Congenital Tracheoesophageal Fistula	Q39.1, Q39.2
Cystic Fibrosis	E84.*
Eosinophilic Esophagitis	K20.0
Eosinophilic Gastritis	K52.81
Gastrointestinal Hemorrhage	K92.2
Gastrointestinal Mucositis (Ulcerative)	K92.81
Malignant Mast Cell Tumors	C96.2*
Multiple Endocrine Adenomas	D44.0, D44.2, D44.9
Tracheoesophageal Fistula	J86.0
Ulcer of Esophagus with OR without Bleeding	K22.1*
Zollinger-Ellison Syndrome	E16.4

\* Any number or letter or combination of **UP TO FOUR** numbers and letters of an assigned ICD-10-CM diagnosis code

Claims for beneficiaries under six years of age are excluded from the PPI duration of therapy module. In addition, claims for beneficiaries receiving pancreatic enzymes are excluded from the PPI duration of therapy module as well.

**Early Refill**

The Medicaid Program denies pharmacy claims for early refills if the patient has requested the same medication at the same pharmacy prior to 85 percent of medication being utilized. This translates into a five day window based on a 30-day supply.

Prescriptions for narcotic analgesics will deny for an early refill edit when less than 90 percent of the medication had been utilized. This translates into a two day window based on a 30- day supply.



**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

Pharmacists must enter the actual days' supply for each pharmacy claim. If the number of days is not apparent, an estimate must be given based on professional judgment.

In some cases, the pharmacist may have knowledge of dosage changes which would warrant a beneficiary's request for medication earlier than previously reported in the estimated days' supply. The pharmacist must document the circumstances on the prescription hard copy.

**NOTE:** The *POS User Guide* can be accessed at: [www.lamedicaid.com/Provweb1/Pharmacy/LAPOS\\_User\\_Manual\\_static.pdf](http://www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf) or by visiting Section 37.5.1 for detailed billing instructions and override procedures.

**Duplicate Drug Therapy**

A claim denial will occur if the beneficiary attempts to obtain the same drug (form and strength) from a different pharmacy sooner than is anticipated based on the estimated days' supply.

After consultation with the physician, beneficiary and/or the POS help desk, the provider must determine whether there are extenuating circumstances which substantiate the dispensing of a duplicate claim.

The pharmacy provider shall record documentation of circumstances and specific contacts for the override.

For those isolated instances when one pharmacy has billed a claim, and special circumstances prevented the beneficiary from receiving the prescription from the pharmacy originally billing the claim an override is allowed. An override should only be used if the second pharmacy attempting to bill a claim for the same ingredient for the same beneficiary and cannot have the first claim reversed by the original billing pharmacy. A notation to that effect must be written on the hardcopy prescription. Pharmacy claims submitted with an override code are subject to the pharmacy audit process.

When both duplicate drug therapy and early refill clinical events occur, reimbursement will not be made. These situations indicate multiple pharmacy shopping patterns.

**NOTE:** The *POS User Guide* can be accessed at: [www.lamedicaid.com/Provweb1/Pharmacy/LAPOS\\_User\\_Manual\\_static.pdf](http://www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf) or by visiting Section 37.5.1 for detailed billing instructions and override procedures.

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES**

---

**SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

---

**Pregnancy and FDA Category X Drugs**

The Medicaid Program denies pharmacy claims with FDA Pregnancy Category for pregnant women. Pharmacy claims submitted for a drug in this category for beneficiaries with a co-payment designation of pregnancy will be denied.

The specific drugs that are currently included in FDA Pregnancy Category X are listed below. The Medicaid Program may add drugs to these lists as new drugs appear on the market or as FDA indications change.

There is no override option for these claims.

**Pregnancy and FDA Category D Drugs**

Pharmacy claims submitted with FDA Pregnancy Category D drugs will receive an educational edit in the response from the Medicaid Program. These claims will not deny.

**Prior Drug Use**

Pharmacy claims for select drugs will require prior use of other drug(s) before reimbursement.

Olmesartan/amlodipine/hydrochlorothiazide (Tribenzor®) and amlodipine/valsartan/hydrochlorothiazide (Exforge HCT®) will require prior drug use of two drug therapies from these select drug classes: calcium channel blockers, angiotensin receptor blockers, and/or diuretics. If previous claims for drugs in two of these three drug classes (calcium channel blockers, angiotensin receptor blockers, and/or diuretics) are not identified, the pharmacy claim will deny.

**NOTE:** The *POS User Guide* can be accessed at:

[www.lamedicaid.com/Provweb1/Pharmacy/LAPOS\\_User\\_Manual\\_static.pdf](http://www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf) or by visiting Section 37.5.1 for detailed billing instructions and override procedures.

**Therapeutic Duplication**

The Medicaid Program denies pharmacy claims for oral formulations of drugs in the following classes and specific drugs if the beneficiary has an active paid claim on file for another drug in the same therapeutic class. An active prescription is a prescription in which the days' supply has not expired.

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES**

---

**SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

---

If an override is determined appropriate after contacting the prescriber, additional hard-copy documentation of the reason for service code, professional service code and result of service code is required on the new prescription for audit purposes. Additional requirements may be associated with certain drug classes or specific drugs.

**First Generation Antihistamine**

Brompheniramine Maleate  
Carbinoxamine Maleate  
Clemastine Fumarate  
Cyproheptadine HCL

If a first generation antihistamine is given with another first and/or second generation antihistamine or antihistamine-decongestant product, the claim will deny due to a therapeutic duplication.

**Second Generation Antihistamine**

Cetirizine HCL  
Desloratadine  
Fexofenadine HCL  
Levocetirizine Dihydrochloride  
Loratadine

If a second generation antihistamine is given with another first and/or second generation antihistamine or antihistamine-decongestant product, the claim will deny due to a therapeutic duplication.

**First Generation Antihistamine-Decongestant**

Pseudoephedrine HCL /Brompheniramine  
Pseudoephedrine HCL /Triprolidine HCL  
Phenylephrine/Diphenhydramine  
Pseudoephedrine HCL/Chlorpheniramine

If a first generation antihistamine-decongestant product, is given with another first and/or second generation antihistamine or antihistamine-decongestant product, the claim will deny due to a therapeutic duplication.

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142****Second Generation Antihistamine-Decongestant**

Cetirizine HCL/Pseudoephedrine  
Fexofenadine/Pseudoephedrine  
Loratadine/Pseudoephedrine  
Desloratadine/Pseudoephedrine

If a second generation antihistamine-decongestant product, is given with another first and/or second generation antihistamine or antihistamine-decongestant product, the claim will deny due to a therapeutic duplication.

Claims for diphenhydramine, hydroxyzine HCl, and hydroxyzine pamoate are not included in the antihistamine edits for therapeutic duplication.

**Angiotensin Converting Enzyme (ACE) Inhibitors and ACE Inhibitor/Diuretic Combinations**

Benazepril HCl	Lisinopril/Hydrochlorothiazide
Benazepril HCl/Hydrochlorothiazide	Moexipril HCl
Captopril	Moexipril/Hydrochlorothiazide
Captopril/Hydrochlorothiazide	Perindopril Erbumine
Enalapril Maleate	Quinapril HCl
Enalapril/Hydrochlorothiazide	Quinapril/Hydrochlorothiazide
Fosinopril Sodium	Fosinopril Sodium
Fosinopril/Hydrochlorothiazide	Ramipril
Lisinopril	Trandolapril

**ACE Inhibitors/Calcium Channel Blocker Combinations**

Benazepril/Amlodipine  
Trandolapril/Verapamil HCl

**Angiotensin Receptor Antagonists (ARB) and ARB/Diuretic Combinations**

Candesartan Cilexetil	Losartan/Hydrochlorothiazide
Candesartan/Hydrochlorothiazide	Olmesartan Medoxomil
Eprosartan Mesylate	Olmesartan/Hydrochlorothiazide
Eprosartan/Hydrochlorothiazide	Telmisartan

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

Irbesartan  
Irbesartan/Hydrochlorothiazide  
Losartan Potassium

Telmisartan/Hydrochlorothiazide  
Valsartan  
Valsartan/Hydrochlorothiazide

**ARB/Calcium Channel Blocker Combinations**

Olmesartan Medoxomil/Amlodipine  
Valsartan/Amlodipine

**Beta-Adrenergic Blocking Agents and Beta-Adrenergic Blocking Agent/Diuretic Combinations**

Acebutolol HCl  
Atenolol  
Atenolol/Chlorthalidone  
Betaxolol HCl  
Bisoprolol Fumarate  
Bisoprolol/Hydrochlorothiazide  
Carvedilol  
Carvedilol CR  
Labetalol HCl  
Metoprolol ER  
Metoprolol Tartrate  
Metoprolol/Hydrochlorothiazide

Nadolol  
Nadolol/Bendroflumethiazide  
Nebivolol HCl  
Penbutolol Sulfate  
Pindolol  
Propranolol HCl  
Propranolol/Hydrochlorothiazide  
Sotalol AF  
Sotalol HCl  
Timolol Maleate  
Timolol/Hydrochlorothiazide

**Calcium Channel Blockers**

Amlodipine  
Diltiazem  
Felodipine  
Isradipine  
Nicardipine

Nifedipine  
Nimodipine  
Nisoldipine  
Verapamil

**Calcium Channel Blocker/Antihyperlipemia Agent Combination**

Amlodipine/Atorvastatin Calcium

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142****Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist/ Dipeptidyl Peptidase-4 (DPP-4) Inhibitor**

A pharmacy claim for a Glucagon-Like Peptide-1 (GLP-1) receptor agonist will deny with a therapeutic duplication if there is an active claim on the beneficiary's file for a Dipeptidyl Peptidase-4 (DPP-4) inhibitor. A pharmacy claim for a DPP-4 inhibitor will deny with a therapeutic duplication if there is an active claim on the beneficiary's file for a GLP-1 receptor agonist.

**Potassium Replacement**Potassium Acetate  
Potassium ChloridePotassium Bicarbonate / Citric Acid  
Potassium Citrate**Tricyclic Antidepressants**Amitriptyline HCl  
Amoxapine  
Clomipramine HCl  
Desipramine HCl  
Doxepin HCl  
Imipramine HClImipramine Pamoate  
Maprotiline HCl  
Nortriptyline HCl  
Protriptyline HCl  
Trimipramine Maleate**Selective Serotonin Reuptake Inhibitors**Citalopram HBr  
Escitalopram Oxalate  
Fluoxetine HCl  
Fluvoxamine MaleateParoxetine HCl  
Paroxetine Mesylate  
Sertraline HCl**Antipsychotic Agents (Typical and Atypical)**

Prescriptions for antipsychotic agents will deny for therapeutic duplication when the beneficiary has two active antipsychotic prescriptions on their file. The pharmacist must document on the hard copy prescription the reason the prescriber required the beneficiary to receive a third antipsychotic agent.

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

**Note:** Refer to “Drugs with Special Payment Criteria/Limitations” in this section for further policy regarding antipsychotic agents.

**Typical Antipsychotic Agents**

Chlorpromazine	Pimozide
Fluphenazine	Thioridazine
Haloperidol	Thiothixene
Loxapine	Trifluoperazine
Molindone	
Perphenazine	

**Atypical Antipsychotic Agents**

Aripiprazole	Lurasidone
Asenapine	Olanzapine
Brexipiprazole	Paliperidone
Cariprazine	Quetiapine
Clozapine	Risperidone
Iloperidone	Ziprasidone

**Antipsychotic /Selective Serotonin Reuptake Inhibitor Combinations**

Pharmacy claims for olanzapine/fluoxetine will deny when there are two active prescriptions for antipsychotic agents on the beneficiary’s file or when there is one active prescription for a selective serotonin reuptake inhibitor (SSRI) on the beneficiary’s history file.

Olanzapine/Fluoxetine

**Anti-Anxiety Agents**

Alprazolam	Hydroxyzine
Buspirone	Lorazepam
Chlordiazepoxide	Meprobamate
Chlorazepate	Oxazepam
Diazepam	

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

The pharmacist must document on the hardcopy prescription the reason an additional anti-anxiety agent was requested by the prescriber.

An additional anti-anxiety agent may be submitted without a therapeutic duplication when the beneficiary has a diagnosis of seizures. The diagnosis code must be documented on the hardcopy prescription after written or verbal consultation with the prescriber and submitted electronically for the override.

Acceptable diagnosis codes are:

ICD-10-CM Diagnosis Code(s)	Description
P90	Convulsions in Newborn
G40.*	Epilepsy, Seizures
R56.*	Other Convulsions

**Sedative Hypnotic Agents**

Estazolam	Temazepam
Eszopiclone	Triazolam
Flurazepam HCl	Zaleplon
Quazepam	Zolpidem Tartrate

**Attention Deficit Disorder (ADD) Agents**

Armodafinil	Guanfacine
Atomoxetine	Lisdexamfetamine
Dexmethylphenidate	Methylphenidate
Dextroamphetamine	Modafinil
Dextroamphetamine/amphetamine	

An incoming pharmacy claim for any of the above ADD agents will deny when there is an active paid claim for any of these agents on the beneficiary's file written by a different prescriber.



**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142****Non-Steroidal Anti-Inflammatory Agents**

Celecoxib	Ibuprofen	Meloxicam
Diclofenac Potassium	Ibuprofen/Hydrocodone Bitartrate	Nabumetone
Diclofenac Sodium	Ibuprofen/Oxycodone	Naproxen
Diclofenac Sodium/Misoprostol	Indomethacin	Naproxen Sodium
Diflunisal	Ketoprofen	Naproxen/Lansoprazole
Etodolac	Ketorolac Tromethamine	Oxaprozin
Fenoprofen Calcium	Meclofenamate Sodium	Piroxicam
Flurbiprofen	Mefenamic Acid	Sulindac
		Tolmetin Sodium

**Short-Acting Beta<sub>2</sub> Agonist Inhalers**

Albuterol  
Pirbuterol  
Levalbuterol

Pharmacy claims billed for concurrent use of different short-acting beta<sub>2</sub> agonist inhalers (SABAs) will deny with a therapeutic duplication.

**Note:** Refer to ‘Drugs with Special Payment Criteria/Limitations’ in this section for further policy regarding short-acting beta<sub>2</sub> agonist inhalers.

**Short-Acting Opiate Agents**

Buprenorphine*	Hydrocodone/APAP
Buprenorphine/Naloxone*	Hydrocodone/Ibuprofen
Butorphanol Tartrate	Hydromorphone HCl IR
Codeine Phosphate	Levorphanol Tartrate
Codeine Phosphate/APAP	Meperidine HCl
Codeine/ASA	Methadone HCl
Codeine Sulfate	Morphine Sulfate IR
Codeine/APAP/Caffeine/Butalbital	Oxycodone HCl IR
Codeine/ASA/Caffeine/Butalbital	Oxycodone/APAP
Codeine/Carisoprodol/ASA	Oxycodone ASA
Dihydrocodeine/APAP/Caffeine	Oxycodone/Ibuprofen
Fentanyl Citrate Buccal	Oxymorphone

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

Pentazocine/APAP  
Pentazocine/Naloxone  
Propoxyphene HCl  
Propoxyphene/Napsylate

Propoxyphene/APAP  
Tramadol HCl  
Tramadol HCl/APAP

**NOTE:** Concurrent prescriptions for opioid analgesics with buprenorphine agents may only be overridden when issued by the same physician.

**Long-Acting Opiate Agents**

Fentanyl Transdermal  
Morphine Sulfate CR

Oxycodone HCl CR  
Oxymorphone ER

**Proton Pump Inhibitors**

Esomeprazole  
Lansoprazole  
Omeprazole

Omeprazole/Sodium Bicarbonate  
Pantoprazole  
Rabeprazole

**Sulfonylureas**

A pharmacy claim for a sulfonylurea will deny if there is an active claim on the beneficiary's file for another sulfonylurea.

The Department may add drugs to these lists as new drugs appear on the market.

**NOTE:** Refer to Section 37.5.8 - Claim Submission and Processing Payments for override information as well as the *POS User Guide* accessed at: [www.lamedicaid.com/Provweb1/Pharmacy/LAPOS\\_User\\_Manual\\_static.pdf](http://www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf) or by visiting Section 37.5.1 for detailed billing information.

**Drug/Drug Interaction**

There may be some situations where adverse interactions could potentially occur between two drugs. In these instances the UniDUR system denies one or both of these claims.

Prescriptions for nitrates will deny when there is an active prescription for Sildenafil (Revatio®) or Tadalafil (Adcirca®) on the beneficiary's drug history file. Conversely, prescriptions for

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES**

---

**SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND  
EXCLUSIONS****PAGE(S) 142**

---

Sildenafil (Revatio®) and Tadalafil (Adcirca®) will deny when there is an active prescription for nitrates on the drug history file.

Upon consultation with the prescriber, the pharmacist may override this interaction. The pharmacist must document the reason the prescriber required the beneficiary to receive a nitrate and Sildenafil (Revatio®) or Tadalafil (Adcirca®). In addition, documentation of the reason for service code, professional service code and result of service code is required on the hardcopy prescription. These DUR codes are required for the claim submission.

**Unnecessary Drug Therapy****Selective Cox-2 Inhibitor**

Pharmacy claims for the selective COX-2 inhibitor, celecoxib (Celebrex®) will deny for “drug use not warranted” if they are not submitted with an appropriate diagnosis code and reason for treatment documented on the hard prescription.

The FDA issued a public health advisory which stated that use of a COX-2 selective agent may be associated with an increased risk of serious cardiovascular events, especially when it is used for long periods of time or in very high-risk settings (e.g. immediately after heart surgery).

The FDA made the following interim recommendations:

1. Practitioners prescribing Celecoxib (Celebrex®) should consider this emerging information when weighing the benefits against risks for individual patients. Patients who are at a high risk of gastrointestinal (GI) bleeding, have a history of intolerance to non-selective NSAIDs or are not doing well on non-selective NSAIDs may be appropriate candidates for COX-2 selective agents; and
2. Individual patient risk for cardiovascular events and other risks commonly associated with NSAIDs should be taken into account for each prescribing situation.

As a result of this public health advisory and to help ensure the safety and well-being of Medicaid beneficiaries, the prescribing practitioner must include:

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

1. The condition being treated with the COX-2 selective agent by indicating the diagnosis code of the treated condition on all new prescriptions written for a COX-2 selective agent; and
2. The reason a COX-2 selective agent is used rather than a non-selective NSAID (e.g. treatment failure or history of a GI bleed).

The diagnosis code and the rationale for the choice of a COX-2 selective agent must be noted in the prescriber's handwriting. A rubber stamp notation is not acceptable. The diagnosis code and the rationale may be submitted as an attachment to the original prescription via facsimile. The attachment must be dated and written in the prescriber's handwriting.

A prescription written for a COX-2 selective agent for a Medicaid beneficiary will only process without an override when the following conditions are met:

1. A diagnosis code indicating the reason for treatment is documented and submitted; and
2. When one of the following conditions exists:
  - a. Beneficiary has current prescription for H2 receptor antagonist;
  - b. Beneficiary has current prescription for proton pump inhibitor;
  - c. Beneficiary has current prescription for warfarin;
  - d. Beneficiary has current prescriptions indicating chronic use of oral steroids; or
  - e. Beneficiary is 60 years of age or older.

If, in the professional judgment of the prescriber, a determination is made which necessitates therapy with a COX-2 selective agent, the pharmacist may override this edit. The pharmacy provider must supply the reason for service code, professional service code and result of service code with the POS submission of the claim and have the information recorded on the hardcopy.

**NOTE:** Refer to Section 37.5.8 - Claim Submission and Processing Payments for override information as well as the *POS User Guide* accessed at:

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES**

---

**SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

---

[www.lamedicaid.com/Provweb1/Pharmacy/LAPOS\\_User\\_Manual\\_static.pdf](http://www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf) or by visiting Section 37.5.1 for detailed billing information.

**Maximum Dosage****Atypical Antipsychotic Agents**

Pharmacy claims for doses of antipsychotic agents which exceed the maximum recommended doses will deny.

**NOTE:** Refer to Antipsychotic Agents of this section for the age limits and dosage schedules for antipsychotic agents.

The prescriber may choose to override an age or dosage limit for an antipsychotic medication. Overrides for antipsychotic medications can be addressed by the provider contacting the RxPA Unit. When the pharmacist cannot reach the prescriber or the RxPA Unit is closed, the pharmacist, using his/her professional judgment, may deem the filling of the antipsychotic prescription to be an “emergency.” In these emergency cases, the pharmacist must indicate “Emergency Prescription” on the hardcopy prescription or in the pharmacy’s electronic recordkeeping system and override the age or dosage limit.

**Agents Containing Acetaminophen or Aspirin**

**Due to the potential of hepatotoxicity, claims billed with a dosage of acetaminophen that exceeds four grams per day will deny.** Claims for products containing aspirin will deny payment when the maximum daily dosage billed exceeds six grams per day. Please note that patients may also be consuming over the counter products that contain either acetaminophen or aspirin.

The maximum regimens apply to both brand name and generic products. As new products are added to the drug file, maximum daily dosages will apply.

**Overrides for the (high dose) denial are only acceptable when the prescriber is consulted and approval is given. A notation stating the reason and the codes used to override the claim should be noted on the hardcopy prescription.**

It is imperative that pharmacists use their professional judgment to determine an appropriate days’ supply based upon the directions noted by the prescriber.

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142****Suspending Agents**

Pharmacy claims for the following select suspending agents are reimbursable:

Generic Name	Trade Name <sup>1</sup>
Compounding Vehicle Suspension No. 19	Mx-Sol Blend; Ora Blend
Compound Vehicle Suspension SF No. 20	Ora Plus
Compounding Vehicle No. 8	Ora Sweet
Compound Vehicle Sugar Free No. 9	Ora Sweet SF

**Sedative Hypnotic Agents**

Pharmacy claims which exceed the maximum daily dosage limit for selected sedative hypnotic agents will deny at POS.

The maximum daily doses for the selected sedative hypnotic agents are as follows:

Generic Name	Brand Name	Maximum Dose Per Day
Doxepin (sedative-hypnotic only)	Silenor®	6 mg/day
Estazolam	Prosom®	2 mg/day
Eszopiclone	Lunesta®	3 mg/day
Flurazepam	Dalmane®	30 mg/day
Quazepam	Doral®	15 mg/day
Ramelteon	Rozerem®	8 mg/day
Temazepam	Restoril®	30 mg/day

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

Generic Name	Brand Name	Maximum Dose Per Day
Triazolam	Halcion®	0.5 mg/day
Zaleplon	Sonata®	20 mg/day
Zolpidem IR tablet	Ambien®	10 mg/day
Zolpidem SL tablet	Edluar®	10 mg/day
Zolpidem oral spray	Zolpimist®	10 mg (2sprays)/day
Zolpidem ER tablet	Ambien CR®	12.5 mg/day
Zolpidem SL tablet	Intermezzo®	1.75mg/day (female)
Zolpidem SL tablet	Intermezzo®	3.5 mg/day (male)

**NOTE:** The *POS User Guide* can be accessed at:

[www.lamedicaid.com/Provweb1/Pharmacy/LAPOS\\_User\\_Manual\\_static.pdf](http://www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf) for by visiting Section 37.5.1 for detailed billing instructions and override procedures.

Pharmacy claims for select sedative hypnotics will be subject to the following quantity limits:

Medication	Naïve 7-day supply per rolling 30 days <sup>1</sup>	Chronic Use 15-day supply per 30 rolling days <sup>2</sup>
Doxepin Tablet (Silenor®)	7 tablets	15 tablets
Flurazepam Capsule	7 capsules	15 capsules
Estazolam Tablet	7 tablets	15 tablets
Eszopiclone Tablet (Lunesta®)	7 tablets	15 tablets
Ramelteon Tablet (Rozerem®)	7 tablets	15 tablets
Suvorexant Tablet (Belsomra®)	7 tablets	15 tablets
Triazolam Tablet (Halcion®)	7 tablets	15 tablets
Temazepam Capsule (Restoril®)	7 capsules	15 capsules
Zaleplon Capsule (Sonata®)	7 capsules	15 capsules

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

Zolpidem Tartrate (Ambien®; Ambien CR®)	7 tablets	15 tablets
Zolpidem Tartrate Sublingual (Edluar®; Intermezzo®)	7 tablets	15 tablets

<sup>1</sup> Oral sedative hypnotics for a naïve beneficiary have a 7 day supply per rolling 30 days.

Naïve is defined as having no paid claims for a sedative hypnotic in the previous 60 days.

<sup>2</sup> Oral sedative hypnotics for chronic use have a 15 day supply per rolling 30 days.

Chronic use is defined as having a paid claim for a sedative hypnotic in the previous 60 days.

**Additional information for oral sedative hypnotics:**

1. Pharmacy claims for all sedative/hypnotic agents (except lemborexant, tasimelteon and zolpidem tartrate oral spray) are limited to:
  - a. A quantity of 7 per rolling 30 days for beneficiaries who have no sedative/hypnotic pharmacy claims in the previous 60-day period;
  - b. A quantity of 15 per rolling 30 days for beneficiaries who have any sedative/hypnotic pharmacy claim in the previous 60-day period; and
  - c. Lemborexant (Dayvigo™) is limited to a maximum quantity of 7 tablets per rolling 30 days.

**Exclusions for quantity limit edits for oral sedative hypnotics:**

1. Pharmacy claims submitted with an ICD-10-CM diagnosis code of palliative care (Z51.5) in NCPDP field 424-DO will bypass the quantity limit; and
2. Pharmacy claims submitted for tasimelteon capsule (Hetlioz®) and zolpidem tartrate oral spray (ZolpiMist®) are excluded.

**NOTE:** Refer to Section 37.5.5 of this manual chapter to access the Single Preferred Drug List (PDL), which is inclusive of the preferred/non-preferred drug list, clinical authorization list, drug specific forms, criteria, and Point of Sale edits (i.e. maximum daily dose and quantity limits) at: <http://ldh.la.gov/assets/HealthyLa/Pharmacy/PDL.pdf>



**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142****Tapentadol (Nucynta®)**

When the cumulative daily dosage for Tapentadol (Nucynta®) exceeds the maximum daily dosage of 700mg per day, the claim will deny.

If the prescribing practitioner chooses to exceed the maximum daily dosage, the prescribing practitioner must provide the reason why the daily dosage limit needs to be exceeded. The pharmacist may override the dosage limit after consultation with the prescriber. The pharmacist must document on the hardcopy prescription the prescriber's reason why the daily dosage limit needs to be exceeded. The pharmacist must document on the hardcopy prescription or in the pharmacy's electronic recordkeeping system the reason for service code, professional service code and result of service code with the POS submission.

**Agents containing Tramadol**

Pharmacy claims for doses of agents containing Tramadol which exceed the maximum recommended doses will deny.

The maximum daily doses for agents containing Tramadol are as follows:

Generic Name	Maximum Dose per Day	Age
Tramadol Immediate Release	400mg/day	<76 years
Tramadol Immediate Release	300mg/day	>75 years
Tramadol Sustained Release	300mg/day	
Tramadol/Acetaminophen	8 tablets/day	

If the prescribing practitioner chooses to exceed the maximum daily dosage, the prescribing practitioner must provide the reason why the daily dosage limit needs to be exceeded. The \*\*\*pharmacist may override the dosage limit after consultation with the prescriber. The pharmacist must document on the hardcopy prescription the prescriber's reason why the daily dosage limit needs to be exceeded. The pharmacist must document on the hardcopy prescription and supply the reason for service code, professional service code and result of service code with the POS submission.

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES**

---

**SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

---

**NOTE:** The *POS User Guide* can be accessed at:

[www.lamedicaid.com/Provweb1/Pharmacy/LAPOS\\_User\\_Manual\\_static.pdf](http://www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf) or by visiting Section 37.5.1 for detailed billing instructions and override procedures.

**Botulinum Toxins OnabotulinumtoxinA (Botox®), IncobotulinumtoxinA (Xeomin®), RimabotulinumtoxinB (Myobloc®)**

**Quantity Limit**

Pharmacy claims for onabotulinumtoxinA (Botox®) will have quantity limits of 6 units every rolling 84 days for the 100 unit vial and 3 units every rolling 84 days for the 200 unit vial. Pharmacy claims for incobotulinumtoxinA (Xeomin®) will have quantity limits of 400 units every rolling 84 days.

**Diagnosis Code Requirement**

Prescriptions for onabotulinumtoxinA (Botox®) and incobotulinumtoxinA (Xeomin®) require an appropriate diagnosis code documented on the hard copy prescription by either the prescriber or pharmacist. The diagnosis code may be communicated to the pharmacist electronically, via telephone, or facsimile. After consultation with the prescriber, the pharmacist must document the diagnosis code on the hard copy prescription or in the pharmacy's electronic recordkeeping system. The diagnosis code is required for the claim submission.

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142****Acceptable Diagnosis Codes for OnabotulinumtoxinA (Botox®)**

ICD-10-CM Diagnosis Code(s)	Description
L74.510	Axillary Hyperhidrosis
G24.5	Blepharospasm
G24.3	Cervical Dystonia
G43.7*	Chronic Migraine (Prophylaxis)
N32.81	Overactive Bladder
H49*, H50*, H51*	Strabismus
G35	Upper or Lower Limb Spasticity Associated with Multiple Sclerosis (Relapsing)
G80.0, G80.1, G80.2, G80.4, G80.8, G80.9	Upper or Lower Limb Spasticity Associated with Cerebral Palsy
G81.1*	Upper or Lower Limb Spasticity Associated with Spastic Hemiplegia
G82.53	Upper or Lower Limb Spasticity Associated with Complete Quadriplegia
G82.54	Upper or Lower Limb Spasticity Associated with Incomplete Quadriplegia
G83.0	Upper Limb Spasticity Associated with Diplegia of Upper Limb
G83.1*, G83.2*, G83.3*	Spasticity Associated with Monoplegia of Upper or Lower Limb
I69.●31, I69.●32, I69.●33, I69.●34, I69.●39, I69.●41, I69.●42, I69.●43, I69.●44, I69.●49	Spasticity Associated with Monoplegia of Upper or Lower Limb due to Late Effects Cerebrovascular Disease
S06.1*, S06.2*, S06.3*, S06.4*, S06.5*, S06.6*, S06.8*, S06.9*	Upper or Lower Limb Spasticity Associated with Intracranial Injury of Other and Unspecified Nature (Traumatic Brain Injury)
S14.0*, S14.1●5*, S14.1●6*, S14.1●7*	Upper or Lower Limb Spasticity Associated with Spinal Cord Injury without Evidence of Spinal Bone Injury
N36.44, N31.9	Urinary Incontinence (Detrusor Overactivity Associated with Neurological Disease)

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

- \* - any number or letter or combination of UP TO FOUR numbers and letters of a valid ICD-10-CM diagnosis code  
 • - any ONE number or letter of a valid ICD-10-CM diagnosis code

**Acceptable Diagnosis Codes for IncobotulinumtoxinA (Xeomin®)**

<b>ICD-10-CM Diagnosis Code(s)</b>	<b>Description</b>
G24.5	Blepharospasm
G24.3	Cervical Dystonia
K11.7	Chronic Sialorrhea
G35	Upper Limb Spasticity (ULS) Associated with Multiple Sclerosis (Relapsing)
G80.0, G80.1, G80.2, G80.4, G80.8, G80.9	Upper Limb Spasticity (ULS) Associated with Cerebral Palsy
G81.1*	Upper Limb Spasticity (ULS) Associated with Spastic Hemiplegia
G82.53	Upper Limb Spasticity (ULS) Associated with C5-C7 Complete Quadriplegia
G82.54	Upper Limb Spasticity (ULS) Associated with C5-C7 Incomplete Quadriplegia
G83.0	Upper Limb Spasticity (ULS) Associated with Diplegia of Upper Limb
I69.□31, I69.□32, I69.□33, I69.□34, I69.□39	Upper Limb Spasticity (ULS) Associated with Monoplegia of Upper Limb due to Late Effects of Cerebrovascular Disease
I69.□51, I69.□52, I69.□53, I69.□54, I69.□59	Upper Limb Spasticity (ULS) Associated with Hemiplegia due to Late Effects of Cerebrovascular Disease
S06.1*, S06.2*, S06.3*, S06.4*, S06.5*, S06.6*, S06.8*, S06.9*	Upper Limb Spasticity (ULS) Associated with Intracranial Injury of Other and Unspecified Nature (Traumatic Brain Injury)
G83.2*	Upper Limb Spasticity (ULS) Associated with Monoplegia of Upper Limb
S14.0*, S14.1□5, S14.1□6, S14.1□7	Upper Limb Spasticity (ULS) Associated with Spinal Cord Injury without Evidence of Spinal Bone Injury (C5-C7)

- \* - any number or letter or combination of UP TO FOUR numbers and letters of a valid ICD-10-CM diagnosis code  
 • - any ONE number or letter of a valid ICD-10-CM diagnosis code

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142****Acceptable Diagnosis Codes for RimabotulinumtoxinB (Myobloc®)**

ICD-10-CM Diagnosis Code(s)	Description
K11.7	Chronic sialorrhea

**Hydrocodone Containing Agents**

Prescriptions for hydrocodone containing drugs will be limited to:

1. 45 units per 15 days for hydrocodone/acetaminophen;
2. 30 units per 15 days for hydrocodone bitartrate capsule ER 12 hour;
3. 15 units per 15 days for hydrocodone bitartrate tablet ER 24 hour; and
4. 30 units per 15 days for hydrocodone/ibuprofen within a 30-day period.

If a prescriber chooses to exceed the 15-day quantity limit for hydrocodone, he/she must submit a Rx PA16 to the RxPA Unit.

**NOTE:** All Schedule II prescriptions require a valid diagnosis code to process. Hydrocodone claims will not be subject to the 15-day quantity limit when one of the diagnosis codes below is submitted.

ICD-10 Diagnosis Code(s)	Diagnosis
C00.*-C96.*	Cancer
Z51.5	Palliative Care

\* - any number or letter or combination of UP TO FOUR numbers and letters of an assigned ICD-10-CM diagnosis code

**NOTE:** The *POS User Guide* can be accessed at:

[www.lamedicaid.com/Provweb1/Pharmacy/LAPOS\\_User\\_Manual\\_static.pdf](http://www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf) or by visiting Section 37.5.1 for detailed billing instructions and override procedures.

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142****Lidocaine Patches (Lidoderm®)**

Pharmacy claims for lidocaine patches (Lidoderm®) have a quantity limit of 30 patches every rolling thirty days.

Select lidocaine patches (Lidoderm®) and lidocaine patch kits may require prior authorization or clinical authorization.

**Lofexidine (Lucemyra®)**

Pharmacy claims for lofexidine (Lucemyra®) are subject to the following:

1. Age limit;
2. Maximum Daily Dose;
3. Quantity Limit; and
4. Diagnosis Code Requirement.

Pharmacy claims for lofexidine (Lucemyra®) will deny for beneficiaries 17 years or younger.

<b>Generic – Brand Example</b>	<b>Diagnosis Description</b>	<b>ICD-10-CM Diagnosis Code(s)</b>
Lofexidine – Lucemyra®	Opioid abuse with withdrawal	F11.13
	Opioid dependence with withdrawal	F11.23
	Opioid use, unspecified with withdrawal	F11.93

Lofexidine (Lucemyra®) pharmacy claims are subject to a maximum daily dose of 2.88 mg (16 tablets) per day.

Pharmacy claims for lofexidine (Lucemyra®) tablets are limited to a 14-day supply (224 tablets) per 6-month period (180 days).

Lofexidine (Lucemyra®) pharmacy claims have the following diagnosis code requirement.

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142****Naltrexone Tablets**

Naltrexone tablets are subject to the following:

1. Age limit;
2. Diagnosis code requirement;
3. Drug-Drug Interaction; and
4. Therapeutic Duplication.

Pharmacy claims for naltrexone tablets will deny for beneficiaries 17 years or younger.

Pharmacy claims for naltrexone tablets have the following diagnosis code requirement.

Generic Name	Diagnosis Description	ICD-10-CM Diagnosis Code(s)
Naltrexone Tablets	Opioid dependence	F11.2*
	Alcohol dependence	F10.2*
	* – any number or letter or combination of <b>UP TO FOUR</b> numbers and letters of an assigned ICD–10–CM diagnosis code	

Pharmacy claims for naltrexone tablets will deny at POS with a drug-drug interaction when there is an active claim on the beneficiary's file for an opioid or buprenorphine-containing product. Pharmacy claims for opioids or buprenorphine-containing products will deny with a drug-drug interaction when there is an active claim on the beneficiary's file for naltrexone tablet.

Incoming pharmacy claims for any naltrexone agent will deny for therapeutic duplication when the beneficiary has an active prescription on file for any other naltrexone agent.

**Naltrexone Injection (Vivitrol®)**

Pharmacy claims for naltrexone injection (Vivitrol®) are subject to the following for reimbursement:

1. Diagnosis code requirement;

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

2. Age Limit;
3. Quantity Limit; and
4. Drug-Drug Interaction.

**Diagnosis Code Requirement**

The acceptable diagnosis code(s) for naltrexone injection (Vivitrol®) are listed below:

Medication	Diagnosis Description	ICD-10-CM Diagnosis Code
Naltrexone Injection (Vivitrol®)	Alcohol Dependence	F10.2*
	Opioid Dependence	F11.2*

\* any number or letter or combination of UP TO FOUR numbers and letters of an assigned ICD-10-CM diagnosis code

**Age Limit**

Pharmacy claims for naltrexone injection (Vivitrol®) have a minimum age requirement of 18 years old and older.

**Quantity Limit**

Pharmacy claims for naltrexone injection (Vivitrol®) have a quantity limit of 1 unit (380mg/vial dose kit) per 28 rolling days.

**Drug-Drug Interaction**

Pharmacy claims for naltrexone injection (Vivitrol®) prescriptions will deny if there is an active claim on the beneficiary's file for an opioid. Pharmacy claims for opioid prescriptions will deny if there is an active claim on the beneficiary's file for naltrexone injection (Vivitrol®).

**Opioids**

Opioid prescription drugs have the following clinical edits:



**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

1. Diagnosis code requirement for all Schedule II narcotics;
2. 30-day quantity limit for long-acting opioids;
3. 7-day quantity limit for select opioids for opioid naïve beneficiaries;
4. Maximum of 90 Morphine Milligram Equivalent (MME) per day; and
5. Prior drug use required for long-acting opioids.

**Opioid 30-day Quantity Limit**

Pharmacy claims for opioids will be subject to a 30-day quantity limit as listed in the following chart.

<b>Description</b>	<b>Dosage Form</b>	<b>LIMITS Units / 30 Days</b>	<b>Representative Brand</b>
Hydromorphone HCl	Tablet ER 24 hr	30 units	Exalgo®
Morphine Sulfate	CPMP 24 hr	30 units	Avinza®
Morphine Sulfate	Capsule SR Pellet	30 units	Kadian®
Morphine Sulfate	Tablet LA	60 units	MS Contin®
Morphine Sulfate	Tablet ER	60 Units	Arymo ER®
Morphine Sulfate/Naltrexone	Capsule SR Pellet	60 units	Embeda®
Oxycodone HCl	Tablet SR 12 hr	60 units	Oxycontin®
Oxycodone/Acetaminophen	Tablet ER 12 hr	60 units	Xartemis XR®

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

Description	Dosage Form	LIMITS Units / 30 Days	Representative Brand
Oxymorphone HCl	Tablet SR 12 hr	60 units	Opana ER®
Tapentadol	Tablet ER 12 hr	60 units	Nucynta ER®
Hydrocodone Bitartrate	Capsule ER 12hr	60 units	Zohydro ER®
Hydrocodone Bitartrate	Tablet ER 24 hr	30 units	Hysingla ER®
Oxycodone Myristate	Capsule ER 12hr	60 units	Xtampza ER®
Tramadol ER	Tablet ER 24 hr	30 units	Conzip ®

Fentanyl Transdermal Patch Quantity Limits- Units per 30 Rolling Day Period					
Description	Dosage Form	Route	Strength	Units/30 Rolling Days	Representative Brand
Fentanyl	Patch	Transdermal	12, 25, 37.5, and 50 mcg/hr	10 units	Duragesic®
Fentanyl	Patch	Transdermal	62.5, 75, 87.5, and 100 mcg/hr	20 units	Duragesic®

**NOTE:** The *POS User Guide* can be accessed at:

[www.lamedicaid.com/Provweb1/Pharmacy/LAPOS\\_User\\_Manual\\_static.pdf](http://www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf) or by visiting Section 37.5.1 for detailed billing instructions and override procedures.

**Short-Acting Opioid 7-Day Quantity Limit (Opioid Naïve Beneficiaries)**

Short-acting opioids will be limited to a 7-day supply for opioid-naïve beneficiaries. For this edit, opioid-naïve beneficiaries are defined as those who have not had an opioid claim paid within the last 90 days. The following chart lists short-acting opioids and corresponding quantity limits for opioid-naïve beneficiaries.

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

Description	Dosage Form	Units/7 days	Representative Brand
Codeine/Acetaminophen	Tablet	28	Tylenol® with Codeine
Hydrocodone/Acetaminophen	Tablet	28	Lortab®, Vicodin®
Hydrocodone/Ibuprofen	Tablet	28	Vicoprofen®
Hydromorphone HCl	Tablet	28	Dilaudid®
Meperidine	Tablet	28	Demerol®
Morphine Sulfate	Tablet/Capsule	28	
Oxycodone		28	Roxicodone®
Oxycodone/Acetaminophen		28	Endocet®, Percocet®, Roxicet®
Oxycodone/Aspirin		28	
Oxycodone/Ibuprofen	Tablet	28	
Oxymorphone HCl	Tablet	28	Opana®
Tapentadol	Tablet	28	Nucynta®
Tramadol	Tablet	28	Ultram®
Tramadol/Acetaminophen	Tablet	28	Ultracet®

**NOTE:** The *POS User Guide* can be accessed at:

[www.lamedicaid.com/Provweb1/Pharmacy/LAPOS\\_User\\_Manual\\_static.pdf](http://www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf) or by visiting Section 37.5.1 for detailed billing instructions and override procedures.

**Morphine Milligram Equivalent (MME) Limit**

The Morphine Milligram Equivalent (MME) per day for all active opioid prescriptions for a beneficiary will be calculated. For each beneficiary, the cumulative daily MME for all active opioid prescriptions will be limited to a maximum of 90 MME per day.

Opioid pharmacy claims with a total daily Morphine Milligram Equivalent (MME)  $\geq$  50 MME per day will flag at Point of Sale (POS) as an educational alert for review by the pharmacist.

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

Buprenorphine products for the treatment of Substance Use Disorder (SUD) will not be included in the MME limit.

**NOTE:** The *POS User Guide* can be accessed at: [www.lamedicaid.com/Provweb1/Pharmacy/LAPOS\\_User\\_Manual\\_static.pdf](http://www.lamedicaid.com/Provweb1/Pharmacy/LAPOS_User_Manual_static.pdf) or by visiting Section 37.5.1 for detailed billing instructions and override procedures.

**Long-Acting Opioid Prior Use Requirement**

Pharmacy claims for an incoming prescription for a long-acting opioid will deny if there is not a paid claim for either a short-acting or long-acting opioid medication within the previous 90 days.

**Opioid Quantity and MME Limit Exemptions**

All Schedule II opioid prescriptions require a valid diagnosis code to process. There are exemptions to the edits for quantity limits and maximum daily MME limits for opioids. Pharmacy claims for opioid products will not be subject to the opioid quantity limits or 90 MME per day limit when the beneficiary has a diagnosis of burn, sickle cell crisis, cancer and/or palliative care. The exemptions to the opioid quantity and MME limit are listed in the chart.

ICD-10-CM Diagnosis Code	Description
T20.2*	Burn of second degree of head, face, and neck
T20.3*	Burn of third degree of head, face, and neck
T20.6*	Corrosion of second degree of head, face, and neck
T20.7*	Corrosion of third degree of head, face, and neck
T21.2*	Burn of second degree trunk
T21.3*	Burn of third degree trunk
T21.6*	Corrosion of second degree of trunk
T21.7*	Corrosion of third degree trunk
T22.2*	Burn of second degree of shoulder and upper limb, except wrist and hand
T22.3*	Burn of third degree of shoulder and upper limb, except wrist and hand
T22.6*	Corrosion of second degree of shoulder and upper limb, except wrist and hand

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

ICD-10-CM Diagnosis Code	Description
T22.7*	Corrosion of third degree of shoulder and upper limb, except wrist and hand
T23.2*	Burn of second degree of wrist and hand
T23.3*	Burn of third degree of wrist and hand
T23.6*	Corrosion of second degree of wrist and hand
T23.7*	Corrosion of third degree of wrist and hand
T24.2*	Burn of second degree of lower limb, except ankle and foot
T24.3*	Burn of third degree of lower limb, except ankle and foot
T24.6*	Corrosion of second degree of lower limb, except ankle and foot
T24.7*	Corrosion of third degree of lower limb, except ankle and foot
T25.2*	Burn of second degree of ankle and foot
T25.3*	Burn of third degree of ankle and foot
T25.6*	Corrosion of second degree of ankle and foot
T25.7*	Corrosion of third degree of ankle and foot
D57.0	Hb-SS disease with crisis
D57.00	Hb-SS disease with crisis, unspecified
D57.01	Hb-SS disease with acute chest syndrome
D57.02	Hb-SS disease with splenic sequestration
D57.21	Sickle-cell/Hb-C disease with crisis
D57.211	Sickle-cell/Hb-C disease with acute chest syndrome
D57.212	Sickle-cell/Hb-C disease with splenic sequestration
D57.219	Sickle-cell/Hb-C disease with splenic sequestration
D57.41	Sickle-cell thalassemia with crisis
D57.411	Sickle-cell thalassemia with acute chest syndrome
D57.412	Sickle-cell thalassemia with splenic sequestration
D57.419	Sickle-cell thalassemia with crisis, unspecified
D57.81	Other sickle-cell disorders with crisis
D57.811	Other sickle-cell disorders with acute chest syndrome

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

ICD-10-CM Diagnosis Code	Description
D57.812	Other sickle-cell disorders with splenic sequestration
D57.819	Other sickle-cell disorders with crisis, unspecified
C00.*-C96.*	Cancer
Z51.5	Palliative Care

\* - any number or letter or combination of UP TO FOUR numbers and letters of an assigned ICD-10-CM diagnosis code.

**Opioid (Oral) Liquids**

Prescriptions for opioid oral liquids will have a quantity limit of 180 mls or a 7-day supply, whichever is less.

**Serotonin Agents (Tryptans)**

Pharmacy claims for quantities of Serotonin agents (Tryptans) which are in excess of the quantity limit will deny. Quantity limits are cumulative and are based on a rolling 30 days. Unless otherwise specified, quantity limits apply to all strengths of an agent.

Quantity limits for Serotonin agents (Tryptans) are as follows:

Generic Name	Dosage Form	Quantity Limit per 30 Rolling Days
Almotriptan Maleate	Tablet	12 units
Eletriptan HBr	Tablet	6 units
Frovatriptan Succinate	Tablet	9 units
Naratriptan HCl	Tablet	9 units
Rizatriptan Benzoate	Tablet, Tablet rapid dissolve	12 units
Sumatriptan Succinate (Nasal)	Exhaler Powder	1 kit* (package size = 16)
Sumatriptan Succinate/ Naproxen Na	Tablet	9 units

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

Generic Name	Dosage Form	Quantity Limit per 30 Rolling Days
Sumatriptan Succinate	Tablet	9 units
Zolmitriptan	Tablet, Tablet rapid dissolve	6 units

If the prescribing practitioner chooses to exceed the quantity limit, the prescribing practitioner must provide the reason why the quantity limit needs to be exceeded. The pharmacist may override the quantity limit after consulting with the prescriber. The pharmacist must document on the hardcopy prescription the prescriber's reason why the quantity limit needs to be exceeded. The pharmacist must document on the hardcopy prescription or in the pharmacy's electronic record keeping system the reason for service code, professional service code and result of service code with the POS submission.

**Quantity Limitations**

Prescriptions payable under the Medicaid Program are limited as follows:

**Maximum Allowable Quantities**

The maximum quantity payable is either a one month's supply or 100 unit doses, whichever is greater.

**Maintenance Medication Quantities**

Prescribed maintenance drugs for chronic illnesses should be prescribed and dispensed in economic quantities sufficient to meet the medical needs of the beneficiary. Listed below are drugs to be considered as maintenance drugs; these drugs should be dispensed in a one month's supply:

1. Anti-coagulants;
2. Anti-convulsants;
3. Oral anti-diabetics;
4. Calcium gluconate and calcium lactate;

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

5. Cardiovascular drugs, including diuretics, anti-hypertensives, and anti-hyperlipidemics;
6. Estrogens;
7. Iron supplements;
8. Potassium supplements;
9. Thyroids and anti-thyroid drugs; and
10. Vitamins – D, K, B12 injections, folic acid, and nicotinic acid.

**Coverage and Limitations for Long-Term Care Beneficiaries****Quantities for Long-Term Care Beneficiaries**

Providers shall dispense a one month's supply, unless the prescribing provider specifies a smaller quantity for medical reasons, to beneficiaries in long-term care facilities. Dispensing a smaller quantity should only be done in exceptional cases.

Specific quantity limitations for maintenance medications and prn prescriptions are as follows:

1. "Maintenance" medications are those used to treat chronic conditions or illnesses. Initial therapy of a "maintenance" medication may be dispensed in a small quantity (e.g. a 10-day supply) to ensure patient tolerance before dispensing a one month's supply of medication. The prospective DUR compliance module will only allow a refill on the eighth day of a ten-day therapy period. If on the eighth day of therapy the patient has progressed with no adverse effects, a one-month's supply shall be dispensed unless otherwise specified by the prescriber; and
2. "PRN" prescriptions are those prescriptions that patients utilize on an "as needed" basis. For "prn" prescriptions, thirty units or a 10-day supply shall be supplied, unless otherwise specified by the prescriber.

The nursing home pharmacy consultant should periodically review if the "prn" order has become a "maintenance" one. In that event, refer to the "maintenance" drug policy. Otherwise, if every six months, a quantity of the "prn" medication remains unused by the resident, the health care team



**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

(nursing home administration, medical, nursing, or pharmacy consultant) should reevaluate the necessity of the order as well as the quantity of the prescribed medication. Should the prescriber authorize an additional “prn” medication, then the subsequent dispensed quantity shall be reduced to an amount equal to the utilization of the prior six-month period.

Pharmacies are providing twenty-four hours coverage to the long-term care facilities. Prescription reorders should not be made until a three-day supply remains.

**Co-Payment Exemption**

Long-term care beneficiaries are exempt from co-payments and monthly prescriptions limits.

**NOTE:** Refer to Chapters 26: Intermediate Care Facilities for Individuals with Intellectual Disabilities and 34 – Nursing Facilities of the *Medicaid Services Manual* for detailed information regarding beneficiaries in LTC facilities.

**Over the Counter Drugs**

LTC facilities are responsible for providing all over the counter (OTC) drugs to Medicaid beneficiaries. OTC drugs are part of the per diem for LTC beneficiaries.

**Over the Counter Drugs for Preventive Care**

Select OTC agents for preventive care will be reimbursed when:

1. The prescribing practitioner issues the beneficiary a prescription for the preventive care OTC agent; and
2. The beneficiary meets the criteria to obtain the preventive care OTC agent.

OTC Drug	Medicaid Beneficiary	Preventive Care
Aspirin 81 mg	Women greater than 12 years of age Men greater than 44 years of age	Cardiovascular disease, colorectal cancer, and preeclampsia prevention
Folic Acid 0.4mg and 0.8mg	Women ages 12-54	Pregnancy planning

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES****SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND  
EXCLUSIONS****PAGE(S) 142**

OTC Drug	Medicaid Beneficiary	Preventive Care
Vitamin D 400 IU	Women and men greater than 64 years of age	Fall prevention

**Age Restriction**

Pharmacy claims submitted for beneficiaries outside of the age limits listed above will deny at POS.

**Days' Supply**

Quantities of 100 units with 100 days' supply will be allowed to process for payment.

**Copayment**

Pharmacy claims for the select preventive care OTC agents listed above will be exempt from copayment.

Coverage for aspirin 81 mg will be continued for beneficiaries greater than 79 years old; however, these pharmacy claims will be subject to copayment.

**Diabetic Supplies**

Medicaid will not reimburse pharmacies for claims for diabetic supplies when an individual resides in a long-term care facility.

**NOTE:** Refer to "Drugs with Special Payment Criteria/Limitations; Diabetic Testing Supplies" in this section for detailed information.

**Nebulizer Medications**

Medicaid will reimburse pharmacies for the nebulizer medications for those individuals who reside in a long-term care facility who do not have Medicare.

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES**

---

**SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND  
EXCLUSIONS****PAGE(S) 142**

---

**Medicare Skilled Nursing Facilities**

When a resident of a skilled nursing facility is in Medicare payment status, payment for prescription medications is the responsibility of the facility, as prescription services are included in the per diem paid by Medicare.

**Emergency Kits**

All drugs dispensed from an emergency kit shall be billed to the Medicaid Program indicating the date of service that coincides with the date of administration.

**Outpatient Drugs Covered by Medicare Part B**

Medicare Part B covers oral anticancer drugs, antiemetics, diabetic supplies, glucometers, antihemophilia factor products, oral immunosuppressive drugs, nebulizer medication and some other medications. Providers must be enrolled as Medicare suppliers and must bill Medicare first if the beneficiary receives Medicare benefits. Medicaid will pay any applicable deductibles and coinsurances.

**NOTE:** Refer to Section 37.5.7 Medicare Prescription Drug Coverage for detailed information on drugs covered by Medicare Part B.

**Drug Services for Hospice Beneficiaries**

“Hospice” is a concept that extends a process of care to terminally ill patients.

Hospice is a program of palliative (control of pain and symptoms) and supportive services that provides physical, psychological, social and spiritual care for dying persons and their families. Hospice care concentrates on assuring the quality of the terminal patient’s remaining life rather than on trying to prolong the length of that life.

For Medicare/Medicaid patients who have elected hospice, services covered in the beneficiary’s plan of care should not be billed to Medicaid. These services are covered in the hospice reimbursement.

To ensure the correct billing of drug services, it is imperative that the hospice provider communicate with the pharmacist to verify which drugs are related to the terminal illness (billed to the hospice) and which drugs are not related to the terminal illness (billed to Medicaid). The

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES**

---

**SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

---

hospice shall assume that the distinction in billing drugs is understood by enrolled pharmacists who render services to the Medicaid beneficiaries who have elected hospice.

**The pharmacy provider shall bill Louisiana Medicaid for out-patient pharmacy claims only for those drugs unrelated to the terminal illness.**

Recoupment of drug claims erroneously paid to a pharmacy provider through Medicaid for those Medicaid beneficiaries who have elected hospice will be performed as they are identified. Any provider of services to a hospice beneficiary needs to clear with the hospice provider that the billed service is not included in the beneficiary's plan of care. Erroneous payment will be recouped as identified.

**NOTE:** Refer to Chapter 24 - Hospice of the *Medicaid Services Manual* for detailed information.

**GENERAL PROGRAM INFORMATION**

The Pharmacy Program within the Louisiana Department of Health (LDH), Bureau of Health Services Financing (BHSF) covers all Food and Drug Administration (FDA) approved legend drugs that meet the Omnibus Budget Reconciliation Act (OBRA) '90 and OBRA '93 criteria with a few exceptions. The Pharmacy Program determines the reimbursement methodology for both the drug ingredient cost and the maximum allowable overhead cost (dispensing fee) for covered drugs.

The Pharmacy Program is responsible for the following components:

1. Policy;
2. Program development and implementation;
3. Network development;
4. Program coverage;
5. Preferred drug list development and implementation and prior authorization for certain therapeutic classes;
6. Federal upper limit (FUL) for multiple source drugs;

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES**

---

**SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND  
EXCLUSIONS****PAGE(S) 142**

---

7. Claims management;
8. Annual provider recertification;
9. Clinical interventions;
10. Prospective and retrospective drug utilization review (DUR);
11. Federal and state supplemental pharmaceutical manufacturer rebates;
12. Pharmacy provider desk audits;
13. Beneficiary Lock-In program;
14. Provider help desk;
15. Beneficiary help desk;
16. Provider relations; and
17. Provider education for prescribers and pharmacists.

**The Pharmacy Program:**

1. Initiates policy development;
2. Implements new policies and clarifies existing pharmacy policies, which include the services associated with outpatient drugs and Medicare/Medicaid pharmacy claims crossovers;
3. Approves all new drugs added to program coverage; and
4. Establishes any limitations on reimbursement or coverage in accordance with the federally approved reimbursement methodology.

The Pharmacy Program directs an extensive network of pharmacy providers and is also responsible for the integrity of several subsystems, including the drug file component of reference subsystem, the DUR subsystem and the drug portion of the Surveillance Utilization Review Subsystem

**CHAPTER 37: PHARMACY BENEFITS MANAGEMENT SERVICES**

---

**SECTION 37.1: COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS****PAGE(S) 142**

---

(SURS).

**Medicaid Management Information System**

The Medicaid Management Information System (MMIS) is a computerized claims processing and information system designed to manage the Medicaid Program's expenditures through effective claims processing and utilization control.

LDH contracts with a fiscal intermediary who operates the federally approved MMIS which is consistent with the Centers for Medicare and Medicaid Services (CMS) and LDH requirements. The fiscal intermediary (FI) is contracted to provide the following pharmacy-related services:

1. Pharmacy claim processing through an on-line, real-time POS system;
2. Coordination of the federally mandated Omnibus Budget Reconciliation Act of 1990 Drug Utilization Review (DUR) Board activities;
3. Retrospective Drug Utilization Review (LaDUR);
4. Prospective Drug Utilization Review (UniDUR);
5. Educational articles - *Provider Update* newsletter article;
6. Lock-In Program;
7. DUR Board coordination;
8. Preferred Drug List and prior authorization system;
9. Monthly prescription limit system; and
10. Electronic Data Inquiry/Clinical Drug Inquiry System (e-CDI).